[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Studies on PARPi + ARPI combinations have shown longer radiological progression-free survival, and better OS with [OBJ]talazoparib[/OBJ] + [SUBJ]enzalutamide[/SUBJ], regardless of mutational status for DNA repair genes, with synergistic activity identified.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJmAsDPX66Mr7QcNmjVDeFcCTO", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"synergizes_with\",\n  \"confidence\": 0.85,\n  \"explanation\": \"The text explicitly mentions 'synergistic activity identified' for the combination of talazoparib (PARP inhibitor) and enzalutamide (ARPI), indicating a synergistic interaction between the two chemicals.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 164, "completion_tokens": 528, "total_tokens": 692, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 448, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 5, "sentence": "Studies on PARPi + ARPI combinations have shown longer radiological progression-free survival, and better OS with talazoparib + enzalutamide, regardless of mutational status for DNA repair genes, with synergistic activity identified.", "subject": {"text": "enzalutamide", "class": "Chemical", "start": 128, "end": 140, "ids": [], "id": "Chemical:enzalutamide"}, "object": {"text": "talazoparib", "class": "Chemical", "start": 114, "end": 125, "ids": [], "id": "Chemical:talazoparib"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Studies on [OBJ]PARPi[/OBJ] + ARPI combinations have shown longer radiological progression-free survival, and better OS with [SUBJ]talazoparib[/SUBJ] + enzalutamide, regardless of mutational status for DNA repair genes, with synergistic activity identified.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJj4tJh7nlmfMlGxQpS0oh3Tyi", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"synergizes_with\",\n  \"confidence\": 0.88,\n  \"explanation\": \"The sentence explicitly states there is 'synergistic activity identified' for the PARPi + ARPI combination, indicating a synergistic interaction. There is no evidence of overcoming resistance or sequential therapy in the statement.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 165, "completion_tokens": 590, "total_tokens": 755, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 512, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 5, "sentence": "Studies on PARPi + ARPI combinations have shown longer radiological progression-free survival, and better OS with talazoparib + enzalutamide, regardless of mutational status for DNA repair genes, with synergistic activity identified.", "subject": {"text": "talazoparib", "class": "Chemical", "start": 114, "end": 125, "ids": [], "id": "Chemical:talazoparib"}, "object": {"text": "PARPi", "class": "Chemical", "start": 11, "end": 16, "ids": [], "id": "Chemical:parpi"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Studies on [OBJ]PARPi[/OBJ] + ARPI combinations have shown longer radiological progression-free survival, and better OS with talazoparib + [SUBJ]enzalutamide[/SUBJ], regardless of mutational status for DNA repair genes, with synergistic activity identified.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJYXmJ25quhJYZPc6jZXEBlZzQ", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"synergizes_with\",\n  \"confidence\": 0.85,\n  \"explanation\": \"The sentence explicitly states 'synergistic activity identified' for the PARP inhibitor and ARPI combination (talazoparib + enzalutamide), indicating a synergistic interaction between the two chemicals.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 164, "completion_tokens": 654, "total_tokens": 818, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 576, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 5, "sentence": "Studies on PARPi + ARPI combinations have shown longer radiological progression-free survival, and better OS with talazoparib + enzalutamide, regardless of mutational status for DNA repair genes, with synergistic activity identified.", "subject": {"text": "enzalutamide", "class": "Chemical", "start": 128, "end": 140, "ids": [], "id": "Chemical:enzalutamide"}, "object": {"text": "PARPi", "class": "Chemical", "start": 11, "end": 16, "ids": [], "id": "Chemical:parpi"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Studies on PARPi + ARPI combinations have shown longer radiological progression-free survival, and better OS with [SUBJ]talazoparib[/SUBJ] + [OBJ]enzalutamide[/OBJ], regardless of mutational status for DNA repair genes, with synergistic activity identified.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJtCTLS0PK3w9zTJuhKHKngBbN", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"synergizes_with\",\n  \"confidence\": 0.85,\n  \"explanation\": \"The sentence explicitly mentions synergistic activity for the talazoparib + enzalutamide combination, indicating a synergistic chemical interaction between the two agents, which matches the 'synergizes_with' predicate.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 164, "completion_tokens": 591, "total_tokens": 755, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 512, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 5, "sentence": "Studies on PARPi + ARPI combinations have shown longer radiological progression-free survival, and better OS with talazoparib + enzalutamide, regardless of mutational status for DNA repair genes, with synergistic activity identified.", "subject": {"text": "talazoparib", "class": "Chemical", "start": 114, "end": 125, "ids": [], "id": "Chemical:talazoparib"}, "object": {"text": "enzalutamide", "class": "Chemical", "start": 128, "end": 140, "ids": [], "id": "Chemical:enzalutamide"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Studies on [SUBJ]PARPi[/SUBJ] + ARPI combinations have shown longer radiological progression-free survival, and better OS with [OBJ]talazoparib[/OBJ] + enzalutamide, regardless of mutational status for DNA repair genes, with synergistic activity identified.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJc4Mbei5Zsqevjl8euVAPBrGE", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"synergizes_with\",\n  \"confidence\": 0.92,\n  \"explanation\": \"The sentence explicitly mentions 'synergistic activity identified' for the PARPi + ARPI combination (e.g., talazoparib + enzalutamide), indicating a synergistic interaction between the two chemicals.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 165, "completion_tokens": 592, "total_tokens": 757, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 512, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 5, "sentence": "Studies on PARPi + ARPI combinations have shown longer radiological progression-free survival, and better OS with talazoparib + enzalutamide, regardless of mutational status for DNA repair genes, with synergistic activity identified.", "subject": {"text": "PARPi", "class": "Chemical", "start": 11, "end": 16, "ids": [], "id": "Chemical:parpi"}, "object": {"text": "talazoparib", "class": "Chemical", "start": 114, "end": 125, "ids": [], "id": "Chemical:talazoparib"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of PARPi agents available (olaparib, [OBJ]niraparib[/OBJ], [SUBJ]rucaparib[/SUBJ], and talazoparib) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJ3dIWpXd8VjzYEBbcAAKcyJse", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.6,\n  \"explanation\": \"The sentence discusses efficacy and OS prolongation of PARP inhibitors in metastatic CRPC; it does not express a relationship of synergy, overcoming resistance via a combination, or sequential therapy after progression.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 181, "completion_tokens": 583, "total_tokens": 764, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 512, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 4, "sentence": "KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of PARPi agents available (olaparib, niraparib, rucaparib, and talazoparib) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.", "subject": {"text": "rucaparib", "class": "Chemical", "start": 118, "end": 127, "ids": [], "id": "Chemical:rucaparib"}, "object": {"text": "niraparib", "class": "Chemical", "start": 107, "end": 116, "ids": [], "id": "Chemical:niraparib"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: By analysis of experimental and public clinical data, we identified new UC-specific [OBJ]PARPi[/OBJ] response predictors SLFN5, [SUBJ]SLFN11[/SUBJ], and OAS1.\nAllowed predicates:\n- confers_resistance_to: Gene/protein mediates resistance to chemical/drug with specified mechanism and context (intrinsic/acquired, cancer type, fold-change).\n\n- sensitizes_to: Gene/protein or mutation increases vulnerability to chemical/drug. Include biomarker status if validated.\n\n- predicts_response_to: Gene or mutation status predicts treatment response. Specify FDA-approved/investigational biomarker status when applicable.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJjZIGzTR3k1p3HNUXhE7vHlSr", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"predicts_response_to\",\n  \"confidence\": 0.86,\n  \"explanation\": \"The sentence identifies SLFN5, SLFN11, and OAS1 as UC-specific predictors of PARPi (PARP inhibitor) response, indicating these genes serve as biomarkers that predict treatment response rather than conferring resistance or sensitizing.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 178, "completion_tokens": 596, "total_tokens": 774, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 512, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41216708", "sentence_id": 5, "sentence": "By analysis of experimental and public clinical data, we identified new UC-specific PARPi response predictors SLFN5, SLFN11, and OAS1.", "subject": {"text": "SLFN11", "class": "Gene", "start": 108, "end": 113, "ids": [], "id": "Gene:slfn11"}, "object": {"text": "PARPi", "class": "Chemical", "start": 75, "end": 79, "ids": [], "id": "Chemical:parpi"}, "predicate_names": ["confers_resistance_to", "sensitizes_to", "predicts_response_to"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Studies on PARPi + [OBJ]ARPI[/OBJ] combinations have shown longer radiological progression-free survival, and better OS with talazoparib + [SUBJ]enzalutamide[/SUBJ], regardless of mutational status for DNA repair genes, with synergistic activity identified.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJyZy6OhkEJomCUOUY24vlMmcY", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"synergizes_with\",\n  \"confidence\": 0.85,\n  \"explanation\": \"The sentence explicitly mentions synergistic activity for the PARPi + ARPI combination (talazoparib + enzalutamide), indicating a synergistic effect.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 164, "completion_tokens": 645, "total_tokens": 809, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 576, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 5, "sentence": "Studies on PARPi + ARPI combinations have shown longer radiological progression-free survival, and better OS with talazoparib + enzalutamide, regardless of mutational status for DNA repair genes, with synergistic activity identified.", "subject": {"text": "enzalutamide", "class": "Chemical", "start": 128, "end": 140, "ids": [], "id": "Chemical:enzalutamide"}, "object": {"text": "ARPI", "class": "Chemical", "start": 19, "end": 23, "ids": [], "id": "Chemical:arpi"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Clinical trials with [SUBJ]PARP inhibitors[/SUBJ] (PARPi), particularly in Cisplatin-treated [OBJ]UC[/OBJ], yielded limited response.\nAllowed predicates:\n- approved_for: FDA/EMA approved for cancer subtype. Specify line of therapy and combination/monotherapy.\n\n- in_trials_for: In clinical trials. Specify phase I/II/III and NCT number if available.\n\n- resistance_emerges_in: Resistance commonly emerges in disease. Specify median time to resistance and frequency.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJpO51r5KeSpExsVoI4i5Owkeu", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"in_trials_for\",\n  \"confidence\": 0.72,\n  \"explanation\": \"The sentence discusses PARP inhibitors in the context of clinical trials, specifically mentioning UC (urothelial carcinoma) and cisplatin-treated cases, and reports limited response. This aligns with the 'in_trials_for' predicate (clinical trials). There is no information about approval status or resistance timing.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 150, "completion_tokens": 670, "total_tokens": 820, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 576, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41216708", "sentence_id": 1, "sentence": "Clinical trials with PARP inhibitors (PARPi), particularly in Cisplatin-treated UC, yielded limited response.", "subject": {"text": "PARP inhibitors", "class": "Chemical", "start": 21, "end": 36, "ids": [], "id": "Chemical:parp_inhibitors"}, "object": {"text": "UC", "class": "Disease", "start": 80, "end": 82, "ids": [], "id": "Disease:uc"}, "predicate_names": ["approved_for", "in_trials_for", "resistance_emerges_in"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Studies on [SUBJ]PARPi[/SUBJ] + ARPI combinations have shown longer radiological progression-free survival, and better OS with talazoparib + [OBJ]enzalutamide[/OBJ], regardless of mutational status for DNA repair genes, with synergistic activity identified.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJ9jMqDGGfc7Q8RZKLJRbGnhti", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"synergizes_with\",\n  \"confidence\": 0.85,\n  \"explanation\": \"The sentence reports synergistic activity for the PARPi + ARPI combination (e.g., talazoparib + enzalutamide) with improved radiological PFS and OS, which aligns with a synergistic interaction.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 164, "completion_tokens": 530, "total_tokens": 694, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 448, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 5, "sentence": "Studies on PARPi + ARPI combinations have shown longer radiological progression-free survival, and better OS with talazoparib + enzalutamide, regardless of mutational status for DNA repair genes, with synergistic activity identified.", "subject": {"text": "PARPi", "class": "Chemical", "start": 11, "end": 16, "ids": [], "id": "Chemical:parpi"}, "object": {"text": "enzalutamide", "class": "Chemical", "start": 128, "end": 140, "ids": [], "id": "Chemical:enzalutamide"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Studies on [OBJ]PARPi[/OBJ] + [SUBJ]ARPI[/SUBJ] combinations have shown longer radiological progression-free survival, and better OS with talazoparib + enzalutamide, regardless of mutational status for DNA repair genes, with synergistic activity identified.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJMsp4xHdYzYqqCCYJjxHUjcHX", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"synergizes_with\",\n  \"confidence\": 0.92,\n  \"explanation\": \"The sentence explicitly mentions 'synergistic activity identified' for the PARPi + ARPI combination, which corresponds to a synergistic effect between chemicals.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 165, "completion_tokens": 706, "total_tokens": 871, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 640, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 5, "sentence": "Studies on PARPi + ARPI combinations have shown longer radiological progression-free survival, and better OS with talazoparib + enzalutamide, regardless of mutational status for DNA repair genes, with synergistic activity identified.", "subject": {"text": "ARPI", "class": "Chemical", "start": 19, "end": 23, "ids": [], "id": "Chemical:arpi"}, "object": {"text": "PARPi", "class": "Chemical", "start": 11, "end": 16, "ids": [], "id": "Chemical:parpi"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: We investigated a new combination treatment using [SUBJ]PLX51107[/SUBJ], an epigenetic BET protein inhibitor, to increase [OBJ]PARPi[/OBJ] efficacy.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJgJw4BTNNjnoPcmuY9wVMIkfH", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"synergizes_with\",\n  \"confidence\": 0.85,\n  \"explanation\": \"The sentence describes a new combination treatment using PLX51107 with a PARP inhibitor to increase PARPi efficacy, indicating a synergistic interaction between the two chemicals.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 142, "completion_tokens": 645, "total_tokens": 787, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 576, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41216708", "sentence_id": 6, "sentence": "We investigated a new combination treatment using PLX51107, an epigenetic BET protein inhibitor, to increase PARPi efficacy.", "subject": {"text": "PLX51107", "class": "Chemical", "start": 50, "end": 58, "ids": [], "id": "Chemical:plx51107"}, "object": {"text": "PARPi", "class": "Chemical", "start": 109, "end": 114, "ids": [], "id": "Chemical:parpi"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Studies on PARPi + [SUBJ]ARPI[/SUBJ] combinations have shown longer radiological progression-free survival, and better OS with talazoparib + [OBJ]enzalutamide[/OBJ], regardless of mutational status for DNA repair genes, with synergistic activity identified.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJ1JAOCsQSSRT9WLywAeQ1qXuU", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\"predicate\": \"synergizes_with\", \"confidence\": 0.8, \"explanation\": \"The sentence explicitly states 'with synergistic activity identified' for the PARPi + ARPI combination (e.g., talazoparib + enzalutamide), indicating a synergistic effect between the two chemicals.\"}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 164, "completion_tokens": 716, "total_tokens": 880, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 640, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 5, "sentence": "Studies on PARPi + ARPI combinations have shown longer radiological progression-free survival, and better OS with talazoparib + enzalutamide, regardless of mutational status for DNA repair genes, with synergistic activity identified.", "subject": {"text": "ARPI", "class": "Chemical", "start": 19, "end": 23, "ids": [], "id": "Chemical:arpi"}, "object": {"text": "enzalutamide", "class": "Chemical", "start": 128, "end": 140, "ids": [], "id": "Chemical:enzalutamide"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of PARPi agents available ([SUBJ]olaparib[/SUBJ], [OBJ]niraparib[/OBJ], rucaparib, and talazoparib) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HIiS6vh9wHrhMrSNa63jmCHOKE", "object": "chat.completion", "created": 1763442648, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.65,\n  \"explanation\": \"The sentence discusses that PARP inhibitors prolong overall survival in metastatic CRPC, but none of the allowed predicates (synergizes_with, overcomes_resistance_with, sequential_therapy_after) are described.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 180, "completion_tokens": 842, "total_tokens": 1022, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 768, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 4, "sentence": "KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of PARPi agents available (olaparib, niraparib, rucaparib, and talazoparib) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.", "subject": {"text": "olaparib", "class": "Chemical", "start": 97, "end": 105, "ids": [], "id": "Chemical:olaparib"}, "object": {"text": "niraparib", "class": "Chemical", "start": 107, "end": 116, "ids": [], "id": "Chemical:niraparib"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of [SUBJ]PARPi[/SUBJ] agents available (olaparib, niraparib, [OBJ]rucaparib[/OBJ], and talazoparib) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HInh7Xh0ASQtph4mdt068NLjYL", "object": "chat.completion", "created": 1763442648, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.85,\n  \"explanation\": \"The sentence reports phase 3 studies showing PARP inhibitors prolong overall survival in metastatic CRPC, particularly in BRCA1/2-mutated patients. It does not describe synergy with another agent, overcoming resistance, or sequential therapy after progression.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 182, "completion_tokens": 785, "total_tokens": 967, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 704, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 4, "sentence": "KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of PARPi agents available (olaparib, niraparib, rucaparib, and talazoparib) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.", "subject": {"text": "PARPi", "class": "Chemical", "start": 73, "end": 78, "ids": [], "id": "Chemical:parpi"}, "object": {"text": "rucaparib", "class": "Chemical", "start": 118, "end": 127, "ids": [], "id": "Chemical:rucaparib"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of PARPi agents available (olaparib, niraparib, [SUBJ]rucaparib[/SUBJ], and talazoparib) for the treatment of [OBJ]metastatic CRPC[/OBJ] have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.\nAllowed predicates:\n- approved_for: FDA/EMA approved for cancer subtype. Specify line of therapy and combination/monotherapy.\n\n- in_trials_for: In clinical trials. Specify phase I/II/III and NCT number if available.\n\n- resistance_emerges_in: Resistance commonly emerges in disease. Specify median time to resistance and frequency.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJZrEjXmm6dmqZSxhIbTWZDi9r", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"in_trials_for\",\n  \"confidence\": 0.82,\n  \"explanation\": \"The sentence describes Phase 3 studies evaluating the efficacy of PARP inhibitors in metastatic CRPC, indicating clinical trials. It specifies the phase (III) but provides no NCT numbers.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 196, "completion_tokens": 776, "total_tokens": 972, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 704, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 4, "sentence": "KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of PARPi agents available (olaparib, niraparib, rucaparib, and talazoparib) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.", "subject": {"text": "rucaparib", "class": "Chemical", "start": 118, "end": 127, "ids": [], "id": "Chemical:rucaparib"}, "object": {"text": "metastatic CRPC", "class": "Disease", "start": 167, "end": 182, "ids": [], "id": "Disease:metastatic_crpc"}, "predicate_names": ["approved_for", "in_trials_for", "resistance_emerges_in"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of PARPi agents available (olaparib, [SUBJ]niraparib[/SUBJ], rucaparib, and talazoparib) for the treatment of [OBJ]metastatic CRPC[/OBJ] have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.\nAllowed predicates:\n- approved_for: FDA/EMA approved for cancer subtype. Specify line of therapy and combination/monotherapy.\n\n- in_trials_for: In clinical trials. Specify phase I/II/III and NCT number if available.\n\n- resistance_emerges_in: Resistance commonly emerges in disease. Specify median time to resistance and frequency.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJV0QZoeY1JqQAG1VE02KDhYsj", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"in_trials_for\",\n  \"confidence\": 0.82,\n  \"explanation\": \"The sentence discusses Phase III studies evaluating the efficacy of PARP inhibitors for metastatic castration-resistant prostate cancer (CRPC), indicating the agents are being studied in clinical trials for this cancer type rather than being approved for it or about resistance.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 196, "completion_tokens": 786, "total_tokens": 982, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 704, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 4, "sentence": "KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of PARPi agents available (olaparib, niraparib, rucaparib, and talazoparib) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.", "subject": {"text": "niraparib", "class": "Chemical", "start": 107, "end": 116, "ids": [], "id": "Chemical:niraparib"}, "object": {"text": "metastatic CRPC", "class": "Disease", "start": 167, "end": 182, "ids": [], "id": "Disease:metastatic_crpc"}, "predicate_names": ["approved_for", "in_trials_for", "resistance_emerges_in"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: CONCLUSIONS AND CLINICAL IMPLICATIONS: Promising results have led to the approval of several [SUBJ]PARPi[/SUBJ] agents as monotherapy or in combination with ARPIs in selected or unselected patients when [OBJ]chemotherapy[/OBJ] is not clinically indicated.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJ0vtrABY0LfgivUbpfwKFTab6", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.85,\n  \"explanation\": \"The sentence discusses approval of PARPi agents as monotherapy or in combination with ARPIs when chemotherapy is not indicated. It does not express synergy, resistance-overcoming, or sequential therapy relationships between chemicals.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 165, "completion_tokens": 970, "total_tokens": 1135, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 896, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 7, "sentence": "CONCLUSIONS AND CLINICAL IMPLICATIONS: Promising results have led to the approval of several PARPi agents as monotherapy or in combination with ARPIs in selected or unselected patients when chemotherapy is not clinically indicated.", "subject": {"text": "PARPi", "class": "Chemical", "start": 93, "end": 98, "ids": [], "id": "Chemical:parpi"}, "object": {"text": "chemotherapy", "class": "Chemical", "start": 190, "end": 202, "ids": [], "id": "Chemical:chemotherapy"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Clinical trials with PARP inhibitors ([SUBJ]PARPi[/SUBJ]), particularly in Cisplatin-treated [OBJ]UC[/OBJ], yielded limited response.\nAllowed predicates:\n- approved_for: FDA/EMA approved for cancer subtype. Specify line of therapy and combination/monotherapy.\n\n- in_trials_for: In clinical trials. Specify phase I/II/III and NCT number if available.\n\n- resistance_emerges_in: Resistance commonly emerges in disease. Specify median time to resistance and frequency.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJ2x2MEfNTHBfqK0SFfBQosHYm", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"in_trials_for\",\n  \"confidence\": 0.75,\n  \"explanation\": \"The sentence discusses clinical trials involving PARP inhibitors in urothelial carcinoma (cisplatin-treated) and mentions limited response, which aligns with the 'in_trials_for' predicate. There is no stated approval or resistance emergence.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 148, "completion_tokens": 720, "total_tokens": 868, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 640, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41216708", "sentence_id": 1, "sentence": "Clinical trials with PARP inhibitors (PARPi), particularly in Cisplatin-treated UC, yielded limited response.", "subject": {"text": "PARPi", "class": "Chemical", "start": 38, "end": 43, "ids": [], "id": "Chemical:parpi"}, "object": {"text": "UC", "class": "Disease", "start": 80, "end": 82, "ids": [], "id": "Disease:uc"}, "predicate_names": ["approved_for", "in_trials_for", "resistance_emerges_in"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: By analysis of experimental and public clinical data, we identified new [OBJ]UC[/OBJ]-specific [SUBJ]PARPi[/SUBJ] response predictors SLFN5, SLFN11, and OAS1.\nAllowed predicates:\n- approved_for: FDA/EMA approved for cancer subtype. Specify line of therapy and combination/monotherapy.\n\n- in_trials_for: In clinical trials. Specify phase I/II/III and NCT number if available.\n\n- resistance_emerges_in: Resistance commonly emerges in disease. Specify median time to resistance and frequency.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJtGhNs9v6kauAPmKtvetTTqED", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.8,\n  \"explanation\": \"The sentence reports identification of UC-specific PARPi response predictors (SLFN5, SLFN11, OAS1) and does not mention regulatory approval, clinical trial status, or resistance characteristics, so none of the provided predicates apply.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 160, "completion_tokens": 656, "total_tokens": 816, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 576, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41216708", "sentence_id": 5, "sentence": "By analysis of experimental and public clinical data, we identified new UC-specific PARPi response predictors SLFN5, SLFN11, and OAS1.", "subject": {"text": "PARPi", "class": "Chemical", "start": 75, "end": 79, "ids": [], "id": "Chemical:parpi"}, "object": {"text": "UC", "class": "Disease", "start": 63, "end": 64, "ids": [], "id": "Disease:uc"}, "predicate_names": ["approved_for", "in_trials_for", "resistance_emerges_in"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Current strategies are moving towards personalised treatment, with the emergence of [SUBJ]PARP inhibitors (PARPi)[/SUBJ] that exploit a vulnerability in the DNA repair system in patients with alterations in genes involved in [OBJ]homologous recombination[/OBJ].\nAllowed predicates:\n- inhibits: Chemical inhibits pathway. Include IC50/potency and selectivity.\n\n- targets: Chemical targets multiple nodes in pathway.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HI44qixZj9ahvmjYrDR4wtrimg", "object": "chat.completion", "created": 1763442648, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"inhibits\",\n  \"confidence\": 0.8,\n  \"explanation\": \"PARP inhibitors (PARPi) function by inhibiting the PARP enzyme, a key component of the DNA damage repair pathway; the sentence describes their use to exploit vulnerabilities in homologous recombination, which aligns with inhibition of the DNA repair pathway.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 132, "completion_tokens": 853, "total_tokens": 985, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 768, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 2, "sentence": "Current strategies are moving towards personalised treatment, with the emergence of PARP inhibitors (PARPi) that exploit a vulnerability in the DNA repair system in patients with alterations in genes involved in homologous recombination.", "subject": {"text": "PARP inhibitors (PARPi)", "class": "Chemical", "start": 84, "end": 106, "ids": [], "id": "Chemical:parp_inhibitors_parpi"}, "object": {"text": "homologous recombination", "class": "Pathway", "start": 213, "end": 236, "ids": [], "id": "Pathway:homologous_recombination"}, "predicate_names": ["inhibits", "targets"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Studies on PARPi + [OBJ]ARPI[/OBJ] combinations have shown longer radiological progression-free survival, and better OS with [SUBJ]talazoparib[/SUBJ] + enzalutamide, regardless of mutational status for DNA repair genes, with synergistic activity identified.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJXAwjKhKMiPUxTI64eDcof0be", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"synergizes_with\",\n  \"confidence\": 0.85,\n  \"explanation\": \"The sentence reports synergistic activity for the combination of talazoparib (PARP inhibitor) with enzalutamide, and notes that PARPi + ARPI combinations yield longer PFS and better OS, indicating a synergistic interaction.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 165, "completion_tokens": 789, "total_tokens": 954, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 704, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 5, "sentence": "Studies on PARPi + ARPI combinations have shown longer radiological progression-free survival, and better OS with talazoparib + enzalutamide, regardless of mutational status for DNA repair genes, with synergistic activity identified.", "subject": {"text": "talazoparib", "class": "Chemical", "start": 114, "end": 125, "ids": [], "id": "Chemical:talazoparib"}, "object": {"text": "ARPI", "class": "Chemical", "start": 19, "end": 23, "ids": [], "id": "Chemical:arpi"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of [SUBJ]PARPi[/SUBJ] agents available (olaparib, niraparib, rucaparib, and [OBJ]talazoparib[/OBJ]) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HIfhxX3QjwUBCi4fyFWE4s7smi", "object": "chat.completion", "created": 1763442648, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.6,\n  \"explanation\": \"The sentence reports that PARP inhibitors prolong overall survival in metastatic CRPC but does not describe a synergistic interaction with another chemical, overcoming resistance to monotherapy, or sequential therapy after another treatment.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 182, "completion_tokens": 712, "total_tokens": 894, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 640, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 4, "sentence": "KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of PARPi agents available (olaparib, niraparib, rucaparib, and talazoparib) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.", "subject": {"text": "PARPi", "class": "Chemical", "start": 73, "end": 78, "ids": [], "id": "Chemical:parpi"}, "object": {"text": "talazoparib", "class": "Chemical", "start": 133, "end": 144, "ids": [], "id": "Chemical:talazoparib"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Clinical trials with PARP inhibitors (PARPi), particularly in [SUBJ]Cisplatin[/SUBJ]-treated [OBJ]UC[/OBJ], yielded limited response.\nAllowed predicates:\n- approved_for: FDA/EMA approved for cancer subtype. Specify line of therapy and combination/monotherapy.\n\n- in_trials_for: In clinical trials. Specify phase I/II/III and NCT number if available.\n\n- resistance_emerges_in: Resistance commonly emerges in disease. Specify median time to resistance and frequency.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJuH6Gbmk5Us8peHL5F6WqRdia", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"in_trials_for\",\n  \"confidence\": 0.8,\n  \"explanation\": \"The sentence discusses clinical trials involving PARP inhibitors, specifically mentioning cisplatin-treated urothelial carcinoma and noting limited response, which indicates a trial context rather than an approval or resistance emergence.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 151, "completion_tokens": 713, "total_tokens": 864, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 640, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41216708", "sentence_id": 1, "sentence": "Clinical trials with PARP inhibitors (PARPi), particularly in Cisplatin-treated UC, yielded limited response.", "subject": {"text": "Cisplatin", "class": "Chemical", "start": 62, "end": 71, "ids": [], "id": "Chemical:cisplatin"}, "object": {"text": "UC", "class": "Disease", "start": 80, "end": 82, "ids": [], "id": "Disease:uc"}, "predicate_names": ["approved_for", "in_trials_for", "resistance_emerges_in"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: We investigated a new combination treatment using [OBJ]PLX51107[/OBJ], an epigenetic BET protein inhibitor, to increase [SUBJ]PARPi[/SUBJ] efficacy.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJ4il9IuRxea3hOgrUOHEkmGDb", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"synergizes_with\",\n  \"confidence\": 0.78,\n  \"explanation\": \"The sentence describes using PLX51107 in combination to increase PARPi efficacy, indicating a synergistic interaction between the two agents (combination more effective than either alone).\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 142, "completion_tokens": 711, "total_tokens": 853, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 640, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41216708", "sentence_id": 6, "sentence": "We investigated a new combination treatment using PLX51107, an epigenetic BET protein inhibitor, to increase PARPi efficacy.", "subject": {"text": "PARPi", "class": "Chemical", "start": 109, "end": 114, "ids": [], "id": "Chemical:parpi"}, "object": {"text": "PLX51107", "class": "Chemical", "start": 50, "end": 58, "ids": [], "id": "Chemical:plx51107"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of [SUBJ]PARPi[/SUBJ] agents available ([OBJ]olaparib[/OBJ], niraparib, rucaparib, and talazoparib) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HIBHjUZMkec15lyws4K5D41PdU", "object": "chat.completion", "created": 1763442648, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.72,\n  \"explanation\": \"The sentence reports phase 3 evidence that PARP inhibitors prolong overall survival in metastatic CRPC, particularly in BRCA1/2-mutant patients. It does not describe synergistic interaction, overcoming resistance to monotherapy, or a sequential therapy relationship.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 181, "completion_tokens": 723, "total_tokens": 904, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 640, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 4, "sentence": "KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of PARPi agents available (olaparib, niraparib, rucaparib, and talazoparib) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.", "subject": {"text": "PARPi", "class": "Chemical", "start": 73, "end": 78, "ids": [], "id": "Chemical:parpi"}, "object": {"text": "olaparib", "class": "Chemical", "start": 97, "end": 105, "ids": [], "id": "Chemical:olaparib"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: To identify the most suitable PARPi for UC, we compared [SUBJ]Olaparib[/SUBJ] with [OBJ]Talazoparib[/OBJ].\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJcC3jwEt0o6Lc3wLlkKMavfQ9", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.65,\n  \"explanation\": \"The sentence describes a direct comparison between Olaparib and Talazoparib to identify the most suitable PARPi for UC. It does not describe synergy, overcoming resistance, or sequential therapy, so none of the provided predicates apply.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 139, "completion_tokens": 848, "total_tokens": 987, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 768, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41216708", "sentence_id": 3, "sentence": "To identify the most suitable PARPi for UC, we compared Olaparib with Talazoparib.", "subject": {"text": "Olaparib", "class": "Chemical", "start": 56, "end": 64, "ids": [], "id": "Chemical:olaparib"}, "object": {"text": "Talazoparib", "class": "Chemical", "start": 70, "end": 81, "ids": [], "id": "Chemical:talazoparib"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of [SUBJ]PARPi[/SUBJ] agents available (olaparib, niraparib, rucaparib, and talazoparib) for the treatment of [OBJ]metastatic CRPC[/OBJ] have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.\nAllowed predicates:\n- approved_for: FDA/EMA approved for cancer subtype. Specify line of therapy and combination/monotherapy.\n\n- in_trials_for: In clinical trials. Specify phase I/II/III and NCT number if available.\n\n- resistance_emerges_in: Resistance commonly emerges in disease. Specify median time to resistance and frequency.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HIiZfrxJbG2LklVr218BUl3Wr7", "object": "chat.completion", "created": 1763442648, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"in_trials_for\",\n  \"confidence\": 0.85,\n  \"explanation\": \"The sentence discusses Phase 3 studies evaluating the efficacy of PARP inhibitors for metastatic CRPC, indicating these agents are being studied in clinical trials for this indication.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 197, "completion_tokens": 835, "total_tokens": 1032, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 768, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 4, "sentence": "KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of PARPi agents available (olaparib, niraparib, rucaparib, and talazoparib) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.", "subject": {"text": "PARPi", "class": "Chemical", "start": 73, "end": 78, "ids": [], "id": "Chemical:parpi"}, "object": {"text": "metastatic CRPC", "class": "Disease", "start": 167, "end": 182, "ids": [], "id": "Disease:metastatic_crpc"}, "predicate_names": ["approved_for", "in_trials_for", "resistance_emerges_in"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of PARPi agents available ([SUBJ]olaparib[/SUBJ], niraparib, [OBJ]rucaparib[/OBJ], and talazoparib) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HIkYiDrVvvfNFuIpBMzr9d2zEC", "object": "chat.completion", "created": 1763442648, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.92,\n  \"explanation\": \"The sentence discusses phase 3 studies showing PARP inhibitors prolong overall survival in metastatic CRPC, especially in BRCA1/2 mutation carriers. It does not mention any synergistic interaction with another chemical, overcoming resistance to monotherapy, or sequential therapy after a different chemical.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 180, "completion_tokens": 728, "total_tokens": 908, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 640, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 4, "sentence": "KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of PARPi agents available (olaparib, niraparib, rucaparib, and talazoparib) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.", "subject": {"text": "olaparib", "class": "Chemical", "start": 97, "end": 105, "ids": [], "id": "Chemical:olaparib"}, "object": {"text": "rucaparib", "class": "Chemical", "start": 118, "end": 127, "ids": [], "id": "Chemical:rucaparib"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of PARPi agents available (olaparib, niraparib, [SUBJ]rucaparib[/SUBJ], and [OBJ]talazoparib[/OBJ]) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJcoxpm2kh21xLY71cwuIjqM5k", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\"predicate\": \"none\", \"confidence\": 0.85, \"explanation\": \"The sentence discusses the efficacy of PARP inhibitors as monotherapy and their ability to prolong overall survival in metastatic CRPC, with no mention of combination therapy, overcoming resistance to another agent, or sequential therapy after progression.\"}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 181, "completion_tokens": 712, "total_tokens": 893, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 640, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 4, "sentence": "KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of PARPi agents available (olaparib, niraparib, rucaparib, and talazoparib) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.", "subject": {"text": "rucaparib", "class": "Chemical", "start": 118, "end": 127, "ids": [], "id": "Chemical:rucaparib"}, "object": {"text": "talazoparib", "class": "Chemical", "start": 133, "end": 144, "ids": [], "id": "Chemical:talazoparib"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Clinical trials with PARP inhibitors ([OBJ]PARPi[/OBJ]), particularly in [SUBJ]Cisplatin[/SUBJ]-treated UC, yielded limited response.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJLL8bVVmKMDjPXC5hXlcl5o2U", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.75,\n  \"explanation\": \"The sentence mentions PARP inhibitors in Cisplatin-treated urothelial cancer with limited response but does not express any of the specified relational predicates (synergizes_with, overcomes_resistance_with, sequential_therapy_after). Therefore, none of the allowed predicates apply.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 138, "completion_tokens": 855, "total_tokens": 993, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 768, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41216708", "sentence_id": 1, "sentence": "Clinical trials with PARP inhibitors (PARPi), particularly in Cisplatin-treated UC, yielded limited response.", "subject": {"text": "Cisplatin", "class": "Chemical", "start": 62, "end": 71, "ids": [], "id": "Chemical:cisplatin"}, "object": {"text": "PARPi", "class": "Chemical", "start": 38, "end": 43, "ids": [], "id": "Chemical:parpi"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of [OBJ]PARPi[/OBJ] agents available ([SUBJ]olaparib[/SUBJ], niraparib, rucaparib, and talazoparib) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HIS7japyuwJMmw4MoiXfYAbiyH", "object": "chat.completion", "created": 1763442648, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.78,\n  \"explanation\": \"The sentence discusses that PARP inhibitor agents prolong overall survival in metastatic CRPC, especially in BRCA1/2 mutation carriers. It does not describe a synergistic interaction with another chemical, overcoming resistance to a monotherapy, or sequential therapy after progression.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 181, "completion_tokens": 916, "total_tokens": 1097, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 832, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 4, "sentence": "KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of PARPi agents available (olaparib, niraparib, rucaparib, and talazoparib) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.", "subject": {"text": "olaparib", "class": "Chemical", "start": 97, "end": 105, "ids": [], "id": "Chemical:olaparib"}, "object": {"text": "PARPi", "class": "Chemical", "start": 73, "end": 78, "ids": [], "id": "Chemical:parpi"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of [OBJ]PARPi[/OBJ] agents available (olaparib, niraparib, rucaparib, and [SUBJ]talazoparib[/SUBJ]) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJpgGueaOS2evklR4uepscGrEp", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.9,\n  \"explanation\": \"The sentence discusses PARP inhibitors prolonging overall survival in metastatic CRPC, especially in BRCA1/2 mutation carriers, but does not mention synergy with another chemical, overcoming resistance via combination therapy, or sequential therapy after progression.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 182, "completion_tokens": 783, "total_tokens": 965, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 704, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 4, "sentence": "KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of PARPi agents available (olaparib, niraparib, rucaparib, and talazoparib) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.", "subject": {"text": "talazoparib", "class": "Chemical", "start": 133, "end": 144, "ids": [], "id": "Chemical:talazoparib"}, "object": {"text": "PARPi", "class": "Chemical", "start": 73, "end": 78, "ids": [], "id": "Chemical:parpi"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Studies on PARPi + [SUBJ]ARPI[/SUBJ] combinations have shown longer radiological progression-free survival, and better OS with [OBJ]talazoparib[/OBJ] + enzalutamide, regardless of mutational status for DNA repair genes, with synergistic activity identified.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJjCPBBh6g8QUIXrDFC3alybkK", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"synergizes_with\",\n  \"confidence\": 0.85,\n  \"explanation\": \"The sentence reports that the combination of talazoparib (PARP inhibitor) and enzalutamide (ARPI) shows synergistic activity and improved outcomes, indicating a synergistic interaction between the two chemicals.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 165, "completion_tokens": 912, "total_tokens": 1077, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 832, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 5, "sentence": "Studies on PARPi + ARPI combinations have shown longer radiological progression-free survival, and better OS with talazoparib + enzalutamide, regardless of mutational status for DNA repair genes, with synergistic activity identified.", "subject": {"text": "ARPI", "class": "Chemical", "start": 19, "end": 23, "ids": [], "id": "Chemical:arpi"}, "object": {"text": "talazoparib", "class": "Chemical", "start": 114, "end": 125, "ids": [], "id": "Chemical:talazoparib"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: By analysis of experimental and public clinical data, we identified new UC-specific [OBJ]PARPi[/OBJ] response predictors [SUBJ]SLFN5[/SUBJ], SLFN11, and OAS1.\nAllowed predicates:\n- confers_resistance_to: Gene/protein mediates resistance to chemical/drug with specified mechanism and context (intrinsic/acquired, cancer type, fold-change).\n\n- sensitizes_to: Gene/protein or mutation increases vulnerability to chemical/drug. Include biomarker status if validated.\n\n- predicts_response_to: Gene or mutation status predicts treatment response. Specify FDA-approved/investigational biomarker status when applicable.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJTeHzOLVTZvV6GtQkpD18RW2p", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"predicts_response_to\",\n  \"confidence\": 0.92,\n  \"explanation\": \"The sentence identifies SLFN5, SLFN11, and OAS1 as PARP inhibitor response predictors in urothelial cancer, indicating they are biomarkers that predict treatment response to PARP inhibitors.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 178, "completion_tokens": 972, "total_tokens": 1150, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 896, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41216708", "sentence_id": 5, "sentence": "By analysis of experimental and public clinical data, we identified new UC-specific PARPi response predictors SLFN5, SLFN11, and OAS1.", "subject": {"text": "SLFN5", "class": "Gene", "start": 101, "end": 105, "ids": [], "id": "Gene:slfn5"}, "object": {"text": "PARPi", "class": "Chemical", "start": 75, "end": 79, "ids": [], "id": "Chemical:parpi"}, "predicate_names": ["confers_resistance_to", "sensitizes_to", "predicts_response_to"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of PARPi agents available (olaparib, niraparib, rucaparib, and [SUBJ]talazoparib[/SUBJ]) for the treatment of [OBJ]metastatic CRPC[/OBJ] have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.\nAllowed predicates:\n- approved_for: FDA/EMA approved for cancer subtype. Specify line of therapy and combination/monotherapy.\n\n- in_trials_for: In clinical trials. Specify phase I/II/III and NCT number if available.\n\n- resistance_emerges_in: Resistance commonly emerges in disease. Specify median time to resistance and frequency.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJRbnSovwp36VYvQKNKoM3Pfl9", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"in_trials_for\",\n  \"confidence\": 0.78,\n  \"explanation\": \"The sentence discusses Phase III studies evaluating the efficacy of PARP inhibitors (olaparib, niraparib, rucaparib, talazoparib) for metastatic CRPC, indicating these agents are being tested in clinical trials. No approval status or resistance data are stated.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 196, "completion_tokens": 796, "total_tokens": 992, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 704, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 4, "sentence": "KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of PARPi agents available (olaparib, niraparib, rucaparib, and talazoparib) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.", "subject": {"text": "talazoparib", "class": "Chemical", "start": 133, "end": 144, "ids": [], "id": "Chemical:talazoparib"}, "object": {"text": "metastatic CRPC", "class": "Disease", "start": 167, "end": 182, "ids": [], "id": "Disease:metastatic_crpc"}, "predicate_names": ["approved_for", "in_trials_for", "resistance_emerges_in"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of PARPi agents available (olaparib, [OBJ]niraparib[/OBJ], rucaparib, and [SUBJ]talazoparib[/SUBJ]) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJPwdjxkapuibPaBa1VovQFCP5", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.6,\n  \"explanation\": \"The sentence reports that PARP inhibitors prolong overall survival in metastatic CRPC, but does not express a relationship of synergy with another chemical, overcoming resistance via combination, or sequential therapy after progression.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 181, "completion_tokens": 839, "total_tokens": 1020, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 768, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 4, "sentence": "KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of PARPi agents available (olaparib, niraparib, rucaparib, and talazoparib) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.", "subject": {"text": "talazoparib", "class": "Chemical", "start": 133, "end": 144, "ids": [], "id": "Chemical:talazoparib"}, "object": {"text": "niraparib", "class": "Chemical", "start": 107, "end": 116, "ids": [], "id": "Chemical:niraparib"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of PARPi agents available ([SUBJ]olaparib[/SUBJ], niraparib, rucaparib, and [OBJ]talazoparib[/OBJ]) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HIOm8PkFOhlDme2NcElR0OE3rB", "object": "chat.completion", "created": 1763442648, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"no_applicable_predicate\",\n  \"confidence\": 0.85,\n  \"explanation\": \"The sentence discusses OS prolongation by PARP inhibitors in metastatic CRPC and BRCA1/2 mutations, but does not describe synergistic combination therapy, overcoming resistance with a combination, or sequential therapy after progression.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 180, "completion_tokens": 784, "total_tokens": 964, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 704, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 4, "sentence": "KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of PARPi agents available (olaparib, niraparib, rucaparib, and talazoparib) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.", "subject": {"text": "olaparib", "class": "Chemical", "start": 97, "end": 105, "ids": [], "id": "Chemical:olaparib"}, "object": {"text": "talazoparib", "class": "Chemical", "start": 133, "end": 144, "ids": [], "id": "Chemical:talazoparib"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Studies on [SUBJ]PARPi[/SUBJ] + [OBJ]ARPI[/OBJ] combinations have shown longer radiological progression-free survival, and better OS with talazoparib + enzalutamide, regardless of mutational status for DNA repair genes, with synergistic activity identified.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJQR44guIZhLfyR34TnTc82Mqz", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"synergizes_with\",\n  \"confidence\": 0.78,\n  \"explanation\": \"The sentence states there is 'synergistic activity identified' for the PARPi + ARPI combination (e.g., talazoparib + enzalutamide), indicating a synergistic interaction between the two agents.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 165, "completion_tokens": 849, "total_tokens": 1014, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 768, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 5, "sentence": "Studies on PARPi + ARPI combinations have shown longer radiological progression-free survival, and better OS with talazoparib + enzalutamide, regardless of mutational status for DNA repair genes, with synergistic activity identified.", "subject": {"text": "PARPi", "class": "Chemical", "start": 11, "end": 16, "ids": [], "id": "Chemical:parpi"}, "object": {"text": "ARPI", "class": "Chemical", "start": 19, "end": 23, "ids": [], "id": "Chemical:arpi"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: In conclusion, we suggest [SUBJ]Talazoparib[/SUBJ] treatment of [OBJ]UC[/OBJ] to be highly efficacious on all models examined when combined with PLX51107.\nAllowed predicates:\n- approved_for: FDA/EMA approved for cancer subtype. Specify line of therapy and combination/monotherapy.\n\n- in_trials_for: In clinical trials. Specify phase I/II/III and NCT number if available.\n\n- resistance_emerges_in: Resistance commonly emerges in disease. Specify median time to resistance and frequency.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJzR9cjfNMWFFR6LL98B7JMwWY", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.6,\n  \"explanation\": \"The sentence reports preclinical efficacy of a talazoparib + PLX51107 combination for urothelial cancer in modeling studies. It does not state FDA/EMA approval (approved_for), any clinical trial status (in_trials_for), or resistance emergence (resistance_emerges_in).\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 159, "completion_tokens": 925, "total_tokens": 1084, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 832, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41216708", "sentence_id": 9, "sentence": "In conclusion, we suggest Talazoparib treatment of UC to be highly efficacious on all models examined when combined with PLX51107.", "subject": {"text": "Talazoparib", "class": "Chemical", "start": 26, "end": 37, "ids": [], "id": "Chemical:talazoparib"}, "object": {"text": "UC", "class": "Disease", "start": 51, "end": 53, "ids": [], "id": "Disease:uc"}, "predicate_names": ["approved_for", "in_trials_for", "resistance_emerges_in"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of PARPi agents available (olaparib, [SUBJ]niraparib[/SUBJ], [OBJ]rucaparib[/OBJ], and talazoparib) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJamVSRE2C6o35qOYfgBTYnF4V", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none_of_the_above\",\n  \"confidence\": 0.72,\n  \"explanation\": \"The sentence reports that Phase 3 studies show PARP inhibitors prolong overall survival in metastatic CRPC, especially in BRCA1/2 mutation carriers. It does not describe a synergistic interaction with another chemical, overcoming resistance to monotherapy in combination, nor sequential therapy after progression.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 181, "completion_tokens": 861, "total_tokens": 1042, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 768, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 4, "sentence": "KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of PARPi agents available (olaparib, niraparib, rucaparib, and talazoparib) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.", "subject": {"text": "niraparib", "class": "Chemical", "start": 107, "end": 116, "ids": [], "id": "Chemical:niraparib"}, "object": {"text": "rucaparib", "class": "Chemical", "start": 118, "end": 127, "ids": [], "id": "Chemical:rucaparib"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of PARPi agents available (olaparib, [SUBJ]niraparib[/SUBJ], rucaparib, and [OBJ]talazoparib[/OBJ]) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJHa6qBegGEn7Dv4bHJAQC6tv6", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.62,\n  \"explanation\": \"The sentence discusses the efficacy of PARP inhibitors in prolonging overall survival in metastatic CRPC with BRCA1/2 mutations. It does not describe synergistic chemical combinations, overcoming resistance through combination therapy, or sequential therapy after progression.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 181, "completion_tokens": 848, "total_tokens": 1029, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 768, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 4, "sentence": "KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of PARPi agents available (olaparib, niraparib, rucaparib, and talazoparib) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.", "subject": {"text": "niraparib", "class": "Chemical", "start": 107, "end": 116, "ids": [], "id": "Chemical:niraparib"}, "object": {"text": "talazoparib", "class": "Chemical", "start": 133, "end": 144, "ids": [], "id": "Chemical:talazoparib"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: To identify the most suitable PARPi for UC, we compared [OBJ]Olaparib[/OBJ] with [SUBJ]Talazoparib[/SUBJ].\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJCUgRT6mAj25F3A4Fd5SEphSu", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.80,\n  \"explanation\": \"The sentence merely states a comparison between two PARP inhibitors to identify the best option for UC. It does not indicate a synergistic interaction, overcoming resistance via combination, or sequential therapy.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 139, "completion_tokens": 1030, "total_tokens": 1169, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 960, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41216708", "sentence_id": 3, "sentence": "To identify the most suitable PARPi for UC, we compared Olaparib with Talazoparib.", "subject": {"text": "Talazoparib", "class": "Chemical", "start": 70, "end": 81, "ids": [], "id": "Chemical:talazoparib"}, "object": {"text": "Olaparib", "class": "Chemical", "start": 56, "end": 64, "ids": [], "id": "Chemical:olaparib"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: CONCLUSIONS AND CLINICAL IMPLICATIONS: Promising results have led to the approval of several [OBJ]PARPi[/OBJ] agents as monotherapy or in combination with ARPIs in selected or unselected patients when [SUBJ]chemotherapy[/SUBJ] is not clinically indicated.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJNIyIqmR3Yc9QIyxOZaxyJMTY", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.55,\n  \"explanation\": \"The sentence discusses approval of PARPi agents as monotherapy or in combination with ARPIs when chemotherapy is not indicated, but it does not state any of the three specific relationships (synergy, overcoming resistance, or sequential therapy). Therefore, none of the provided predicates directly fit.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 165, "completion_tokens": 1049, "total_tokens": 1214, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 960, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 7, "sentence": "CONCLUSIONS AND CLINICAL IMPLICATIONS: Promising results have led to the approval of several PARPi agents as monotherapy or in combination with ARPIs in selected or unselected patients when chemotherapy is not clinically indicated.", "subject": {"text": "chemotherapy", "class": "Chemical", "start": 190, "end": 202, "ids": [], "id": "Chemical:chemotherapy"}, "object": {"text": "PARPi", "class": "Chemical", "start": 93, "end": 98, "ids": [], "id": "Chemical:parpi"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of [SUBJ]PARPi[/SUBJ] agents available (olaparib, [OBJ]niraparib[/OBJ], rucaparib, and talazoparib) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HIsdIsurxMVw2qr2f23LHQWRFL", "object": "chat.completion", "created": 1763442648, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.62,\n  \"explanation\": \"The sentence discusses the efficacy and survival benefit of PARP inhibitors as monotherapy in metastatic CRPC, with no mention of drug synergy, overcoming resistance, or sequential therapy after progression.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 182, "completion_tokens": 901, "total_tokens": 1083, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 832, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 4, "sentence": "KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of PARPi agents available (olaparib, niraparib, rucaparib, and talazoparib) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.", "subject": {"text": "PARPi", "class": "Chemical", "start": 73, "end": 78, "ids": [], "id": "Chemical:parpi"}, "object": {"text": "niraparib", "class": "Chemical", "start": 107, "end": 116, "ids": [], "id": "Chemical:niraparib"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of PARPi agents available ([OBJ]olaparib[/OBJ], [SUBJ]niraparib[/SUBJ], rucaparib, and talazoparib) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HI367a36VHkv8LDRPgkl5cTXgs", "object": "chat.completion", "created": 1763442648, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.6,\n  \"explanation\": \"The sentence reports that Phase 3 studies show PARP inhibitors prolong overall survival in metastatic CRPC, especially in BRCA1/2 mutation carriers. It does not mention a synergistic effect with another chemical, overcoming resistance to monotherapy, or sequential therapy after progression. Therefore, none of the provided predicates apply.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 180, "completion_tokens": 1056, "total_tokens": 1236, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 960, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 4, "sentence": "KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of PARPi agents available (olaparib, niraparib, rucaparib, and talazoparib) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.", "subject": {"text": "niraparib", "class": "Chemical", "start": 107, "end": 116, "ids": [], "id": "Chemical:niraparib"}, "object": {"text": "olaparib", "class": "Chemical", "start": 97, "end": 105, "ids": [], "id": "Chemical:olaparib"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of PARPi agents available ([OBJ]olaparib[/OBJ], niraparib, [SUBJ]rucaparib[/SUBJ], and talazoparib) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJD4zanDWAuT46kkaBElgSvyDV", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.65,\n  \"explanation\": \"The sentence reports that PARP inhibitors prolong overall survival in metastatic CRPC, particularly in BRCA1/2 mutations, as monotherapy. None of the allowed predicates (synergizes_with, overcomes_resistance_with, sequential_therapy_after) describe this monotherapy efficacy or OS outcome.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 180, "completion_tokens": 988, "total_tokens": 1168, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 896, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 4, "sentence": "KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of PARPi agents available (olaparib, niraparib, rucaparib, and talazoparib) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.", "subject": {"text": "rucaparib", "class": "Chemical", "start": 118, "end": 127, "ids": [], "id": "Chemical:rucaparib"}, "object": {"text": "olaparib", "class": "Chemical", "start": 97, "end": 105, "ids": [], "id": "Chemical:olaparib"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: By analysis of experimental and public clinical data, we identified new [OBJ]UC[/OBJ]-specific PARPi response predictors SLFN5, SLFN11, and [SUBJ]OAS1[/SUBJ].\nAllowed predicates:\n- prognostic_biomarker_in: Gene predicts outcome in specific cancer subtype. Specify ER+, TNBC, HER2+, and validation level.\n\n- predictive_biomarker_for: Gene predicts treatment response in cancer subtype. Distinguish from prognostic biomarkers. Specify FDA-approved/investigational status.\n\n- driver_in: Gene drives oncogenesis in specific cancer subtype. Requires evidence of causal role in tumor initiation or progression.\n\n- tumor_suppressor_in: Gene suppresses tumorigenesis in specific cancer subtype. Requires evidence of loss-of-function leading to cancer.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJ5H18PdoOpd59Yhoy7kuagmA7", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\"predicate\": \"predictive_biomarker_for\", \"confidence\": 0.86, \"explanation\": \"The sentence calls SLFN5, SLFN11, and OAS1 'PARPi response predictors' specific to UC (urothelial carcinoma), indicating they predict treatment response to PARP inhibitors. This aligns with a predictive biomarker for a cancer subtype rather than a prognostic, driver, or tumor-suppressor role.\"}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 207, "completion_tokens": 1060, "total_tokens": 1267, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 960, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41216708", "sentence_id": 5, "sentence": "By analysis of experimental and public clinical data, we identified new UC-specific PARPi response predictors SLFN5, SLFN11, and OAS1.", "subject": {"text": "OAS1", "class": "Gene", "start": 120, "end": 123, "ids": [], "id": "Gene:oas1"}, "object": {"text": "UC", "class": "Disease", "start": 63, "end": 64, "ids": [], "id": "Disease:uc"}, "predicate_names": ["prognostic_biomarker_in", "predictive_biomarker_for", "driver_in", "tumor_suppressor_in"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: CONCLUSIONS AND CLINICAL IMPLICATIONS: Promising results have led to the approval of several PARPi agents as monotherapy or in combination with [SUBJ]ARPIs[/SUBJ] in selected or unselected patients when [OBJ]chemotherapy[/OBJ] is not clinically indicated.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJG40awW6kqWwffOCUddKJflgK", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.0,\n  \"explanation\": \"The sentence notes PARP inhibitors are used as monotherapy or in combination with ARPIs when chemotherapy is not indicated, but it does not state a synergistic effect, resistance overcoming, or sequential therapy.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 164, "completion_tokens": 1098, "total_tokens": 1262, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1024, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 7, "sentence": "CONCLUSIONS AND CLINICAL IMPLICATIONS: Promising results have led to the approval of several PARPi agents as monotherapy or in combination with ARPIs in selected or unselected patients when chemotherapy is not clinically indicated.", "subject": {"text": "ARPIs", "class": "Chemical", "start": 144, "end": 149, "ids": [], "id": "Chemical:arpis"}, "object": {"text": "chemotherapy", "class": "Chemical", "start": 190, "end": 202, "ids": [], "id": "Chemical:chemotherapy"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of PARPi agents available ([OBJ]olaparib[/OBJ], niraparib, rucaparib, and talazoparib) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying [SUBJ]BRCA1/2 mutations[/SUBJ].\nAllowed predicates:\n- sensitizes_to: Gene/protein or mutation increases vulnerability to chemical/drug. Include biomarker status if validated.\n\n- predicts_response_to: Gene or mutation status predicts treatment response. Specify FDA-approved/investigational biomarker status when applicable.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJYSCc88r2r1eqZcktd4n9ypku", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\"predicate\":\"sensitizes_to\",\"confidence\":0.72,\"explanation\":\"BRCA1/2 mutations create vulnerability to PARP inhibitors, and the sentence notes that patients with these mutations derive especially prolonged OS from PARPi therapy, consistent with sensitization to the drug.\"}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 177, "completion_tokens": 962, "total_tokens": 1139, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 896, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 4, "sentence": "KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of PARPi agents available (olaparib, niraparib, rucaparib, and talazoparib) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.", "subject": {"text": "BRCA1/2 mutations", "class": "Mutation", "start": 259, "end": 276, "ids": [], "id": "Mutation:brca1_2_mutations"}, "object": {"text": "olaparib", "class": "Chemical", "start": 97, "end": 105, "ids": [], "id": "Chemical:olaparib"}, "predicate_names": ["sensitizes_to", "predicts_response_to"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of PARPi agents available (olaparib, niraparib, [OBJ]rucaparib[/OBJ], and [SUBJ]talazoparib[/SUBJ]) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJEEMWdbIYwUtuYvncJBVSLozn", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.65,\n  \"explanation\": \"The sentence reports that PARP inhibitors prolong overall survival in metastatic CRPC, particularly in BRCA1/2 mutation carriers. None of the provided predicates (synergizes_with, overcomes_resistance_with, sequential_therapy_after) capture this direct efficacy outcome.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 181, "completion_tokens": 918, "total_tokens": 1099, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 832, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 4, "sentence": "KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of PARPi agents available (olaparib, niraparib, rucaparib, and talazoparib) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.", "subject": {"text": "talazoparib", "class": "Chemical", "start": 133, "end": 144, "ids": [], "id": "Chemical:talazoparib"}, "object": {"text": "rucaparib", "class": "Chemical", "start": 118, "end": 127, "ids": [], "id": "Chemical:rucaparib"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Clinical trials with PARP inhibitors ([SUBJ]PARPi[/SUBJ]), particularly in [OBJ]Cisplatin[/OBJ]-treated UC, yielded limited response.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJy9RmXVPOED4v01NG5Oua9k5p", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.25,\n  \"explanation\": \"The sentence describes limited response to PARP inhibitors in Cisplatin-treated urothelial carcinoma and does not indicate synergy, overcoming resistance, or sequential therapy as defined by the allowed predicates.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 138, "completion_tokens": 1094, "total_tokens": 1232, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1024, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41216708", "sentence_id": 1, "sentence": "Clinical trials with PARP inhibitors (PARPi), particularly in Cisplatin-treated UC, yielded limited response.", "subject": {"text": "PARPi", "class": "Chemical", "start": 38, "end": 43, "ids": [], "id": "Chemical:parpi"}, "object": {"text": "Cisplatin", "class": "Chemical", "start": 62, "end": 71, "ids": [], "id": "Chemical:cisplatin"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of [OBJ]PARPi[/OBJ] agents available (olaparib, niraparib, [SUBJ]rucaparib[/SUBJ], and talazoparib) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJnZm1auk5NZPx64v3J9nH7ai0", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.75,\n  \"explanation\": \"The sentence describes phase 3 data showing PARP inhibitors prolong overall survival in metastatic CRPC, particularly in BRCA1/2 mutation carriers. It does not mention synergistic drug combinations, overcoming resistance with a combination, or sequential therapy after progression.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 182, "completion_tokens": 788, "total_tokens": 970, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 704, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 4, "sentence": "KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of PARPi agents available (olaparib, niraparib, rucaparib, and talazoparib) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.", "subject": {"text": "rucaparib", "class": "Chemical", "start": 118, "end": 127, "ids": [], "id": "Chemical:rucaparib"}, "object": {"text": "PARPi", "class": "Chemical", "start": 73, "end": 78, "ids": [], "id": "Chemical:parpi"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of PARPi agents available (olaparib, niraparib, [OBJ]rucaparib[/OBJ], and talazoparib) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying [SUBJ]BRCA1/2 mutations[/SUBJ].\nAllowed predicates:\n- sensitizes_to: Gene/protein or mutation increases vulnerability to chemical/drug. Include biomarker status if validated.\n\n- predicts_response_to: Gene or mutation status predicts treatment response. Specify FDA-approved/investigational biomarker status when applicable.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJY3LiQLz2mkBPOo8c941B5g8m", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"predicts_response_to\",\n  \"confidence\": 0.76,\n  \"explanation\": \"The sentence indicates that PARP inhibitors prolong OS particularly in patients with BRCA1/2 mutations, implying that BRCA1/2 mutation status predicts response to PARP inhibitor therapy (a predictive biomarker).\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 178, "completion_tokens": 911, "total_tokens": 1089, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 832, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 4, "sentence": "KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of PARPi agents available (olaparib, niraparib, rucaparib, and talazoparib) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.", "subject": {"text": "BRCA1/2 mutations", "class": "Mutation", "start": 259, "end": 276, "ids": [], "id": "Mutation:brca1_2_mutations"}, "object": {"text": "rucaparib", "class": "Chemical", "start": 118, "end": 127, "ids": [], "id": "Chemical:rucaparib"}, "predicate_names": ["sensitizes_to", "predicts_response_to"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Clinical trials with [OBJ]PARP inhibitors[/OBJ] (PARPi), particularly in [SUBJ]Cisplatin[/SUBJ]-treated UC, yielded limited response.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJ3iCLxjVx4vjWZQPjOFiXMZyF", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none_of_the_above\",\n  \"confidence\": 0.60,\n  \"explanation\": \"The sentence reports limited response to PARP inhibitors in cisplatin-treated urothelial carcinoma and does not indicate synergy, overcoming resistance, or sequential therapy between chemicals.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 140, "completion_tokens": 966, "total_tokens": 1106, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 896, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41216708", "sentence_id": 1, "sentence": "Clinical trials with PARP inhibitors (PARPi), particularly in Cisplatin-treated UC, yielded limited response.", "subject": {"text": "Cisplatin", "class": "Chemical", "start": 62, "end": 71, "ids": [], "id": "Chemical:cisplatin"}, "object": {"text": "PARP inhibitors", "class": "Chemical", "start": 21, "end": 36, "ids": [], "id": "Chemical:parp_inhibitors"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: METHODS: We reviewed the literature on [SUBJ]PARPi[/SUBJ] treatment for [OBJ]CRPC[/OBJ] and provide a narrative synthesis of the evidence for the rapidly evolving treatment landscape in this setting.\nAllowed predicates:\n- approved_for: FDA/EMA approved for cancer subtype. Specify line of therapy and combination/monotherapy.\n\n- in_trials_for: In clinical trials. Specify phase I/II/III and NCT number if available.\n\n- resistance_emerges_in: Resistance commonly emerges in disease. Specify median time to resistance and frequency.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HIz0LyC9I743KYI4LDcZcdxAE0", "object": "chat.completion", "created": 1763442648, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.55,\n  \"explanation\": \"The sentence describes a methods section with a literature review on PARPi treatment for CRPC and a narrative synthesis of evidence. It does not state approval status, trial status, or resistance data, so none of the provided predicates (approved_for, in_trials_for, resistance_emerges_in) directly apply.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 160, "completion_tokens": 1117, "total_tokens": 1277, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1024, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 3, "sentence": "METHODS: We reviewed the literature on PARPi treatment for CRPC and provide a narrative synthesis of the evidence for the rapidly evolving treatment landscape in this setting.", "subject": {"text": "PARPi", "class": "Chemical", "start": 39, "end": 43, "ids": [], "id": "Chemical:parpi"}, "object": {"text": "CRPC", "class": "Disease", "start": 59, "end": 62, "ids": [], "id": "Disease:crpc"}, "predicate_names": ["approved_for", "in_trials_for", "resistance_emerges_in"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: CONCLUSIONS AND CLINICAL IMPLICATIONS: Promising results have led to the approval of several PARPi agents as monotherapy or in combination with [OBJ]ARPIs[/OBJ] in selected or unselected patients when [SUBJ]chemotherapy[/SUBJ] is not clinically indicated.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJH9tZxT3RxpfoJF2dMVtUmEEG", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"synergizes_with\",\n  \"confidence\": 0.6,\n  \"explanation\": \"The sentence describes PARP inhibitors used in combination with ARPIs, implying a synergistic combination therapy option when chemotherapy is not indicated. It does not mention overcoming resistance or sequential therapy.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 164, "completion_tokens": 1033, "total_tokens": 1197, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 960, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 7, "sentence": "CONCLUSIONS AND CLINICAL IMPLICATIONS: Promising results have led to the approval of several PARPi agents as monotherapy or in combination with ARPIs in selected or unselected patients when chemotherapy is not clinically indicated.", "subject": {"text": "chemotherapy", "class": "Chemical", "start": 190, "end": 202, "ids": [], "id": "Chemical:chemotherapy"}, "object": {"text": "ARPIs", "class": "Chemical", "start": 144, "end": 149, "ids": [], "id": "Chemical:arpis"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of PARPi agents available (olaparib, niraparib, rucaparib, and [OBJ]talazoparib[/OBJ]) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying [SUBJ]BRCA1/2 mutations[/SUBJ].\nAllowed predicates:\n- sensitizes_to: Gene/protein or mutation increases vulnerability to chemical/drug. Include biomarker status if validated.\n\n- predicts_response_to: Gene or mutation status predicts treatment response. Specify FDA-approved/investigational biomarker status when applicable.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJVvBe63YaliOJpKP0jSCIVeoU", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"predicts_response_to\",\n  \"confidence\": 0.78,\n  \"explanation\": \"BRCA1/2 mutation status is associated with greater efficacy of PARP inhibitors in metastatic CRPC, indicating the mutation predicts response to PARP inhibitor therapy.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 178, "completion_tokens": 900, "total_tokens": 1078, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 832, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 4, "sentence": "KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of PARPi agents available (olaparib, niraparib, rucaparib, and talazoparib) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.", "subject": {"text": "BRCA1/2 mutations", "class": "Mutation", "start": 259, "end": 276, "ids": [], "id": "Mutation:brca1_2_mutations"}, "object": {"text": "talazoparib", "class": "Chemical", "start": 133, "end": 144, "ids": [], "id": "Chemical:talazoparib"}, "predicate_names": ["sensitizes_to", "predicts_response_to"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of PARPi agents available ([OBJ]olaparib[/OBJ], niraparib, rucaparib, and [SUBJ]talazoparib[/SUBJ]) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJ3G97GiW7KZgaCZYDE0vhmmwW", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.65,\n  \"explanation\": \"The sentence reports that PARP inhibitors prolong overall survival in metastatic CRPC, especially in BRCA1/2-mutant patients. It does not mention synergy with another agent, overcoming resistance via combination therapy, or sequential therapy after progression, so none of the allowed predicates apply.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 180, "completion_tokens": 984, "total_tokens": 1164, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 896, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 4, "sentence": "KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of PARPi agents available (olaparib, niraparib, rucaparib, and talazoparib) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.", "subject": {"text": "talazoparib", "class": "Chemical", "start": 133, "end": 144, "ids": [], "id": "Chemical:talazoparib"}, "object": {"text": "olaparib", "class": "Chemical", "start": 97, "end": 105, "ids": [], "id": "Chemical:olaparib"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of [OBJ]PARPi[/OBJ] agents available (olaparib, [SUBJ]niraparib[/SUBJ], rucaparib, and talazoparib) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJY0AGOQqa0sEG9GOb72r6mgIM", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"not_applicable\",\n  \"confidence\": 0.8,\n  \"explanation\": \"The sentence reports phase 3 studies showing PARP inhibitors prolong OS in metastatic CRPC, especially in BRCA1/2-mutant patients. It does not describe synergy with another agent, overcoming resistance to monotherapy, or sequential therapy after progression.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 182, "completion_tokens": 917, "total_tokens": 1099, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 832, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 4, "sentence": "KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of PARPi agents available (olaparib, niraparib, rucaparib, and talazoparib) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.", "subject": {"text": "niraparib", "class": "Chemical", "start": 107, "end": 116, "ids": [], "id": "Chemical:niraparib"}, "object": {"text": "PARPi", "class": "Chemical", "start": 73, "end": 78, "ids": [], "id": "Chemical:parpi"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: However, response to [OBJ]PARPi[/OBJ] seems to vary depending on the genes altered, with a greater benefit for patients with mutations in genes encoding the repair effector proteins BRCA1/2, CDK12, and [SUBJ]PALB2[/SUBJ].\nAllowed predicates:\n- confers_resistance_to: Gene/protein mediates resistance to chemical/drug with specified mechanism and context (intrinsic/acquired, cancer type, fold-change).\n\n- sensitizes_to: Gene/protein or mutation increases vulnerability to chemical/drug. Include biomarker status if validated.\n\n- predicts_response_to: Gene or mutation status predicts treatment response. Specify FDA-approved/investigational biomarker status when applicable.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJsRQuYquUXz5atagLyNjKlzl1", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"predicts_response_to\",\n  \"confidence\": 0.82,\n  \"explanation\": \"The sentence indicates that the response to PARP inhibitors varies with gene alterations and that mutations in BRCA1/2, CDK12, and PALB2 are associated with greater benefit, which describes mutations as predictive biomarkers of PARPi response.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 193, "completion_tokens": 1109, "total_tokens": 1302, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1024, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 6, "sentence": "However, response to PARPi seems to vary depending on the genes altered, with a greater benefit for patients with mutations in genes encoding the repair effector proteins BRCA1/2, CDK12, and PALB2.", "subject": {"text": "PALB2", "class": "Gene", "start": 191, "end": 195, "ids": [], "id": "Gene:palb2"}, "object": {"text": "PARPi", "class": "Chemical", "start": 21, "end": 25, "ids": [], "id": "Chemical:parpi"}, "predicate_names": ["confers_resistance_to", "sensitizes_to", "predicts_response_to"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: The [OBJ]Talazoparib[/OBJ] + [SUBJ]PLX51107[/SUBJ] combination had a strong synergistic impact on UC cells and organoids, including Cisplatin-resistant cells, allowing dose reduction to spare benign cells.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJIJvUfhMhhQhUIw2i097N6ITL", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"synergizes_with\",\n  \"confidence\": 0.85,\n  \"explanation\": \"The sentence states that the Talazoparib + PLX51107 combination had a strong synergistic impact on UC cells and organoids (including cisplatin-resistant cells), which directly matches a synergistic interaction between the two chemicals within a specific cancer model.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 157, "completion_tokens": 1242, "total_tokens": 1399, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1152, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41216708", "sentence_id": 7, "sentence": "The Talazoparib + PLX51107 combination had a strong synergistic impact on UC cells and organoids, including Cisplatin-resistant cells, allowing dose reduction to spare benign cells.", "subject": {"text": "PLX51107", "class": "Chemical", "start": 18, "end": 26, "ids": [], "id": "Chemical:plx51107"}, "object": {"text": "Talazoparib", "class": "Chemical", "start": 4, "end": 15, "ids": [], "id": "Chemical:talazoparib"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: By analysis of experimental and public clinical data, we identified new UC-specific PARPi response predictors [SUBJ]SLFN5[/SUBJ], SLFN11, and [OBJ]OAS1[/OBJ].\nAllowed predicates:\n- physically_interacts_with: Protein-protein interaction. Specify method of detection and binding affinity if known.\n\n- co_expressed_with: Genes show correlated expression across samples. Include correlation coefficient and context.\n\n- synthetic_lethal_with: Combined inhibition is lethal in specific cancer context. Requires functional validation.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJRNrp30mfaocJNDYodNSP99dr", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.60,\n  \"explanation\": \"The sentence identifies SLFN5, SLFN11, and OAS1 as predictors of PARP inhibitor (PARPi) response in urothelial cancer, which describes predictive biomarkers or associations with drug response. None of the allowed predicates (physically_interacts_with, co_expressed_with, synthetic_lethal_with) directly capture a biomarker or predictor relationship for a drug response.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 152, "completion_tokens": 1070, "total_tokens": 1222, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 960, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41216708", "sentence_id": 5, "sentence": "By analysis of experimental and public clinical data, we identified new UC-specific PARPi response predictors SLFN5, SLFN11, and OAS1.", "subject": {"text": "SLFN5", "class": "Gene", "start": 101, "end": 105, "ids": [], "id": "Gene:slfn5"}, "object": {"text": "OAS1", "class": "Gene", "start": 120, "end": 123, "ids": [], "id": "Gene:oas1"}, "predicate_names": ["physically_interacts_with", "co_expressed_with", "synthetic_lethal_with"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: In conclusion, we suggest [OBJ]Talazoparib[/OBJ] treatment of UC to be highly efficacious on all models examined when combined with [SUBJ]PLX51107[/SUBJ].\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HO0mC0nH3ohrn9qBLQwnMj9KrK", "object": "chat.completion", "created": 1763442654, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"synergizes_with\",\n  \"confidence\": 0.82,\n  \"explanation\": \"The sentence states that Talazoparib is highly efficacious when combined with PLX51107 in UC models, indicating a synergistic interaction between the two chemicals.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 146, "completion_tokens": 582, "total_tokens": 728, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 512, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41216708", "sentence_id": 9, "sentence": "In conclusion, we suggest Talazoparib treatment of UC to be highly efficacious on all models examined when combined with PLX51107.", "subject": {"text": "PLX51107", "class": "Chemical", "start": 121, "end": 129, "ids": [], "id": "Chemical:plx51107"}, "object": {"text": "Talazoparib", "class": "Chemical", "start": 26, "end": 37, "ids": [], "id": "Chemical:talazoparib"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: BACKGROUND AND INTRODUCTION: Over the past 15\u00a0yr, significant progress has been made in the management of [OBJ]prostate cancer[/OBJ] (PC), including the development of chemotherapy, androgen receptor pathway inhibitors (ARPIs), and, more recently, [SUBJ]radium-223[/SUBJ] radioligand therapy.\nAllowed predicates:\n- approved_for: FDA/EMA approved for cancer subtype. Specify line of therapy and combination/monotherapy.\n\n- in_trials_for: In clinical trials. Specify phase I/II/III and NCT number if available.\n\n- resistance_emerges_in: Resistance commonly emerges in disease. Specify median time to resistance and frequency.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HIaoltqNHdEGwct1ZMfs7wk8BU", "object": "chat.completion", "created": 1763442648, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"approved_for\",\n  \"confidence\": 0.75,\n  \"explanation\": \"Radium-223 radioligand therapy is FDA-approved for metastatic castration-resistant prostate cancer with symptomatic bone metastases as a monotherapy; the sentence describes radium-223 as a management option for prostate cancer, consistent with an approved_for relation.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 187, "completion_tokens": 1045, "total_tokens": 1232, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 960, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 0, "sentence": "BACKGROUND AND INTRODUCTION: Over the past 15\u00a0yr, significant progress has been made in the management of prostate cancer (PC), including the development of chemotherapy, androgen receptor pathway inhibitors (ARPIs), and, more recently, radium-223 radioligand therapy.", "subject": {"text": "radium-223", "class": "Chemical", "start": 236, "end": 246, "ids": [], "id": "Chemical:radium_223"}, "object": {"text": "prostate cancer", "class": "Disease", "start": 106, "end": 121, "ids": [], "id": "Disease:prostate_cancer"}, "predicate_names": ["approved_for", "in_trials_for", "resistance_emerges_in"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: To identify the most suitable PARPi for [OBJ]UC[/OBJ], we compared Olaparib with [SUBJ]Talazoparib[/SUBJ].\nAllowed predicates:\n- approved_for: FDA/EMA approved for cancer subtype. Specify line of therapy and combination/monotherapy.\n\n- in_trials_for: In clinical trials. Specify phase I/II/III and NCT number if available.\n\n- resistance_emerges_in: Resistance commonly emerges in disease. Specify median time to resistance and frequency.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJqXYc5EILo1ZvyCSeMz4unPku", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"not_applicable\",\n  \"confidence\": 0.85,\n  \"explanation\": \"The sentence only notes a comparison between Olaparib and Talazoparib to identify the most suitable PARPi for UC, without stating approval status, current trials, or resistance data.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 149, "completion_tokens": 1161, "total_tokens": 1310, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1088, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41216708", "sentence_id": 3, "sentence": "To identify the most suitable PARPi for UC, we compared Olaparib with Talazoparib.", "subject": {"text": "Talazoparib", "class": "Chemical", "start": 70, "end": 81, "ids": [], "id": "Chemical:talazoparib"}, "object": {"text": "UC", "class": "Disease", "start": 40, "end": 42, "ids": [], "id": "Disease:uc"}, "predicate_names": ["approved_for", "in_trials_for", "resistance_emerges_in"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: By analysis of experimental and public clinical data, we identified new UC-specific [OBJ]PARPi[/OBJ] response predictors SLFN5, SLFN11, and [SUBJ]OAS1[/SUBJ].\nAllowed predicates:\n- confers_resistance_to: Gene/protein mediates resistance to chemical/drug with specified mechanism and context (intrinsic/acquired, cancer type, fold-change).\n\n- sensitizes_to: Gene/protein or mutation increases vulnerability to chemical/drug. Include biomarker status if validated.\n\n- predicts_response_to: Gene or mutation status predicts treatment response. Specify FDA-approved/investigational biomarker status when applicable.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJj84Aoz3D3KetNY5VIQVI67qV", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"predicts_response_to\",\n  \"confidence\": 0.85,\n  \"explanation\": \"The sentence identifies SLFN5, SLFN11, and OAS1 as UC-specific predictors of PARP inhibitor response, i.e., biomarkers that predict treatment response.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 178, "completion_tokens": 1158, "total_tokens": 1336, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1088, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41216708", "sentence_id": 5, "sentence": "By analysis of experimental and public clinical data, we identified new UC-specific PARPi response predictors SLFN5, SLFN11, and OAS1.", "subject": {"text": "OAS1", "class": "Gene", "start": 120, "end": 123, "ids": [], "id": "Gene:oas1"}, "object": {"text": "PARPi", "class": "Chemical", "start": 75, "end": 79, "ids": [], "id": "Chemical:parpi"}, "predicate_names": ["confers_resistance_to", "sensitizes_to", "predicts_response_to"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: However, response to PARPi seems to vary depending on the genes altered, with a greater benefit for patients with mutations in genes encoding the repair effector proteins [OBJ]BRCA1/2[/OBJ], CDK12, and [SUBJ]PALB2[/SUBJ].\nAllowed predicates:\n- physically_interacts_with: Protein-protein interaction. Specify method of detection and binding affinity if known.\n\n- co_expressed_with: Genes show correlated expression across samples. Include correlation coefficient and context.\n\n- synthetic_lethal_with: Combined inhibition is lethal in specific cancer context. Requires functional validation.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJ2o0SD2qjCKXIui8duAnQMisM", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"synthetic_lethal_with\",\n  \"confidence\": 0.8,\n  \"explanation\": \"The sentence links PARP inhibitor response to mutations in HR repair genes (BRCA1/2, PALB2, CDK12), consistent with synthetic lethality between PARP inhibition and HR deficiency. The predicate synthetic_lethal_with captures this gene\u2013drug interaction, though such findings typically require functional validation in specific cancer contexts.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 167, "completion_tokens": 1319, "total_tokens": 1486, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1216, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 6, "sentence": "However, response to PARPi seems to vary depending on the genes altered, with a greater benefit for patients with mutations in genes encoding the repair effector proteins BRCA1/2, CDK12, and PALB2.", "subject": {"text": "PALB2", "class": "Gene", "start": 191, "end": 195, "ids": [], "id": "Gene:palb2"}, "object": {"text": "BRCA1/2", "class": "Gene", "start": 171, "end": 177, "ids": [], "id": "Gene:brca1_2"}, "predicate_names": ["physically_interacts_with", "co_expressed_with", "synthetic_lethal_with"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: The [SUBJ]Talazoparib[/SUBJ] + [OBJ]PLX51107[/OBJ] combination had a strong synergistic impact on UC cells and organoids, including Cisplatin-resistant cells, allowing dose reduction to spare benign cells.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJlfT5xs3lgYSEgCxcFUNfj9Ch", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"synergizes_with\",\n  \"confidence\": 0.85,\n  \"explanation\": \"The sentence states that the Talazoparib + PLX51107 combination had a strong synergistic impact on UC cells and organoids, including cisplatin-resistant cells, which aligns with the 'synergizes_with' predicate describing a synergistic effect in a specific cancer model.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 157, "completion_tokens": 1246, "total_tokens": 1403, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1152, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41216708", "sentence_id": 7, "sentence": "The Talazoparib + PLX51107 combination had a strong synergistic impact on UC cells and organoids, including Cisplatin-resistant cells, allowing dose reduction to spare benign cells.", "subject": {"text": "Talazoparib", "class": "Chemical", "start": 4, "end": 15, "ids": [], "id": "Chemical:talazoparib"}, "object": {"text": "PLX51107", "class": "Chemical", "start": 18, "end": 26, "ids": [], "id": "Chemical:plx51107"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: CONCLUSIONS AND CLINICAL IMPLICATIONS: Promising results have led to the approval of several [OBJ]PARPi[/OBJ] agents as monotherapy or in combination with [SUBJ]ARPIs[/SUBJ] in selected or unselected patients when chemotherapy is not clinically indicated.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJ3kFOFRgERac6i8XXmHj3Mm9b", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"synergizes_with\",\n  \"confidence\": 0.65,\n  \"explanation\": \"The sentence notes PARP inhibitors (PARPi) being used in combination with ARPIs, implying a potential synergistic interaction in combination therapy.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 163, "completion_tokens": 1217, "total_tokens": 1380, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1152, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 7, "sentence": "CONCLUSIONS AND CLINICAL IMPLICATIONS: Promising results have led to the approval of several PARPi agents as monotherapy or in combination with ARPIs in selected or unselected patients when chemotherapy is not clinically indicated.", "subject": {"text": "ARPIs", "class": "Chemical", "start": 144, "end": 149, "ids": [], "id": "Chemical:arpis"}, "object": {"text": "PARPi", "class": "Chemical", "start": 93, "end": 98, "ids": [], "id": "Chemical:parpi"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: In conclusion, we suggest [SUBJ]Talazoparib[/SUBJ] treatment of UC to be highly efficacious on all models examined when combined with [OBJ]PLX51107[/OBJ].\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HO34LesRgYfDCWGdfGShGIkBSc", "object": "chat.completion", "created": 1763442654, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"synergizes_with\",\n  \"confidence\": 0.80,\n  \"explanation\": \"The sentence indicates that Talazoparib is highly efficacious when combined with PLX51107 across all UC models, which aligns with a synergistic interaction (combined effect greater than either alone) as defined for synergizes_with.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 146, "completion_tokens": 723, "total_tokens": 869, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 640, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41216708", "sentence_id": 9, "sentence": "In conclusion, we suggest Talazoparib treatment of UC to be highly efficacious on all models examined when combined with PLX51107.", "subject": {"text": "Talazoparib", "class": "Chemical", "start": 26, "end": 37, "ids": [], "id": "Chemical:talazoparib"}, "object": {"text": "PLX51107", "class": "Chemical", "start": 121, "end": 129, "ids": [], "id": "Chemical:plx51107"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of PARPi agents available ([SUBJ]olaparib[/SUBJ], niraparib, rucaparib, and talazoparib) for the treatment of [OBJ]metastatic CRPC[/OBJ] have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.\nAllowed predicates:\n- approved_for: FDA/EMA approved for cancer subtype. Specify line of therapy and combination/monotherapy.\n\n- in_trials_for: In clinical trials. Specify phase I/II/III and NCT number if available.\n\n- resistance_emerges_in: Resistance commonly emerges in disease. Specify median time to resistance and frequency.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJF34iEoZ5pVLKwQDdoQnhOqoX", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"in_trials_for\",\n  \"confidence\": 0.78,\n  \"explanation\": \"The sentence explicitly mentions Phase 3 studies evaluating the efficacy of PARP inhibitors for metastatic CRPC, indicating these agents are being tested in clinical trials for this indication rather than reporting regulatory approval.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 195, "completion_tokens": 1161, "total_tokens": 1356, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1088, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 4, "sentence": "KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of PARPi agents available (olaparib, niraparib, rucaparib, and talazoparib) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.", "subject": {"text": "olaparib", "class": "Chemical", "start": 97, "end": 105, "ids": [], "id": "Chemical:olaparib"}, "object": {"text": "metastatic CRPC", "class": "Disease", "start": 167, "end": 182, "ids": [], "id": "Disease:metastatic_crpc"}, "predicate_names": ["approved_for", "in_trials_for", "resistance_emerges_in"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: By analysis of experimental and public clinical data, we identified new UC-specific PARPi response predictors [OBJ]SLFN5[/OBJ], SLFN11, and [SUBJ]OAS1[/SUBJ].\nAllowed predicates:\n- physically_interacts_with: Protein-protein interaction. Specify method of detection and binding affinity if known.\n\n- co_expressed_with: Genes show correlated expression across samples. Include correlation coefficient and context.\n\n- synthetic_lethal_with: Combined inhibition is lethal in specific cancer context. Requires functional validation.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJr77lsqjdGrMxRT91xizPHvo4", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"not_applicable\",\n  \"confidence\": 0.35,\n  \"explanation\": \"The sentence designates SLFN5, SLFN11, and OAS1 as PARPi response predictors, but provides no evidence of physical interaction, co-expression, or synthetic lethality among them or with PARPi. Therefore none of the allowed predicates directly apply.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 152, "completion_tokens": 1240, "total_tokens": 1392, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1152, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41216708", "sentence_id": 5, "sentence": "By analysis of experimental and public clinical data, we identified new UC-specific PARPi response predictors SLFN5, SLFN11, and OAS1.", "subject": {"text": "OAS1", "class": "Gene", "start": 120, "end": 123, "ids": [], "id": "Gene:oas1"}, "object": {"text": "SLFN5", "class": "Gene", "start": 101, "end": 105, "ids": [], "id": "Gene:slfn5"}, "predicate_names": ["physically_interacts_with", "co_expressed_with", "synthetic_lethal_with"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of [OBJ]PARPi[/OBJ] agents available (olaparib, niraparib, rucaparib, and talazoparib) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying [SUBJ]BRCA1/2 mutations[/SUBJ].\nAllowed predicates:\n- sensitizes_to: Gene/protein or mutation increases vulnerability to chemical/drug. Include biomarker status if validated.\n\n- predicts_response_to: Gene or mutation status predicts treatment response. Specify FDA-approved/investigational biomarker status when applicable.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJZDS2vg1ovsh0cKn2LL2vLXsk", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"predicts_response_to\",\n  \"confidence\": 0.85,\n  \"explanation\": \"BRCA1/2 mutation status is associated with greater efficacy of PARP inhibitors in metastatic CRPC; phase 3 trials show prolonged OS especially in BRCA1/2 mutation carriers, indicating mutation status predicts treatment response.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 179, "completion_tokens": 1361, "total_tokens": 1540, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1280, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 4, "sentence": "KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of PARPi agents available (olaparib, niraparib, rucaparib, and talazoparib) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.", "subject": {"text": "BRCA1/2 mutations", "class": "Mutation", "start": 259, "end": 276, "ids": [], "id": "Mutation:brca1_2_mutations"}, "object": {"text": "PARPi", "class": "Chemical", "start": 73, "end": 78, "ids": [], "id": "Chemical:parpi"}, "predicate_names": ["sensitizes_to", "predicts_response_to"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: However, response to [OBJ]PARPi[/OBJ] seems to vary depending on the genes altered, with a greater benefit for patients with mutations in genes encoding the repair effector proteins BRCA1/2, [SUBJ]CDK12[/SUBJ], and PALB2.\nAllowed predicates:\n- confers_resistance_to: Gene/protein mediates resistance to chemical/drug with specified mechanism and context (intrinsic/acquired, cancer type, fold-change).\n\n- sensitizes_to: Gene/protein or mutation increases vulnerability to chemical/drug. Include biomarker status if validated.\n\n- predicts_response_to: Gene or mutation status predicts treatment response. Specify FDA-approved/investigational biomarker status when applicable.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJ2EacdLsqCSjVoH5A5WquOUBm", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"predicts_response_to\",\n  \"confidence\": 0.76,\n  \"explanation\": \"Mutations in BRCA1/2, CDK12, and PALB2 are linked to greater benefit from PARPi, suggesting that gene alteration status predicts treatment response.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 193, "completion_tokens": 1159, "total_tokens": 1352, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1088, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 6, "sentence": "However, response to PARPi seems to vary depending on the genes altered, with a greater benefit for patients with mutations in genes encoding the repair effector proteins BRCA1/2, CDK12, and PALB2.", "subject": {"text": "CDK12", "class": "Gene", "start": 180, "end": 184, "ids": [], "id": "Gene:cdk12"}, "object": {"text": "PARPi", "class": "Chemical", "start": 21, "end": 25, "ids": [], "id": "Chemical:parpi"}, "predicate_names": ["confers_resistance_to", "sensitizes_to", "predicts_response_to"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: By analysis of experimental and public clinical data, we identified new [OBJ]UC[/OBJ]-specific PARPi response predictors [SUBJ]SLFN5[/SUBJ], SLFN11, and OAS1.\nAllowed predicates:\n- prognostic_biomarker_in: Gene predicts outcome in specific cancer subtype. Specify ER+, TNBC, HER2+, and validation level.\n\n- predictive_biomarker_for: Gene predicts treatment response in cancer subtype. Distinguish from prognostic biomarkers. Specify FDA-approved/investigational status.\n\n- driver_in: Gene drives oncogenesis in specific cancer subtype. Requires evidence of causal role in tumor initiation or progression.\n\n- tumor_suppressor_in: Gene suppresses tumorigenesis in specific cancer subtype. Requires evidence of loss-of-function leading to cancer.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJaPHK6lrp8KbyHFIdnuEOCqtG", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"predictive_biomarker_for\",\n  \"confidence\": 0.86,\n  \"explanation\": \"The sentence identifies SLFN5, SLFN11, and OAS1 as urothelial carcinoma (UC)-specific predictors of PARP inhibitor (PARPi) response, i.e., predictive biomarkers for PARPi treatment response in UC. The status is investigational (not stated as FDA-approved).\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 207, "completion_tokens": 1251, "total_tokens": 1458, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1152, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41216708", "sentence_id": 5, "sentence": "By analysis of experimental and public clinical data, we identified new UC-specific PARPi response predictors SLFN5, SLFN11, and OAS1.", "subject": {"text": "SLFN5", "class": "Gene", "start": 101, "end": 105, "ids": [], "id": "Gene:slfn5"}, "object": {"text": "UC", "class": "Disease", "start": 63, "end": 64, "ids": [], "id": "Disease:uc"}, "predicate_names": ["prognostic_biomarker_in", "predictive_biomarker_for", "driver_in", "tumor_suppressor_in"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: However, response to PARPi seems to vary depending on the genes altered, with a greater benefit for patients with mutations in genes encoding the repair effector proteins [SUBJ]BRCA1/2[/SUBJ], CDK12, and [OBJ]PALB2[/OBJ].\nAllowed predicates:\n- physically_interacts_with: Protein-protein interaction. Specify method of detection and binding affinity if known.\n\n- co_expressed_with: Genes show correlated expression across samples. Include correlation coefficient and context.\n\n- synthetic_lethal_with: Combined inhibition is lethal in specific cancer context. Requires functional validation.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJDRpFfdhD8EJjn4z80pdvJYvN", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"synthetic_lethal_with\",\n  \"confidence\": 0.77,\n  \"explanation\": \"The sentence discusses differential response to PARP inhibitors based on mutations in DNA repair genes (BRCA1/2, PALB2), which is consistent with the concept that PARP inhibition is synthetically lethal with BRCA/PALB2 repair defects. There is no evidence of physical protein-protein interaction or gene co-expression in the sentence.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 167, "completion_tokens": 1387, "total_tokens": 1554, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1280, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 6, "sentence": "However, response to PARPi seems to vary depending on the genes altered, with a greater benefit for patients with mutations in genes encoding the repair effector proteins BRCA1/2, CDK12, and PALB2.", "subject": {"text": "BRCA1/2", "class": "Gene", "start": 171, "end": 177, "ids": [], "id": "Gene:brca1_2"}, "object": {"text": "PALB2", "class": "Gene", "start": 191, "end": 195, "ids": [], "id": "Gene:palb2"}, "predicate_names": ["physically_interacts_with", "co_expressed_with", "synthetic_lethal_with"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Clinical trials with [SUBJ]PARP inhibitors[/SUBJ] ([OBJ]PARPi[/OBJ]), particularly in Cisplatin-treated UC, yielded limited response.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJozxO6ez9edWKK0MYiXFVSaLr", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.6,\n  \"explanation\": \"The sentence only states that trials with PARP inhibitors in cisplatin-treated urothelial cancer yielded limited response. It does not indicate synergy with another agent, overcoming resistance to monotherapy, or sequential therapy effectiveness after progression. Therefore no provided predicate fits.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 137, "completion_tokens": 1364, "total_tokens": 1501, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1280, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41216708", "sentence_id": 1, "sentence": "Clinical trials with PARP inhibitors (PARPi), particularly in Cisplatin-treated UC, yielded limited response.", "subject": {"text": "PARP inhibitors", "class": "Chemical", "start": 21, "end": 36, "ids": [], "id": "Chemical:parp_inhibitors"}, "object": {"text": "PARPi", "class": "Chemical", "start": 38, "end": 43, "ids": [], "id": "Chemical:parpi"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Poly(ADP-ribose) polymerase (PARP) inhibitors ([SUBJ]PARPi[/SUBJ]) have attracted significant attention in [OBJ]triple negative breast cancer[/OBJ] (TNBC) treatment.\nAllowed predicates:\n- approved_for: FDA/EMA approved for cancer subtype. Specify line of therapy and combination/monotherapy.\n\n- in_trials_for: In clinical trials. Specify phase I/II/III and NCT number if available.\n\n- resistance_emerges_in: Resistance commonly emerges in disease. Specify median time to resistance and frequency.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HQEyze9dmtrplzTuFfb5JSJCDP", "object": "chat.completion", "created": 1763442656, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"in_trials_for\",\n  \"confidence\": 0.6,\n  \"explanation\": \"The sentence indicates PARP inhibitors are being considered in the treatment context of triple-negative breast cancer, implying relevance to clinical investigation or trials, but it does not specify approval status, trial phase, or results.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 162, "completion_tokens": 652, "total_tokens": 814, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 576, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 0, "sentence": "Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) have attracted significant attention in triple negative breast cancer (TNBC) treatment.", "subject": {"text": "PARPi", "class": "Chemical", "start": 49, "end": 54, "ids": [], "id": "Chemical:parpi"}, "object": {"text": "triple negative breast cancer", "class": "Disease", "start": 96, "end": 125, "ids": [], "id": "Disease:triple_negative_breast_cancer"}, "predicate_names": ["approved_for", "in_trials_for", "resistance_emerges_in"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: [SUBJ]Poly(ADP-ribose) polymerase[/SUBJ] (PARP) inhibitors ([OBJ]PARPi[/OBJ]) have attracted significant attention in triple negative breast cancer (TNBC) treatment.\nAllowed predicates:\n- confers_resistance_to: Gene/protein mediates resistance to chemical/drug with specified mechanism and context (intrinsic/acquired, cancer type, fold-change).\n\n- sensitizes_to: Gene/protein or mutation increases vulnerability to chemical/drug. Include biomarker status if validated.\n\n- predicts_response_to: Gene or mutation status predicts treatment response. Specify FDA-approved/investigational biomarker status when applicable.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HP01O3NWDqqJ4g3pn4pNrLQtVk", "object": "chat.completion", "created": 1763442655, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.75,\n  \"explanation\": \"The sentence only notes that PARP inhibitors have attracted attention in TNBC treatment. It does not claim resistance, sensitization, or predictive value regarding treatment response.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 180, "completion_tokens": 577, "total_tokens": 757, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 512, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 0, "sentence": "Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) have attracted significant attention in triple negative breast cancer (TNBC) treatment.", "subject": {"text": "Poly(ADP-ribose) polymerase", "class": "Gene", "start": 0, "end": 29, "ids": [], "id": "Gene:poly_adp_ribose_polymerase"}, "object": {"text": "PARPi", "class": "Chemical", "start": 49, "end": 54, "ids": [], "id": "Chemical:parpi"}, "predicate_names": ["confers_resistance_to", "sensitizes_to", "predicts_response_to"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: However, response to PARPi seems to vary depending on the genes altered, with a greater benefit for patients with mutations in genes encoding the repair effector proteins [OBJ]BRCA1/2[/OBJ], [SUBJ]CDK12[/SUBJ], and PALB2.\nAllowed predicates:\n- physically_interacts_with: Protein-protein interaction. Specify method of detection and binding affinity if known.\n\n- co_expressed_with: Genes show correlated expression across samples. Include correlation coefficient and context.\n\n- synthetic_lethal_with: Combined inhibition is lethal in specific cancer context. Requires functional validation.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJDE6cyEsUwjqb8K9WRaKMOqe7", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"synthetic_lethal_with\",\n  \"confidence\": 0.75,\n  \"explanation\": \"The sentence describes differential PARPi response based on mutations in HR repair genes (BRCA1/2, PALB2), which aligns with the synthetic lethal interaction between PARP inhibition and HR deficiency. Other predicates do not fit the context.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 167, "completion_tokens": 1365, "total_tokens": 1532, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1280, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 6, "sentence": "However, response to PARPi seems to vary depending on the genes altered, with a greater benefit for patients with mutations in genes encoding the repair effector proteins BRCA1/2, CDK12, and PALB2.", "subject": {"text": "CDK12", "class": "Gene", "start": 180, "end": 184, "ids": [], "id": "Gene:cdk12"}, "object": {"text": "BRCA1/2", "class": "Gene", "start": 171, "end": 177, "ids": [], "id": "Gene:brca1_2"}, "predicate_names": ["physically_interacts_with", "co_expressed_with", "synthetic_lethal_with"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: However, response to PARPi seems to vary depending on the genes altered, with a greater benefit for patients with mutations in genes encoding the repair effector proteins BRCA1/2, [OBJ]CDK12[/OBJ], and [SUBJ]PALB2[/SUBJ].\nAllowed predicates:\n- physically_interacts_with: Protein-protein interaction. Specify method of detection and binding affinity if known.\n\n- co_expressed_with: Genes show correlated expression across samples. Include correlation coefficient and context.\n\n- synthetic_lethal_with: Combined inhibition is lethal in specific cancer context. Requires functional validation.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJx6GetLURTWat6Ek5JL9UX4ea", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"synthetic_lethal_with\",\n  \"confidence\": 0.66,\n  \"explanation\": \"The sentence indicates that PARP inhibitor benefit is greater in tumors with mutations in BRCA1/2, CDK12, and PALB2. These genes are involved in homologous recombination repair, and PARP inhibitors exploit HR defects leading to cell death\u2014consistent with a synthetic-lethal interaction between PARP inhibition and these genetic alterations. Note that functional validation is often required.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 167, "completion_tokens": 1394, "total_tokens": 1561, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1280, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 6, "sentence": "However, response to PARPi seems to vary depending on the genes altered, with a greater benefit for patients with mutations in genes encoding the repair effector proteins BRCA1/2, CDK12, and PALB2.", "subject": {"text": "PALB2", "class": "Gene", "start": 191, "end": 195, "ids": [], "id": "Gene:palb2"}, "object": {"text": "CDK12", "class": "Gene", "start": 180, "end": 184, "ids": [], "id": "Gene:cdk12"}, "predicate_names": ["physically_interacts_with", "co_expressed_with", "synthetic_lethal_with"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Clinical trials with [SUBJ]PARP inhibitors[/SUBJ] (PARPi), particularly in [OBJ]Cisplatin[/OBJ]-treated UC, yielded limited response.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJjrCxoM8agC8cypoCDItVXuXH", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.6,\n  \"explanation\": \"The sentence does not express synergy, resistance overcoming, or sequential therapy after progression. It states that PARP inhibitors in cisplatin-treated urothelial carcinoma yielded limited response.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 140, "completion_tokens": 1412, "total_tokens": 1552, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1344, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41216708", "sentence_id": 1, "sentence": "Clinical trials with PARP inhibitors (PARPi), particularly in Cisplatin-treated UC, yielded limited response.", "subject": {"text": "PARP inhibitors", "class": "Chemical", "start": 21, "end": 36, "ids": [], "id": "Chemical:parp_inhibitors"}, "object": {"text": "Cisplatin", "class": "Chemical", "start": 62, "end": 71, "ids": [], "id": "Chemical:cisplatin"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Ataxia telangiectasia and Rad3-related (ATR) regulates genome integrity, and thus, the aberrant activation of ATR could play a significant role in the pathogenesis of [OBJ]TNBC[/OBJ] and be associated with [SUBJ]PARPi[/SUBJ] resistance in especially homologous recombinant deficiency tumors.\nAllowed predicates:\n- approved_for: FDA/EMA approved for cancer subtype. Specify line of therapy and combination/monotherapy.\n\n- in_trials_for: In clinical trials. Specify phase I/II/III and NCT number if available.\n\n- resistance_emerges_in: Resistance commonly emerges in disease. Specify median time to resistance and frequency.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HQTu1miWM1r2hcRvElQIxk3xUl", "object": "chat.completion", "created": 1763442656, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"resistance_emerges_in\",\n  \"confidence\": 0.78,\n  \"explanation\": \"The sentence mentions an association with PARP inhibitor (PARPi) resistance in homologous recombination-deficient tumors, which aligns with the concept that resistance emerges in the disease.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 183, "completion_tokens": 520, "total_tokens": 703, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 448, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 2, "sentence": "Ataxia telangiectasia and Rad3-related (ATR) regulates genome integrity, and thus, the aberrant activation of ATR could play a significant role in the pathogenesis of TNBC and be associated with PARPi resistance in especially homologous recombinant deficiency tumors.", "subject": {"text": "PARPi", "class": "Chemical", "start": 195, "end": 199, "ids": [], "id": "Chemical:parpi"}, "object": {"text": "TNBC", "class": "Disease", "start": 167, "end": 170, "ids": [], "id": "Disease:tnbc"}, "predicate_names": ["approved_for", "in_trials_for", "resistance_emerges_in"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: However, response to PARPi seems to vary depending on the genes altered, with a greater benefit for patients with mutations in genes encoding the repair effector proteins BRCA1/2, [SUBJ]CDK12[/SUBJ], and [OBJ]PALB2[/OBJ].\nAllowed predicates:\n- physically_interacts_with: Protein-protein interaction. Specify method of detection and binding affinity if known.\n\n- co_expressed_with: Genes show correlated expression across samples. Include correlation coefficient and context.\n\n- synthetic_lethal_with: Combined inhibition is lethal in specific cancer context. Requires functional validation.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJ1KOS06zLf6zkddBJkR1nij0V", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"synthetic_lethal_with\",\n  \"confidence\": 0.82,\n  \"explanation\": \"The sentence links PARP inhibitor response to mutations in DNA repair genes (BRCA1/2, CDK12, PALB2). PARP inhibitors are known to be synthetically lethal with defects in homologous recombination repair, so these mutations predict enhanced sensitivity\u2014consistent with the synthetic_lethal_with relation (though functional validation would be required).\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 167, "completion_tokens": 1260, "total_tokens": 1427, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1152, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 6, "sentence": "However, response to PARPi seems to vary depending on the genes altered, with a greater benefit for patients with mutations in genes encoding the repair effector proteins BRCA1/2, CDK12, and PALB2.", "subject": {"text": "CDK12", "class": "Gene", "start": 180, "end": 184, "ids": [], "id": "Gene:cdk12"}, "object": {"text": "PALB2", "class": "Gene", "start": 191, "end": 195, "ids": [], "id": "Gene:palb2"}, "predicate_names": ["physically_interacts_with", "co_expressed_with", "synthetic_lethal_with"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Studies on PARPi + ARPI combinations have shown longer radiological progression-free survival, and better OS with talazoparib + [OBJ]enzalutamide[/OBJ], regardless of mutational status for [SUBJ]DNA repair genes[/SUBJ], with synergistic activity identified.\nAllowed predicates:\n- confers_resistance_to: Gene/protein mediates resistance to chemical/drug with specified mechanism and context (intrinsic/acquired, cancer type, fold-change).\n\n- sensitizes_to: Gene/protein or mutation increases vulnerability to chemical/drug. Include biomarker status if validated.\n\n- predicts_response_to: Gene or mutation status predicts treatment response. Specify FDA-approved/investigational biomarker status when applicable.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJwHlIWNkyNAvkc8ZRkR49NoYS", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.56,\n  \"explanation\": \"The sentence describes improved outcomes with a drug combination and notes that this effect is irrespective of DNA repair gene mutational status, indicating no predictive or modulatory role attributed to the DNA repair gene status. It does not state that a gene confers resistance, sensitizes, or predicts response to the treatment.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 194, "completion_tokens": 1565, "total_tokens": 1759, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1472, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 5, "sentence": "Studies on PARPi + ARPI combinations have shown longer radiological progression-free survival, and better OS with talazoparib + enzalutamide, regardless of mutational status for DNA repair genes, with synergistic activity identified.", "subject": {"text": "DNA repair genes", "class": "Gene", "start": 178, "end": 194, "ids": [], "id": "Gene:dna_repair_genes"}, "object": {"text": "enzalutamide", "class": "Chemical", "start": 128, "end": 140, "ids": [], "id": "Chemical:enzalutamide"}, "predicate_names": ["confers_resistance_to", "sensitizes_to", "predicts_response_to"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: However, response to [OBJ]PARPi[/OBJ] seems to vary depending on the genes altered, with a greater benefit for patients with mutations in genes encoding the repair effector proteins [SUBJ]BRCA1/2[/SUBJ], CDK12, and PALB2.\nAllowed predicates:\n- confers_resistance_to: Gene/protein mediates resistance to chemical/drug with specified mechanism and context (intrinsic/acquired, cancer type, fold-change).\n\n- sensitizes_to: Gene/protein or mutation increases vulnerability to chemical/drug. Include biomarker status if validated.\n\n- predicts_response_to: Gene or mutation status predicts treatment response. Specify FDA-approved/investigational biomarker status when applicable.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJUOkftFUkCTCirsn273AsDywM", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"predicts_response_to\",\n  \"confidence\": 0.78,\n  \"explanation\": \"The sentence indicates that PARPi response varies with gene mutation status and identifies specific mutations associated with greater benefit, describing a biomarker that predicts treatment response.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 193, "completion_tokens": 1474, "total_tokens": 1667, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1408, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 6, "sentence": "However, response to PARPi seems to vary depending on the genes altered, with a greater benefit for patients with mutations in genes encoding the repair effector proteins BRCA1/2, CDK12, and PALB2.", "subject": {"text": "BRCA1/2", "class": "Gene", "start": 171, "end": 177, "ids": [], "id": "Gene:brca1_2"}, "object": {"text": "PARPi", "class": "Chemical", "start": 21, "end": 25, "ids": [], "id": "Chemical:parpi"}, "predicate_names": ["confers_resistance_to", "sensitizes_to", "predicts_response_to"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: CONCLUSIONS AND CLINICAL IMPLICATIONS: Promising results have led to the approval of several [SUBJ]PARPi[/SUBJ] agents as monotherapy or in combination with [OBJ]ARPIs[/OBJ] in selected or unselected patients when chemotherapy is not clinically indicated.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJfFZlCOOIXzYVzSSEmlmfVmgu", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"synergizes_with\",\n  \"confidence\": 0.65,\n  \"explanation\": \"The sentence mentions PARPi agents used in combination with ARPi, implying a beneficial interaction when used together, which aligns with a synergistic relationship.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 163, "completion_tokens": 1473, "total_tokens": 1636, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1408, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 7, "sentence": "CONCLUSIONS AND CLINICAL IMPLICATIONS: Promising results have led to the approval of several PARPi agents as monotherapy or in combination with ARPIs in selected or unselected patients when chemotherapy is not clinically indicated.", "subject": {"text": "PARPi", "class": "Chemical", "start": 93, "end": 98, "ids": [], "id": "Chemical:parpi"}, "object": {"text": "ARPIs", "class": "Chemical", "start": 144, "end": 149, "ids": [], "id": "Chemical:arpis"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Studies on PARPi + ARPI combinations have shown longer radiological progression-free survival, and better OS with talazoparib + [OBJ]enzalutamide[/OBJ], regardless of [SUBJ]mutational status[/SUBJ] for DNA repair genes, with synergistic activity identified.\nAllowed predicates:\n- sensitizes_to: Gene/protein or mutation increases vulnerability to chemical/drug. Include biomarker status if validated.\n\n- predicts_response_to: Gene or mutation status predicts treatment response. Specify FDA-approved/investigational biomarker status when applicable.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJOIGzLkDYO8iiLovX88OdNpqL", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"\",\n  \"confidence\": 0.55,\n  \"explanation\": \"The sentence describes improved outcomes from a drug combination and notes that this is independent of mutational status, but it does not claim that a specific gene/mutation sensitizes to a drug or that a gene/mutation predicts response. The provided predicates (sensitizes_to, predicts_response_to) do not capture the described relation.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 161, "completion_tokens": 1505, "total_tokens": 1666, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1408, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 5, "sentence": "Studies on PARPi + ARPI combinations have shown longer radiological progression-free survival, and better OS with talazoparib + enzalutamide, regardless of mutational status for DNA repair genes, with synergistic activity identified.", "subject": {"text": "mutational status", "class": "Mutation", "start": 156, "end": 173, "ids": [], "id": "Mutation:mutational_status"}, "object": {"text": "enzalutamide", "class": "Chemical", "start": 128, "end": 140, "ids": [], "id": "Chemical:enzalutamide"}, "predicate_names": ["sensitizes_to", "predicts_response_to"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: We aimed to assess the efficacy of ATR and [OBJ]PARP inhibitors[/OBJ] combination in TNBC cells and the reversal of [SUBJ]PARPi[/SUBJ] resistance in resistant cells.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HRv0VwtgIPk0kK9NK970P8cEzh", "object": "chat.completion", "created": 1763442657, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"overcomes_resistance_with\",\n  \"confidence\": 0.75,\n  \"explanation\": \"The sentence mentions reversal of PARPi resistance in resistant cells due to the ATR and PARP inhibitors combination, which aligns with the idea that the combination overcomes resistance to PARP inhibitor monotherapy.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 145, "completion_tokens": 524, "total_tokens": 669, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 448, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 3, "sentence": "We aimed to assess the efficacy of ATR and PARP inhibitors combination in TNBC cells and the reversal of PARPi resistance in resistant cells.", "subject": {"text": "PARPi", "class": "Chemical", "start": 105, "end": 110, "ids": [], "id": "Chemical:parpi"}, "object": {"text": "PARP inhibitors", "class": "Chemical", "start": 43, "end": 58, "ids": [], "id": "Chemical:parp_inhibitors"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Studies on PARPi + ARPI combinations have shown longer radiological progression-free survival, and better OS with [OBJ]talazoparib[/OBJ] + enzalutamide, regardless of [SUBJ]mutational status[/SUBJ] for DNA repair genes, with synergistic activity identified.\nAllowed predicates:\n- sensitizes_to: Gene/protein or mutation increases vulnerability to chemical/drug. Include biomarker status if validated.\n\n- predicts_response_to: Gene or mutation status predicts treatment response. Specify FDA-approved/investigational biomarker status when applicable.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJb6LiUPEcajjs02TsJelWXYMV", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.6,\n  \"explanation\": \"The sentence indicates that the TALAZOPARIB + enzalutamide combination improves outcomes regardless of DNA repair gene mutational status, and mentions synergy. It does not describe a mutation that sensitizes to the drugs or a mutation that predicts response, so neither 'sensitizes_to' nor 'predicts_response_to' applies.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 162, "completion_tokens": 1380, "total_tokens": 1542, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1280, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 5, "sentence": "Studies on PARPi + ARPI combinations have shown longer radiological progression-free survival, and better OS with talazoparib + enzalutamide, regardless of mutational status for DNA repair genes, with synergistic activity identified.", "subject": {"text": "mutational status", "class": "Mutation", "start": 156, "end": 173, "ids": [], "id": "Mutation:mutational_status"}, "object": {"text": "talazoparib", "class": "Chemical", "start": 114, "end": 125, "ids": [], "id": "Chemical:talazoparib"}, "predicate_names": ["sensitizes_to", "predicts_response_to"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: This new combination treatment allows efficient application of PARPi [OBJ]Talazoparib[/OBJ] to all UC patients, independent of [SUBJ]Cisplatin[/SUBJ] pretreatment and genetic BRCAness.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HPVe88DqK1UE56Ni2nfoDB3msa", "object": "chat.completion", "created": 1763442655, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\"predicate\": \"synergizes_with\", \"confidence\": 0.78, \"explanation\": \"The sentence describes a 'new combination treatment' that enables efficient use of Talazoparib across all UC patients, implying a synergistic interaction between Talazoparib and the co-administered component in this cancer context.\"}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 152, "completion_tokens": 911, "total_tokens": 1063, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 832, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41216708", "sentence_id": 10, "sentence": "This new combination treatment allows efficient application of PARPi Talazoparib to all UC patients, independent of Cisplatin pretreatment and genetic BRCAness.", "subject": {"text": "Cisplatin", "class": "Chemical", "start": 116, "end": 125, "ids": [], "id": "Chemical:cisplatin"}, "object": {"text": "Talazoparib", "class": "Chemical", "start": 69, "end": 80, "ids": [], "id": "Chemical:talazoparib"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Ataxia telangiectasia and Rad3-related ([SUBJ]ATR[/SUBJ]) regulates genome integrity, and thus, the aberrant activation of ATR could play a significant role in the pathogenesis of TNBC and be associated with [OBJ]PARPi[/OBJ] resistance in especially homologous recombinant deficiency tumors.\nAllowed predicates:\n- confers_resistance_to: Gene/protein mediates resistance to chemical/drug with specified mechanism and context (intrinsic/acquired, cancer type, fold-change).\n\n- sensitizes_to: Gene/protein or mutation increases vulnerability to chemical/drug. Include biomarker status if validated.\n\n- predicts_response_to: Gene or mutation status predicts treatment response. Specify FDA-approved/investigational biomarker status when applicable.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HQjunLkNA4zv2b6GA2fTn5xbP9", "object": "chat.completion", "created": 1763442656, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"confers_resistance_to\",\n  \"confidence\": 0.65,\n  \"explanation\": \"The sentence links ATR activation to PARP inhibitor (PARPi) resistance in homologous recombination deficiency tumors, implying ATR mediates or contributes to resistance to PARPi in this cancer context.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 200, "completion_tokens": 843, "total_tokens": 1043, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 768, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 2, "sentence": "Ataxia telangiectasia and Rad3-related (ATR) regulates genome integrity, and thus, the aberrant activation of ATR could play a significant role in the pathogenesis of TNBC and be associated with PARPi resistance in especially homologous recombinant deficiency tumors.", "subject": {"text": "ATR", "class": "Gene", "start": 41, "end": 43, "ids": [], "id": "Gene:atr"}, "object": {"text": "PARPi", "class": "Chemical", "start": 195, "end": 199, "ids": [], "id": "Chemical:parpi"}, "predicate_names": ["confers_resistance_to", "sensitizes_to", "predicts_response_to"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: BACKGROUND AND INTRODUCTION: Over the past 15\u00a0yr, significant progress has been made in the management of prostate cancer (PC), including the development of chemotherapy, [OBJ]androgen receptor pathway[/OBJ] inhibitors (ARPIs), and, more recently, [SUBJ]radium-223[/SUBJ] radioligand therapy.\nAllowed predicates:\n- inhibits: Chemical inhibits pathway. Include IC50/potency and selectivity.\n\n- targets: Chemical targets multiple nodes in pathway.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HI86lMsLgoih2Irr9lgzckgRqC", "object": "chat.completion", "created": 1763442648, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"inhibits\",\n  \"confidence\": 0.88,\n  \"explanation\": \"The term 'androgen receptor pathway inhibitors (ARPIs)' indicates chemicals that inhibit the androgen receptor pathway; thus 'inhibits' is the appropriate predicate relating ARPIs (chemical) to the androgen receptor pathway (target). The sentence does not provide IC50/potency or selectivity data.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 149, "completion_tokens": 1824, "total_tokens": 1973, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1728, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 0, "sentence": "BACKGROUND AND INTRODUCTION: Over the past 15\u00a0yr, significant progress has been made in the management of prostate cancer (PC), including the development of chemotherapy, androgen receptor pathway inhibitors (ARPIs), and, more recently, radium-223 radioligand therapy.", "subject": {"text": "radium-223", "class": "Chemical", "start": 236, "end": 246, "ids": [], "id": "Chemical:radium_223"}, "object": {"text": "androgen receptor pathway", "class": "Pathway", "start": 171, "end": 196, "ids": [], "id": "Pathway:androgen_receptor_pathway"}, "predicate_names": ["inhibits", "targets"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Studies on PARPi + ARPI combinations have shown longer radiological progression-free survival, and better OS with [OBJ]talazoparib[/OBJ] + enzalutamide, regardless of mutational status for [SUBJ]DNA repair genes[/SUBJ], with synergistic activity identified.\nAllowed predicates:\n- confers_resistance_to: Gene/protein mediates resistance to chemical/drug with specified mechanism and context (intrinsic/acquired, cancer type, fold-change).\n\n- sensitizes_to: Gene/protein or mutation increases vulnerability to chemical/drug. Include biomarker status if validated.\n\n- predicts_response_to: Gene or mutation status predicts treatment response. Specify FDA-approved/investigational biomarker status when applicable.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJS9iyWBBuoWmYDMhZ6PTxO1dl", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"predicts_response_to\",\n  \"confidence\": 0.65,\n  \"explanation\": \"The sentence discusses whether DNA repair gene mutational status (a biomarker) predicts response to the talazoparib + enzalutamide combination; it states that benefit occurs irrespective of mutation status, addressing the biomarker's predictive value for treatment response.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 195, "completion_tokens": 1688, "total_tokens": 1883, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1600, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 5, "sentence": "Studies on PARPi + ARPI combinations have shown longer radiological progression-free survival, and better OS with talazoparib + enzalutamide, regardless of mutational status for DNA repair genes, with synergistic activity identified.", "subject": {"text": "DNA repair genes", "class": "Gene", "start": 178, "end": 194, "ids": [], "id": "Gene:dna_repair_genes"}, "object": {"text": "talazoparib", "class": "Chemical", "start": 114, "end": 125, "ids": [], "id": "Chemical:talazoparib"}, "predicate_names": ["confers_resistance_to", "sensitizes_to", "predicts_response_to"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: By analysis of experimental and public clinical data, we identified new [OBJ]UC[/OBJ]-specific PARPi response predictors SLFN5, [SUBJ]SLFN11[/SUBJ], and OAS1.\nAllowed predicates:\n- prognostic_biomarker_in: Gene predicts outcome in specific cancer subtype. Specify ER+, TNBC, HER2+, and validation level.\n\n- predictive_biomarker_for: Gene predicts treatment response in cancer subtype. Distinguish from prognostic biomarkers. Specify FDA-approved/investigational status.\n\n- driver_in: Gene drives oncogenesis in specific cancer subtype. Requires evidence of causal role in tumor initiation or progression.\n\n- tumor_suppressor_in: Gene suppresses tumorigenesis in specific cancer subtype. Requires evidence of loss-of-function leading to cancer.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJ1AePYboUEVi8FDJddwbaZpI5", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"predictive_biomarker_for\",\n  \"confidence\": 0.78,\n  \"explanation\": \"The sentence identifies SLFN5, SLFN11, and OAS1 as predictors of PARP inhibitor response in urothelial carcinoma (UC), which corresponds to predictive biomarkers for treatment response in a specific cancer subtype. This is not described as prognostic, and such biomarkers are typically investigational rather than FDA-approved.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 207, "completion_tokens": 1446, "total_tokens": 1653, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1344, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41216708", "sentence_id": 5, "sentence": "By analysis of experimental and public clinical data, we identified new UC-specific PARPi response predictors SLFN5, SLFN11, and OAS1.", "subject": {"text": "SLFN11", "class": "Gene", "start": 108, "end": 113, "ids": [], "id": "Gene:slfn11"}, "object": {"text": "UC", "class": "Disease", "start": 63, "end": 64, "ids": [], "id": "Disease:uc"}, "predicate_names": ["prognostic_biomarker_in", "predictive_biomarker_for", "driver_in", "tumor_suppressor_in"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: This new combination treatment allows efficient application of [SUBJ]PARPi[/SUBJ] Talazoparib to all [OBJ]UC[/OBJ] patients, independent of Cisplatin pretreatment and genetic BRCAness.\nAllowed predicates:\n- approved_for: FDA/EMA approved for cancer subtype. Specify line of therapy and combination/monotherapy.\n\n- in_trials_for: In clinical trials. Specify phase I/II/III and NCT number if available.\n\n- resistance_emerges_in: Resistance commonly emerges in disease. Specify median time to resistance and frequency.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HPBpb95XKlzMniGJvwL259wxNZ", "object": "chat.completion", "created": 1763442655, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.42,\n  \"explanation\": \"The sentence discusses a new combination treatment enabling Talazoparib use in all UC patients, but it does not provide an explicit approval status, trial phase/number, or resistance data. Therefore none of the allowed predicates is explicitly supported by the sentence.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 163, "completion_tokens": 1044, "total_tokens": 1207, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 960, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41216708", "sentence_id": 10, "sentence": "This new combination treatment allows efficient application of PARPi Talazoparib to all UC patients, independent of Cisplatin pretreatment and genetic BRCAness.", "subject": {"text": "PARPi", "class": "Chemical", "start": 63, "end": 68, "ids": [], "id": "Chemical:parpi"}, "object": {"text": "UC", "class": "Disease", "start": 88, "end": 90, "ids": [], "id": "Disease:uc"}, "predicate_names": ["approved_for", "in_trials_for", "resistance_emerges_in"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Studies on PARPi + [OBJ]ARPI[/OBJ] combinations have shown longer radiological progression-free survival, and better OS with talazoparib + enzalutamide, regardless of [SUBJ]mutational status[/SUBJ] for DNA repair genes, with synergistic activity identified.\nAllowed predicates:\n- sensitizes_to: Gene/protein or mutation increases vulnerability to chemical/drug. Include biomarker status if validated.\n\n- predicts_response_to: Gene or mutation status predicts treatment response. Specify FDA-approved/investigational biomarker status when applicable.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJx5UqofoNZuTn9sNPJKRZZd66", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.65,\n  \"explanation\": \"The sentence reports improved outcomes for PARPi + ARPI combinations independent of DNA repair gene mutational status and mentions synergistic activity, but it does not state that a gene/mutation sensitizes to the drug or that mutational status predicts response. Therefore, neither 'sensitizes_to' nor 'predicts_response_to' applies.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 162, "completion_tokens": 1636, "total_tokens": 1798, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1536, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 5, "sentence": "Studies on PARPi + ARPI combinations have shown longer radiological progression-free survival, and better OS with talazoparib + enzalutamide, regardless of mutational status for DNA repair genes, with synergistic activity identified.", "subject": {"text": "mutational status", "class": "Mutation", "start": 156, "end": 173, "ids": [], "id": "Mutation:mutational_status"}, "object": {"text": "ARPI", "class": "Chemical", "start": 19, "end": 23, "ids": [], "id": "Chemical:arpi"}, "predicate_names": ["sensitizes_to", "predicts_response_to"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: HCC1937 and HCC1937-R [SUBJ]Talazoparib[/SUBJ] (TAL) resistant cells were treated with Elimusertib ([OBJ]ELI[/OBJ]) alone as ATR inhibitor (ATRi) and ELI and TAL combination.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HRqvU7lgGDprVjHNaBf7CrP9an", "object": "chat.completion", "created": 1763442657, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"overcomes_resistance_with\",\n  \"confidence\": 0.78,\n  \"explanation\": \"The cells are talazoparib-resistant, and the experiment includes treatment with Elimusertib alone and in combination with TAL, which implies assessing whether the combination can overcome resistance to TAL monotherapy.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 162, "completion_tokens": 910, "total_tokens": 1072, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 832, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 4, "sentence": "HCC1937 and HCC1937-R Talazoparib (TAL) resistant cells were treated with Elimusertib (ELI) alone as ATR inhibitor (ATRi) and ELI and TAL combination.", "subject": {"text": "Talazoparib", "class": "Chemical", "start": 22, "end": 33, "ids": [], "id": "Chemical:talazoparib"}, "object": {"text": "ELI", "class": "Chemical", "start": 87, "end": 90, "ids": [], "id": "Chemical:eli"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Ataxia telangiectasia and Rad3-related ([SUBJ]ATR[/SUBJ]) regulates genome integrity, and thus, the aberrant activation of ATR could play a significant role in the pathogenesis of TNBC and be associated with PARPi resistance in especially homologous recombinant [OBJ]deficiency[/OBJ] tumors.\nAllowed predicates:\n- upregulated_in_resistance: Gene upregulated in resistance to specific drug. Specify fold-change, p-value, cell lines tested, acquired vs intrinsic resistance.\n\n- downregulated_in_resistance: Gene downregulated in resistance to specific drug. Include fold-change, p-value, and cell lines tested.\n\n- correlates_with_survival: Gene expression correlates with overall or progression-free survival. Include hazard ratio and p-value.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HQYnt9VX5WnTP74hho980fiLC3", "object": "chat.completion", "created": 1763442656, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"upregulated_in_resistance\",\n  \"confidence\": 0.70,\n  \"explanation\": \"The sentence links aberrant activation of ATR to PARP inhibitor (PARPi) resistance in homologous recombination\u2013deficient tumors, implying increased ATR activity contributes to resistance. No explicit fold-change, p-value, or experimental details are provided, but the described association fits the 'upregulated_in_resistance' predicate.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 202, "completion_tokens": 997, "total_tokens": 1199, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 896, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 2, "sentence": "Ataxia telangiectasia and Rad3-related (ATR) regulates genome integrity, and thus, the aberrant activation of ATR could play a significant role in the pathogenesis of TNBC and be associated with PARPi resistance in especially homologous recombinant deficiency tumors.", "subject": {"text": "ATR", "class": "Gene", "start": 111, "end": 113, "ids": [], "id": "Gene:atr"}, "object": {"text": "deficiency", "class": "Phenotype", "start": 248, "end": 257, "ids": [], "id": "Phenotype:deficiency"}, "predicate_names": ["upregulated_in_resistance", "downregulated_in_resistance", "correlates_with_survival"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: However, response to PARPi seems to vary depending on the genes altered, with a greater benefit for patients with mutations in genes encoding the repair effector proteins [SUBJ]BRCA1/2[/SUBJ], [OBJ]CDK12[/OBJ], and PALB2.\nAllowed predicates:\n- physically_interacts_with: Protein-protein interaction. Specify method of detection and binding affinity if known.\n\n- co_expressed_with: Genes show correlated expression across samples. Include correlation coefficient and context.\n\n- synthetic_lethal_with: Combined inhibition is lethal in specific cancer context. Requires functional validation.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJvm2uJDUXogPsNMelVwHHdosj", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"synthetic_lethal_with\",\n  \"confidence\": 0.72,\n  \"explanation\": \"The sentence describes enhanced PARP inhibitor benefit in tumors with mutations in HR repair genes (BRCA1/2, PALB2, and CDK12), which aligns with the known synthetic lethal interaction between PARP inhibition and defects in HR repair. It does not indicate direct protein\u2013protein interaction or gene co-expression.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 167, "completion_tokens": 1765, "total_tokens": 1932, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1664, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 6, "sentence": "However, response to PARPi seems to vary depending on the genes altered, with a greater benefit for patients with mutations in genes encoding the repair effector proteins BRCA1/2, CDK12, and PALB2.", "subject": {"text": "BRCA1/2", "class": "Gene", "start": 171, "end": 177, "ids": [], "id": "Gene:brca1_2"}, "object": {"text": "CDK12", "class": "Gene", "start": 180, "end": 184, "ids": [], "id": "Gene:cdk12"}, "predicate_names": ["physically_interacts_with", "co_expressed_with", "synthetic_lethal_with"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Then, the cytotoxic, apoptotic and [SUBJ]ATR[/SUBJ] based DNA damage response (DDR) were evaluated by [OBJ]WST-1[/OBJ], Annexin V, AO/PI, cell cycle and western blot analysis.\nAllowed predicates:\n- confers_resistance_to: Gene/protein mediates resistance to chemical/drug with specified mechanism and context (intrinsic/acquired, cancer type, fold-change).\n\n- sensitizes_to: Gene/protein or mutation increases vulnerability to chemical/drug. Include biomarker status if validated.\n\n- predicts_response_to: Gene or mutation status predicts treatment response. Specify FDA-approved/investigational biomarker status when applicable.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HSNLGyeHHeQrhJ9R3C0emNKC66", "object": "chat.completion", "created": 1763442658, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"\",\n  \"confidence\": 0.72,\n  \"explanation\": \"The sentence describes evaluating ATR-based DDR using various assays; it does not state any relationship to drug resistance, sensitization, or treatment-response prediction.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 187, "completion_tokens": 700, "total_tokens": 887, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 640, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 5, "sentence": "Then, the cytotoxic, apoptotic and ATR based DNA damage response (DDR) were evaluated by WST-1, Annexin V, AO/PI, cell cycle and western blot analysis.", "subject": {"text": "ATR", "class": "Gene", "start": 35, "end": 37, "ids": [], "id": "Gene:atr"}, "object": {"text": "WST-1", "class": "Chemical", "start": 89, "end": 93, "ids": [], "id": "Chemical:wst_1"}, "predicate_names": ["confers_resistance_to", "sensitizes_to", "predicts_response_to"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Ataxia telangiectasia and Rad3-related ([SUBJ]ATR[/SUBJ]) regulates genome integrity, and thus, the aberrant activation of ATR could play a significant role in the pathogenesis of TNBC and be associated with PARPi resistance in especially homologous recombinant [OBJ]deficiency[/OBJ] tumors.\nAllowed predicates:\n- upregulated_in_resistance: Gene upregulated in resistance to specific drug. Specify fold-change, p-value, cell lines tested, acquired vs intrinsic resistance.\n\n- downregulated_in_resistance: Gene downregulated in resistance to specific drug. Include fold-change, p-value, and cell lines tested.\n\n- correlates_with_survival: Gene expression correlates with overall or progression-free survival. Include hazard ratio and p-value.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HQ4h6AdU2u8RPElqa9FM5bkuCL", "object": "chat.completion", "created": 1763442656, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"upregulated_in_resistance\",\n  \"confidence\": 0.65,\n  \"explanation\": \"The sentence links ATR activation with PARP inhibitor resistance in homologous recombination-deficient tumors, implying ATR is upregulated/activated in resistant contexts. No explicit data on survival correlation or downregulation are provided.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 202, "completion_tokens": 1040, "total_tokens": 1242, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 960, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 2, "sentence": "Ataxia telangiectasia and Rad3-related (ATR) regulates genome integrity, and thus, the aberrant activation of ATR could play a significant role in the pathogenesis of TNBC and be associated with PARPi resistance in especially homologous recombinant deficiency tumors.", "subject": {"text": "ATR", "class": "Gene", "start": 41, "end": 43, "ids": [], "id": "Gene:atr"}, "object": {"text": "deficiency", "class": "Phenotype", "start": 248, "end": 257, "ids": [], "id": "Phenotype:deficiency"}, "predicate_names": ["upregulated_in_resistance", "downregulated_in_resistance", "correlates_with_survival"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: This new combination treatment allows efficient application of [OBJ]PARPi[/OBJ] Talazoparib to all UC patients, independent of [SUBJ]Cisplatin[/SUBJ] pretreatment and genetic BRCAness.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HPzwDZ6XWcqvnJWj42MSSgiRjF", "object": "chat.completion", "created": 1763442655, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"overcomes_resistance_with\",\n  \"confidence\": 0.65,\n  \"explanation\": \"The sentence describes a combination treatment that enables Talazoparib to be used across all UC patients regardless of Cisplatin pretreatment and BRCAness, implying the combination overcomes resistance barriers to PARP inhibitor monotherapy.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 152, "completion_tokens": 1172, "total_tokens": 1324, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1088, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41216708", "sentence_id": 10, "sentence": "This new combination treatment allows efficient application of PARPi Talazoparib to all UC patients, independent of Cisplatin pretreatment and genetic BRCAness.", "subject": {"text": "Cisplatin", "class": "Chemical", "start": 116, "end": 125, "ids": [], "id": "Chemical:cisplatin"}, "object": {"text": "PARPi", "class": "Chemical", "start": 63, "end": 68, "ids": [], "id": "Chemical:parpi"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: We aimed to assess the efficacy of [SUBJ]ATR[/SUBJ] and PARP inhibitors combination in TNBC cells and the reversal of [OBJ]PARPi[/OBJ] resistance in resistant cells.\nAllowed predicates:\n- confers_resistance_to: Gene/protein mediates resistance to chemical/drug with specified mechanism and context (intrinsic/acquired, cancer type, fold-change).\n\n- sensitizes_to: Gene/protein or mutation increases vulnerability to chemical/drug. Include biomarker status if validated.\n\n- predicts_response_to: Gene or mutation status predicts treatment response. Specify FDA-approved/investigational biomarker status when applicable.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HRERkhbjPCvmWmNZGS4lDR4Pn3", "object": "chat.completion", "created": 1763442657, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"sensitizes_to\",\n  \"confidence\": 0.72,\n  \"explanation\": \"The sentence describes ATR reversing PARP inhibitor resistance, implying ATR increases sensitivity to PARP inhibitors in resistant cells.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 176, "completion_tokens": 1018, "total_tokens": 1194, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 960, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 3, "sentence": "We aimed to assess the efficacy of ATR and PARP inhibitors combination in TNBC cells and the reversal of PARPi resistance in resistant cells.", "subject": {"text": "ATR", "class": "Gene", "start": 35, "end": 38, "ids": [], "id": "Gene:atr"}, "object": {"text": "PARPi", "class": "Chemical", "start": 105, "end": 110, "ids": [], "id": "Chemical:parpi"}, "predicate_names": ["confers_resistance_to", "sensitizes_to", "predicts_response_to"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Then, the cytotoxic, apoptotic and [SUBJ]ATR[/SUBJ] based DNA damage response (DDR) were evaluated by WST-1, Annexin V, [OBJ]AO/PI[/OBJ], cell cycle and western blot analysis.\nAllowed predicates:\n- confers_resistance_to: Gene/protein mediates resistance to chemical/drug with specified mechanism and context (intrinsic/acquired, cancer type, fold-change).\n\n- sensitizes_to: Gene/protein or mutation increases vulnerability to chemical/drug. Include biomarker status if validated.\n\n- predicts_response_to: Gene or mutation status predicts treatment response. Specify FDA-approved/investigational biomarker status when applicable.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HT4QkrymayAsDZGnCVqhzIqYtI", "object": "chat.completion", "created": 1763442659, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.65,\n  \"explanation\": \"The sentence describes the evaluation of ATR-based DNA damage response using various assays. It does not state that ATR confers resistance/sensitivity to a drug or predicts treatment response.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 187, "completion_tokens": 707, "total_tokens": 894, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 640, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 5, "sentence": "Then, the cytotoxic, apoptotic and ATR based DNA damage response (DDR) were evaluated by WST-1, Annexin V, AO/PI, cell cycle and western blot analysis.", "subject": {"text": "ATR", "class": "Gene", "start": 35, "end": 37, "ids": [], "id": "Gene:atr"}, "object": {"text": "AO/PI", "class": "Chemical", "start": 107, "end": 111, "ids": [], "id": "Chemical:ao_pi"}, "predicate_names": ["confers_resistance_to", "sensitizes_to", "predicts_response_to"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Then, the cytotoxic, apoptotic and ATR based DNA damage response (DDR) were evaluated by [SUBJ]WST-1[/SUBJ], Annexin V, [OBJ]AO/PI[/OBJ], cell cycle and western blot analysis.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HTihpUKenwXpU1CKv41rrmjqEL", "object": "chat.completion", "created": 1763442659, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.92,\n  \"explanation\": \"The sentence describes evaluation methods (WST-1, Annexin V, AO/PI, cell cycle, Western blot) for cytotoxicity, apoptosis, and DDR, not a relationship between chemicals or a sequential therapy.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 155, "completion_tokens": 654, "total_tokens": 809, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 576, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 5, "sentence": "Then, the cytotoxic, apoptotic and ATR based DNA damage response (DDR) were evaluated by WST-1, Annexin V, AO/PI, cell cycle and western blot analysis.", "subject": {"text": "WST-1", "class": "Chemical", "start": 89, "end": 93, "ids": [], "id": "Chemical:wst_1"}, "object": {"text": "AO/PI", "class": "Chemical", "start": 107, "end": 111, "ids": [], "id": "Chemical:ao_pi"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Clinical trials with [OBJ]PARP inhibitors[/OBJ] ([SUBJ]PARPi[/SUBJ]), particularly in Cisplatin-treated UC, yielded limited response.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJ9NybgOp7i6Fv4uXZC40Xn7eI", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.25,\n  \"explanation\": \"The sentence does not state a relationship that matches any of the allowed predicates (no explicit synergy with another drug, no claim of overcoming resistance, and no explicit sequential therapy after another agent). It only notes limited response to PARP inhibitors in a cisplatin-treated urothelial cancer context.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 137, "completion_tokens": 1947, "total_tokens": 2084, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1856, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41216708", "sentence_id": 1, "sentence": "Clinical trials with PARP inhibitors (PARPi), particularly in Cisplatin-treated UC, yielded limited response.", "subject": {"text": "PARPi", "class": "Chemical", "start": 38, "end": 43, "ids": [], "id": "Chemical:parpi"}, "object": {"text": "PARP inhibitors", "class": "Chemical", "start": 21, "end": 36, "ids": [], "id": "Chemical:parp_inhibitors"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: By analysis of experimental and public clinical data, we identified new UC-specific PARPi response predictors [SUBJ]SLFN5[/SUBJ], [OBJ]SLFN11[/OBJ], and OAS1.\nAllowed predicates:\n- physically_interacts_with: Protein-protein interaction. Specify method of detection and binding affinity if known.\n\n- co_expressed_with: Genes show correlated expression across samples. Include correlation coefficient and context.\n\n- synthetic_lethal_with: Combined inhibition is lethal in specific cancer context. Requires functional validation.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJkTxNrJJA1BKXuwYTBGuPWjjG", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"co_expressed_with\",\n  \"confidence\": 0.58,\n  \"explanation\": \"The sentence describes identifying genes (SLFN5, SLFN11, OAS1) as predictors of UC-specific PARPi response. Co-expression analyses are a common method to find genes whose expression correlates with a response phenotype across samples, making 'co_expressed_with' the closest fit among the provided options.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 152, "completion_tokens": 1955, "total_tokens": 2107, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1856, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41216708", "sentence_id": 5, "sentence": "By analysis of experimental and public clinical data, we identified new UC-specific PARPi response predictors SLFN5, SLFN11, and OAS1.", "subject": {"text": "SLFN5", "class": "Gene", "start": 101, "end": 105, "ids": [], "id": "Gene:slfn5"}, "object": {"text": "SLFN11", "class": "Gene", "start": 108, "end": 113, "ids": [], "id": "Gene:slfn11"}, "predicate_names": ["physically_interacts_with", "co_expressed_with", "synthetic_lethal_with"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Ataxia telangiectasia and Rad3-related ([SUBJ]ATR[/SUBJ]) regulates genome integrity, and thus, the aberrant activation of ATR could play a significant role in the pathogenesis of [OBJ]TNBC[/OBJ] and be associated with PARPi resistance in especially homologous recombinant deficiency tumors.\nAllowed predicates:\n- prognostic_biomarker_in: Gene predicts outcome in specific cancer subtype. Specify ER+, TNBC, HER2+, and validation level.\n\n- predictive_biomarker_for: Gene predicts treatment response in cancer subtype. Distinguish from prognostic biomarkers. Specify FDA-approved/investigational status.\n\n- driver_in: Gene drives oncogenesis in specific cancer subtype. Requires evidence of causal role in tumor initiation or progression.\n\n- tumor_suppressor_in: Gene suppresses tumorigenesis in specific cancer subtype. Requires evidence of loss-of-function leading to cancer.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HQOH0qePIbXex7qi8fSw8GEQcY", "object": "chat.completion", "created": 1763442656, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"predictive_biomarker_for\",\n  \"confidence\": 0.68,\n  \"explanation\": \"The sentence links ATR activation to TNBC pathogenesis and PARP inhibitor resistance in HR-deficient tumors, implying ATR status could predict treatment response/resistance to PARP inhibitors in TNBC (investigational status).\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 229, "completion_tokens": 1106, "total_tokens": 1335, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1024, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 2, "sentence": "Ataxia telangiectasia and Rad3-related (ATR) regulates genome integrity, and thus, the aberrant activation of ATR could play a significant role in the pathogenesis of TNBC and be associated with PARPi resistance in especially homologous recombinant deficiency tumors.", "subject": {"text": "ATR", "class": "Gene", "start": 41, "end": 43, "ids": [], "id": "Gene:atr"}, "object": {"text": "TNBC", "class": "Disease", "start": 167, "end": 170, "ids": [], "id": "Disease:tnbc"}, "predicate_names": ["prognostic_biomarker_in", "predictive_biomarker_for", "driver_in", "tumor_suppressor_in"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: HCC1937 and HCC1937-R Talazoparib ([SUBJ]TAL[/SUBJ]) resistant cells were treated with Elimusertib ([OBJ]ELI[/OBJ]) alone as ATR inhibitor (ATRi) and ELI and TAL combination.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HRtN8yjDp93v88YbHyCMeh4xa2", "object": "chat.completion", "created": 1763442657, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"overcomes_resistance_with\",\n  \"confidence\": 0.66,\n  \"explanation\": \"The sentence mentions Talazoparib-resistant cells being treated with Elimusertib alone and with the Elimusertib + Talazoparib combination, which indicates evaluating whether the combination can overcome resistance to TAL monotherapy.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 160, "completion_tokens": 980, "total_tokens": 1140, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 896, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 4, "sentence": "HCC1937 and HCC1937-R Talazoparib (TAL) resistant cells were treated with Elimusertib (ELI) alone as ATR inhibitor (ATRi) and ELI and TAL combination.", "subject": {"text": "TAL", "class": "Chemical", "start": 35, "end": 38, "ids": [], "id": "Chemical:tal"}, "object": {"text": "ELI", "class": "Chemical", "start": 87, "end": 90, "ids": [], "id": "Chemical:eli"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: This new combination treatment allows efficient application of [SUBJ]PARPi[/SUBJ] Talazoparib to all UC patients, independent of [OBJ]Cisplatin[/OBJ] pretreatment and genetic BRCAness.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HPABCLEgP8SuebNE4C5pkKBO56", "object": "chat.completion", "created": 1763442655, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{ \"predicate\": \"overcomes_resistance_with\", \"confidence\": 0.72, \"explanation\": \"The sentence indicates that the new combination treatment enables the PARP inhibitor Talazoparib to be used in all UC patients regardless of Cisplatin pretreatment and BRCAness, implying the combination overcomes resistance or limitations of PARP inhibitor monotherapy under those conditions.\" }", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 152, "completion_tokens": 1306, "total_tokens": 1458, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1216, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41216708", "sentence_id": 10, "sentence": "This new combination treatment allows efficient application of PARPi Talazoparib to all UC patients, independent of Cisplatin pretreatment and genetic BRCAness.", "subject": {"text": "PARPi", "class": "Chemical", "start": 63, "end": 68, "ids": [], "id": "Chemical:parpi"}, "object": {"text": "Cisplatin", "class": "Chemical", "start": 116, "end": 125, "ids": [], "id": "Chemical:cisplatin"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: HCC1937 and HCC1937-R [SUBJ]Talazoparib[/SUBJ] (TAL) resistant cells were treated with [OBJ]Elimusertib[/OBJ] (ELI) alone as ATR inhibitor (ATRi) and ELI and TAL combination.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HRb2dBLv1wqSsCPGLvf4ndInrI", "object": "chat.completion", "created": 1763442657, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"overcomes_resistance_with\",\n  \"confidence\": 0.74,\n  \"explanation\": \"The cells are TAL-resistant and are treated with Elimusertib alone and in combination with TAL; the combination is being assessed to overcome resistance to TAL monotherapy.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 164, "completion_tokens": 902, "total_tokens": 1066, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 832, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 4, "sentence": "HCC1937 and HCC1937-R Talazoparib (TAL) resistant cells were treated with Elimusertib (ELI) alone as ATR inhibitor (ATRi) and ELI and TAL combination.", "subject": {"text": "Talazoparib", "class": "Chemical", "start": 22, "end": 33, "ids": [], "id": "Chemical:talazoparib"}, "object": {"text": "Elimusertib", "class": "Chemical", "start": 74, "end": 85, "ids": [], "id": "Chemical:elimusertib"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: This new combination treatment allows efficient application of PARPi [SUBJ]Talazoparib[/SUBJ] to all [OBJ]UC[/OBJ] patients, independent of Cisplatin pretreatment and genetic BRCAness.\nAllowed predicates:\n- approved_for: FDA/EMA approved for cancer subtype. Specify line of therapy and combination/monotherapy.\n\n- in_trials_for: In clinical trials. Specify phase I/II/III and NCT number if available.\n\n- resistance_emerges_in: Resistance commonly emerges in disease. Specify median time to resistance and frequency.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HPtYmma4jyvleW3nyuRyh4j5jw", "object": "chat.completion", "created": 1763442655, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"in_trials_for\",\n  \"confidence\": 0.58,\n  \"explanation\": \"The sentence describes a 'new combination treatment' enabling broader use of Talazoparib across UC patients, which implies a research/trial context. There is no explicit regulatory approval status or resistance data mentioned, making 'in_trials_for' the most appropriate fit among the options.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 163, "completion_tokens": 1115, "total_tokens": 1278, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1024, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41216708", "sentence_id": 10, "sentence": "This new combination treatment allows efficient application of PARPi Talazoparib to all UC patients, independent of Cisplatin pretreatment and genetic BRCAness.", "subject": {"text": "Talazoparib", "class": "Chemical", "start": 69, "end": 80, "ids": [], "id": "Chemical:talazoparib"}, "object": {"text": "UC", "class": "Disease", "start": 88, "end": 90, "ids": [], "id": "Disease:uc"}, "predicate_names": ["approved_for", "in_trials_for", "resistance_emerges_in"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: [SUBJ]Poly(ADP-ribose) polymerase[/SUBJ] (PARP) inhibitors (PARPi) have attracted significant attention in [OBJ]triple negative breast cancer[/OBJ] (TNBC) treatment.\nAllowed predicates:\n- prognostic_biomarker_in: Gene predicts outcome in specific cancer subtype. Specify ER+, TNBC, HER2+, and validation level.\n\n- predictive_biomarker_for: Gene predicts treatment response in cancer subtype. Distinguish from prognostic biomarkers. Specify FDA-approved/investigational status.\n\n- driver_in: Gene drives oncogenesis in specific cancer subtype. Requires evidence of causal role in tumor initiation or progression.\n\n- tumor_suppressor_in: Gene suppresses tumorigenesis in specific cancer subtype. Requires evidence of loss-of-function leading to cancer.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HPUP04Q3dblq7DO6zd4yhBiqS4", "object": "chat.completion", "created": 1763442655, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.65,\n  \"explanation\": \"The sentence discusses PARP inhibitors as a treatment approach in triple-negative breast cancer and does not state that a gene has prognostic or predictive value (or a driver/t tumor suppressor role) in this context. Thus, none of the provided predicates directly apply.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 212, "completion_tokens": 1173, "total_tokens": 1385, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1088, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 0, "sentence": "Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) have attracted significant attention in triple negative breast cancer (TNBC) treatment.", "subject": {"text": "Poly(ADP-ribose) polymerase", "class": "Gene", "start": 0, "end": 29, "ids": [], "id": "Gene:poly_adp_ribose_polymerase"}, "object": {"text": "triple negative breast cancer", "class": "Disease", "start": 96, "end": 125, "ids": [], "id": "Disease:triple_negative_breast_cancer"}, "predicate_names": ["prognostic_biomarker_in", "predictive_biomarker_for", "driver_in", "tumor_suppressor_in"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Then, the cytotoxic, apoptotic and ATR based DNA damage response ([OBJ]DDR[/OBJ]) were evaluated by WST-1, Annexin V, [SUBJ]AO/PI[/SUBJ], cell cycle and western blot analysis.\nAllowed predicates:\n- inhibits: Chemical inhibits pathway. Include IC50/potency and selectivity.\n\n- targets: Chemical targets multiple nodes in pathway.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HUIU1yzRFtJrTG0pypXfM4SKJr", "object": "chat.completion", "created": 1763442660, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\"predicate\": \"none\", \"confidence\": 0.70, \"explanation\": \"The sentence describes evaluation of the ATR-based DNA damage response using various assays; it does not state that a chemical inhibits or targets a node in the pathway.\"}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 128, "completion_tokens": 636, "total_tokens": 764, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 576, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 5, "sentence": "Then, the cytotoxic, apoptotic and ATR based DNA damage response (DDR) were evaluated by WST-1, Annexin V, AO/PI, cell cycle and western blot analysis.", "subject": {"text": "AO/PI", "class": "Chemical", "start": 107, "end": 111, "ids": [], "id": "Chemical:ao_pi"}, "object": {"text": "DDR", "class": "Pathway", "start": 66, "end": 68, "ids": [], "id": "Pathway:ddr"}, "predicate_names": ["inhibits", "targets"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: To identify the most suitable PARPi for [OBJ]UC[/OBJ], we compared [SUBJ]Olaparib[/SUBJ] with Talazoparib.\nAllowed predicates:\n- approved_for: FDA/EMA approved for cancer subtype. Specify line of therapy and combination/monotherapy.\n\n- in_trials_for: In clinical trials. Specify phase I/II/III and NCT number if available.\n\n- resistance_emerges_in: Resistance commonly emerges in disease. Specify median time to resistance and frequency.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJrv9vX6i8BpOomBb36MFTrbm8", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"not_applicable\",\n  \"confidence\": 0.45,\n  \"explanation\": \"The sentence describes comparing Olaparib and Talazoparib to identify the most suitable PARPi for UC, but provides no information about approval status, ongoing trials, or resistance data. None of the allowed predicates directly match this context.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 151, "completion_tokens": 1940, "total_tokens": 2091, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1856, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41216708", "sentence_id": 3, "sentence": "To identify the most suitable PARPi for UC, we compared Olaparib with Talazoparib.", "subject": {"text": "Olaparib", "class": "Chemical", "start": 56, "end": 64, "ids": [], "id": "Chemical:olaparib"}, "object": {"text": "UC", "class": "Disease", "start": 40, "end": 42, "ids": [], "id": "Disease:uc"}, "predicate_names": ["approved_for", "in_trials_for", "resistance_emerges_in"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Studies on [OBJ]PARPi[/OBJ] + ARPI combinations have shown longer radiological progression-free survival, and better OS with talazoparib + enzalutamide, regardless of mutational status for [SUBJ]DNA repair genes[/SUBJ], with synergistic activity identified.\nAllowed predicates:\n- confers_resistance_to: Gene/protein mediates resistance to chemical/drug with specified mechanism and context (intrinsic/acquired, cancer type, fold-change).\n\n- sensitizes_to: Gene/protein or mutation increases vulnerability to chemical/drug. Include biomarker status if validated.\n\n- predicts_response_to: Gene or mutation status predicts treatment response. Specify FDA-approved/investigational biomarker status when applicable.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJH12tWLLtvnCgjcsfHcLpUG46", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"predicts_response_to\",\n  \"confidence\": 0.62,\n  \"explanation\": \"The sentence discusses DNA repair gene mutational status as a potential predictor for response to PARPi + ARPI therapy, i.e., a biomarker that could predict treatment response.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 195, "completion_tokens": 2055, "total_tokens": 2250, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1984, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 5, "sentence": "Studies on PARPi + ARPI combinations have shown longer radiological progression-free survival, and better OS with talazoparib + enzalutamide, regardless of mutational status for DNA repair genes, with synergistic activity identified.", "subject": {"text": "DNA repair genes", "class": "Gene", "start": 178, "end": 194, "ids": [], "id": "Gene:dna_repair_genes"}, "object": {"text": "PARPi", "class": "Chemical", "start": 11, "end": 16, "ids": [], "id": "Chemical:parpi"}, "predicate_names": ["confers_resistance_to", "sensitizes_to", "predicts_response_to"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Then, the cytotoxic, apoptotic and ATR based DNA damage response ([OBJ]DDR[/OBJ]) were evaluated by [SUBJ]WST-1[/SUBJ], Annexin V, AO/PI, cell cycle and western blot analysis.\nAllowed predicates:\n- inhibits: Chemical inhibits pathway. Include IC50/potency and selectivity.\n\n- targets: Chemical targets multiple nodes in pathway.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HT7cMqte8SibpuElccfejL1607", "object": "chat.completion", "created": 1763442659, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.65,\n  \"explanation\": \"The sentence describes measurement/evaluation of ATR-based DDR using assays (WST-1, Annexin V, AO/PI, cell cycle, western blot). It does not state that a chemical inhibits or targets a node in the pathway.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 128, "completion_tokens": 850, "total_tokens": 978, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 768, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 5, "sentence": "Then, the cytotoxic, apoptotic and ATR based DNA damage response (DDR) were evaluated by WST-1, Annexin V, AO/PI, cell cycle and western blot analysis.", "subject": {"text": "WST-1", "class": "Chemical", "start": 89, "end": 93, "ids": [], "id": "Chemical:wst_1"}, "object": {"text": "DDR", "class": "Pathway", "start": 66, "end": 68, "ids": [], "id": "Pathway:ddr"}, "predicate_names": ["inhibits", "targets"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Then, the cytotoxic, apoptotic and ATR based DNA damage response ([OBJ]DDR[/OBJ]) were evaluated by WST-1, [SUBJ]Annexin V[/SUBJ], AO/PI, cell cycle and western blot analysis.\nAllowed predicates:\n- inhibits: Chemical inhibits pathway. Include IC50/potency and selectivity.\n\n- targets: Chemical targets multiple nodes in pathway.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HTnxLy8LkzsGwpIlNc3g3erSO2", "object": "chat.completion", "created": 1763442659, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.72,\n  \"explanation\": \"The sentence describes measurement/evaluation of cytotoxicity, apoptosis, and ATR-based DDR using various assays. It does not state that a chemical inhibits or targets a pathway.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 129, "completion_tokens": 835, "total_tokens": 964, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 768, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 5, "sentence": "Then, the cytotoxic, apoptotic and ATR based DNA damage response (DDR) were evaluated by WST-1, Annexin V, AO/PI, cell cycle and western blot analysis.", "subject": {"text": "Annexin V", "class": "Chemical", "start": 96, "end": 104, "ids": [], "id": "Chemical:annexin_v"}, "object": {"text": "DDR", "class": "Pathway", "start": 66, "end": 68, "ids": [], "id": "Pathway:ddr"}, "predicate_names": ["inhibits", "targets"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: We aimed to assess the efficacy of [SUBJ]ATR[/SUBJ] and PARP inhibitors combination in TNBC cells and the reversal of PARPi [OBJ]resistance[/OBJ] in resistant cells.\nAllowed predicates:\n- upregulated_in_resistance: Gene upregulated in resistance to specific drug. Specify fold-change, p-value, cell lines tested, acquired vs intrinsic resistance.\n\n- downregulated_in_resistance: Gene downregulated in resistance to specific drug. Include fold-change, p-value, and cell lines tested.\n\n- correlates_with_survival: Gene expression correlates with overall or progression-free survival. Include hazard ratio and p-value.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HROmwVlq4NgmLmlxJL4DedpY2A", "object": "chat.completion", "created": 1763442657, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.70,\n  \"explanation\": \"The sentence discusses the efficacy of ATR and PARP inhibitors in TNBC cells and reversal of PARPi resistance, but it does not specify any gene expression changes in resistance (upregulated_in_resistance or downregulated_in_resistance) or a survival association (correlates_with_survival). The allowed predicates require gene-level resistance changes or survival correlations that are not described here.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 178, "completion_tokens": 1132, "total_tokens": 1310, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1024, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 3, "sentence": "We aimed to assess the efficacy of ATR and PARP inhibitors combination in TNBC cells and the reversal of PARPi resistance in resistant cells.", "subject": {"text": "ATR", "class": "Gene", "start": 35, "end": 38, "ids": [], "id": "Gene:atr"}, "object": {"text": "resistance", "class": "Phenotype", "start": 111, "end": 121, "ids": [], "id": "Phenotype:resistance"}, "predicate_names": ["upregulated_in_resistance", "downregulated_in_resistance", "correlates_with_survival"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Ataxia telangiectasia and Rad3-related ([SUBJ][OBJ]ATR[/OBJ][/SUBJ]) regulates genome integrity, and thus, the aberrant activation of ATR could play a significant role in the pathogenesis of TNBC and be associated with PARPi resistance in especially homologous recombinant deficiency tumors.\nAllowed predicates:\n- physically_interacts_with: Protein-protein interaction. Specify method of detection and binding affinity if known.\n\n- co_expressed_with: Genes show correlated expression across samples. Include correlation coefficient and context.\n\n- synthetic_lethal_with: Combined inhibition is lethal in specific cancer context. Requires functional validation.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HQsdVwizn9P8OsACiL6brnrY8c", "object": "chat.completion", "created": 1763442656, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.58,\n  \"explanation\": \"The sentence does not describe a direct protein\u2013protein interaction, gene co-expression, or a synthetic lethal relationship with another gene/protein; it only notes ATR's regulatory role in genome integrity and its possible association with PARP inhibitor resistance in HRD tumors.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 173, "completion_tokens": 1236, "total_tokens": 1409, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1152, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 2, "sentence": "Ataxia telangiectasia and Rad3-related (ATR) regulates genome integrity, and thus, the aberrant activation of ATR could play a significant role in the pathogenesis of TNBC and be associated with PARPi resistance in especially homologous recombinant deficiency tumors.", "subject": {"text": "ATR", "class": "Gene", "start": 111, "end": 113, "ids": [], "id": "Gene:atr"}, "object": {"text": "ATR", "class": "Gene", "start": 41, "end": 43, "ids": [], "id": "Gene:atr"}, "predicate_names": ["physically_interacts_with", "co_expressed_with", "synthetic_lethal_with"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: By analysis of experimental and public clinical data, we identified new UC-specific PARPi response predictors [OBJ]SLFN5[/OBJ], [SUBJ]SLFN11[/SUBJ], and OAS1.\nAllowed predicates:\n- physically_interacts_with: Protein-protein interaction. Specify method of detection and binding affinity if known.\n\n- co_expressed_with: Genes show correlated expression across samples. Include correlation coefficient and context.\n\n- synthetic_lethal_with: Combined inhibition is lethal in specific cancer context. Requires functional validation.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJGJM6fv1SxLWB2nB7MjPKv41X", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"co_expressed_with\",\n  \"confidence\": 0.55,\n  \"explanation\": \"The sentence identifies SLFN5, SLFN11, and OAS1 as predictors of PARPi response in UC but does not indicate protein\u2013protein interactions or synthetic lethality. 'co_expressed_with' best fits a gene\u2013gene expression relationship that could underlie their joint association with PARPi response. No correlation coefficient is provided.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 152, "completion_tokens": 2024, "total_tokens": 2176, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1920, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41216708", "sentence_id": 5, "sentence": "By analysis of experimental and public clinical data, we identified new UC-specific PARPi response predictors SLFN5, SLFN11, and OAS1.", "subject": {"text": "SLFN11", "class": "Gene", "start": 108, "end": 113, "ids": [], "id": "Gene:slfn11"}, "object": {"text": "SLFN5", "class": "Gene", "start": 101, "end": 105, "ids": [], "id": "Gene:slfn5"}, "predicate_names": ["physically_interacts_with", "co_expressed_with", "synthetic_lethal_with"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Ataxia telangiectasia and Rad3-related ([SUBJ][OBJ]ATR[/OBJ][/SUBJ]) regulates genome integrity, and thus, the aberrant activation of ATR could play a significant role in the pathogenesis of TNBC and be associated with PARPi resistance in especially homologous recombinant deficiency tumors.\nAllowed predicates:\n- physically_interacts_with: Protein-protein interaction. Specify method of detection and binding affinity if known.\n\n- co_expressed_with: Genes show correlated expression across samples. Include correlation coefficient and context.\n\n- synthetic_lethal_with: Combined inhibition is lethal in specific cancer context. Requires functional validation.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HQuDszFDEGyXPumrW8UToHV35W", "object": "chat.completion", "created": 1763442656, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\"predicate\":\"none\",\"confidence\":0.45,\"explanation\":\"The sentence discusses ATR's regulatory role and its potential impact on TNBC pathogenesis and PARPi resistance, but does not describe a direct protein-protein interaction, gene co-expression, or a synthetic lethal relationship with another gene/protein. Therefore, none of the allowed predicates clearly applies.\"}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 173, "completion_tokens": 1297, "total_tokens": 1470, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1216, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 2, "sentence": "Ataxia telangiectasia and Rad3-related (ATR) regulates genome integrity, and thus, the aberrant activation of ATR could play a significant role in the pathogenesis of TNBC and be associated with PARPi resistance in especially homologous recombinant deficiency tumors.", "subject": {"text": "ATR", "class": "Gene", "start": 41, "end": 43, "ids": [], "id": "Gene:atr"}, "object": {"text": "ATR", "class": "Gene", "start": 111, "end": 113, "ids": [], "id": "Gene:atr"}, "predicate_names": ["physically_interacts_with", "co_expressed_with", "synthetic_lethal_with"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: This new combination treatment allows efficient application of [OBJ]PARPi[/OBJ] [SUBJ]Talazoparib[/SUBJ] to all UC patients, independent of Cisplatin pretreatment and genetic BRCAness.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HPhikJtTXOOQMnS1NWcNPw3lDI", "object": "chat.completion", "created": 1763442655, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"overcomes_resistance_with\",\n  \"confidence\": 0.72,\n  \"explanation\": \"The sentence indicates that the combination enables Talazoparib (PARPi) to be effectively used across all UC patients regardless of Cisplatin pretreatment and BRCA-like status, implying the combination overcomes resistance to PARP inhibitor monotherapy.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 151, "completion_tokens": 1111, "total_tokens": 1262, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1024, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41216708", "sentence_id": 10, "sentence": "This new combination treatment allows efficient application of PARPi Talazoparib to all UC patients, independent of Cisplatin pretreatment and genetic BRCAness.", "subject": {"text": "Talazoparib", "class": "Chemical", "start": 69, "end": 80, "ids": [], "id": "Chemical:talazoparib"}, "object": {"text": "PARPi", "class": "Chemical", "start": 63, "end": 68, "ids": [], "id": "Chemical:parpi"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Then, the cytotoxic, apoptotic and ATR based DNA damage response (DDR) were evaluated by [OBJ]WST-1[/OBJ], Annexin V, [SUBJ]AO/PI[/SUBJ], cell cycle and western blot analysis.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HUHQ857iyqBvToXoe1BlF1MpcT", "object": "chat.completion", "created": 1763442660, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.85,\n  \"explanation\": \"The sentence describes evaluating cytotoxicity, apoptosis, and ATR-based DDR using assays (WST-1, Annexin V, AO/PI, cell cycle, Western blot). There is no mention of chemical combinations, synergy, overcoming resistance, or sequential therapy, so none of the provided predicates apply.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 155, "completion_tokens": 734, "total_tokens": 889, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 640, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 5, "sentence": "Then, the cytotoxic, apoptotic and ATR based DNA damage response (DDR) were evaluated by WST-1, Annexin V, AO/PI, cell cycle and western blot analysis.", "subject": {"text": "AO/PI", "class": "Chemical", "start": 107, "end": 111, "ids": [], "id": "Chemical:ao_pi"}, "object": {"text": "WST-1", "class": "Chemical", "start": 89, "end": 93, "ids": [], "id": "Chemical:wst_1"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Studies on PARPi + [OBJ]ARPI[/OBJ] combinations have shown longer radiological progression-free survival, and better OS with talazoparib + enzalutamide, regardless of mutational status for [SUBJ]DNA repair genes[/SUBJ], with synergistic activity identified.\nAllowed predicates:\n- confers_resistance_to: Gene/protein mediates resistance to chemical/drug with specified mechanism and context (intrinsic/acquired, cancer type, fold-change).\n\n- sensitizes_to: Gene/protein or mutation increases vulnerability to chemical/drug. Include biomarker status if validated.\n\n- predicts_response_to: Gene or mutation status predicts treatment response. Specify FDA-approved/investigational biomarker status when applicable.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJ3oVeMLpXMPCBgYkQgUNhntzP", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"predicts_response_to\",\n  \"confidence\": 0.55,\n  \"explanation\": \"The sentence discusses whether DNA repair gene mutational status can predict response to PARP inhibitor + ARPI combination therapy. It notes that outcomes improve regardless of mutational status, indicating an assessment of a biomarker (DNA repair gene mutations) for predicting treatment response.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 195, "completion_tokens": 2200, "total_tokens": 2395, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 2112, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 5, "sentence": "Studies on PARPi + ARPI combinations have shown longer radiological progression-free survival, and better OS with talazoparib + enzalutamide, regardless of mutational status for DNA repair genes, with synergistic activity identified.", "subject": {"text": "DNA repair genes", "class": "Gene", "start": 178, "end": 194, "ids": [], "id": "Gene:dna_repair_genes"}, "object": {"text": "ARPI", "class": "Chemical", "start": 19, "end": 23, "ids": [], "id": "Chemical:arpi"}, "predicate_names": ["confers_resistance_to", "sensitizes_to", "predicts_response_to"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Studies on [OBJ]PARPi[/OBJ] + ARPI combinations have shown longer radiological progression-free survival, and better OS with talazoparib + enzalutamide, regardless of [SUBJ]mutational status[/SUBJ] for DNA repair genes, with synergistic activity identified.\nAllowed predicates:\n- sensitizes_to: Gene/protein or mutation increases vulnerability to chemical/drug. Include biomarker status if validated.\n\n- predicts_response_to: Gene or mutation status predicts treatment response. Specify FDA-approved/investigational biomarker status when applicable.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJXLrlYLklC1zEDdvdkh3lGuVQ", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.55,\n  \"explanation\": \"The sentence reports improved outcomes from PARPi+ARPI combinations regardless of DNA repair mutational status and mentions synergy, but it does not state that a gene/mutation sensitizes to the drugs nor that mutational status predicts response.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 162, "completion_tokens": 2128, "total_tokens": 2290, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 2048, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 5, "sentence": "Studies on PARPi + ARPI combinations have shown longer radiological progression-free survival, and better OS with talazoparib + enzalutamide, regardless of mutational status for DNA repair genes, with synergistic activity identified.", "subject": {"text": "mutational status", "class": "Mutation", "start": 156, "end": 173, "ids": [], "id": "Mutation:mutational_status"}, "object": {"text": "PARPi", "class": "Chemical", "start": 11, "end": 16, "ids": [], "id": "Chemical:parpi"}, "predicate_names": ["sensitizes_to", "predicts_response_to"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Then, the cytotoxic, apoptotic and ATR based DNA damage response (DDR) were evaluated by WST-1, [SUBJ]Annexin V[/SUBJ], AO/PI, [OBJ]cell cycle[/OBJ] and western blot analysis.\nAllowed predicates:\n- inhibits: Chemical inhibits pathway. Include IC50/potency and selectivity.\n\n- targets: Chemical targets multiple nodes in pathway.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HURPaG45PsKFcPsSpUWkw17Cbf", "object": "chat.completion", "created": 1763442660, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.84,\n  \"explanation\": \"There is no chemical inhibiting or targeting a node described; the sentence lists assays used to evaluate cytotoxicity, apoptosis, and DDR without specifying any inhibitory or targeting action.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 131, "completion_tokens": 836, "total_tokens": 967, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 768, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 5, "sentence": "Then, the cytotoxic, apoptotic and ATR based DNA damage response (DDR) were evaluated by WST-1, Annexin V, AO/PI, cell cycle and western blot analysis.", "subject": {"text": "Annexin V", "class": "Chemical", "start": 96, "end": 104, "ids": [], "id": "Chemical:annexin_v"}, "object": {"text": "cell cycle", "class": "Pathway", "start": 114, "end": 123, "ids": [], "id": "Pathway:cell_cycle"}, "predicate_names": ["inhibits", "targets"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: This new combination treatment allows efficient application of PARPi [SUBJ]Talazoparib[/SUBJ] to all UC patients, independent of [OBJ]Cisplatin[/OBJ] pretreatment and genetic BRCAness.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HP6cLXVaQB890dtcTd0zxJAPZj", "object": "chat.completion", "created": 1763442655, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"overcomes_resistance_with\",\n  \"confidence\": 0.72,\n  \"explanation\": \"The sentence states that the combination treatment allows Talazoparib to be effectively used across all UC patients independent of Cisplatin pretreatment and BRCAness, implying the combination overcomes resistance/limitations of monotherapy associated with those factors.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 152, "completion_tokens": 1239, "total_tokens": 1391, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1152, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41216708", "sentence_id": 10, "sentence": "This new combination treatment allows efficient application of PARPi Talazoparib to all UC patients, independent of Cisplatin pretreatment and genetic BRCAness.", "subject": {"text": "Talazoparib", "class": "Chemical", "start": 69, "end": 80, "ids": [], "id": "Chemical:talazoparib"}, "object": {"text": "Cisplatin", "class": "Chemical", "start": 116, "end": 125, "ids": [], "id": "Chemical:cisplatin"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Then, the cytotoxic, apoptotic and ATR based DNA damage response (DDR) were evaluated by [SUBJ]WST-1[/SUBJ], Annexin V, AO/PI, [OBJ]cell cycle[/OBJ] and western blot analysis.\nAllowed predicates:\n- inhibits: Chemical inhibits pathway. Include IC50/potency and selectivity.\n\n- targets: Chemical targets multiple nodes in pathway.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HTaVSgweg2vTYoHPVRo6vCp6dB", "object": "chat.completion", "created": 1763442659, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.66,\n  \"explanation\": \"The sentence reports evaluation/measurement of cytotoxicity, apoptosis, and ATR-based DDR using assays; it does not state that a chemical inhibits or targets nodes in a pathway.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 130, "completion_tokens": 964, "total_tokens": 1094, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 896, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 5, "sentence": "Then, the cytotoxic, apoptotic and ATR based DNA damage response (DDR) were evaluated by WST-1, Annexin V, AO/PI, cell cycle and western blot analysis.", "subject": {"text": "WST-1", "class": "Chemical", "start": 89, "end": 93, "ids": [], "id": "Chemical:wst_1"}, "object": {"text": "cell cycle", "class": "Pathway", "start": 114, "end": 123, "ids": [], "id": "Pathway:cell_cycle"}, "predicate_names": ["inhibits", "targets"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Then, the cytotoxic, apoptotic and ATR based DNA damage response (DDR) were evaluated by WST-1, [SUBJ]Annexin V[/SUBJ], [OBJ]AO/PI[/OBJ], cell cycle and western blot analysis.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HUfvSxn6yVdDr5x8qsbfiUFltL", "object": "chat.completion", "created": 1763442660, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\"predicate\":\"no_relation\",\"confidence\":0.85,\"explanation\":\"The sentence describes evaluation methods for cytotoxicity, apoptosis, and DDR (WST-1, Annexin V, AO/PI, cell cycle, Western blot) and does not express any relationship such as synergy, resistance overcoming, or sequential therapy between chemicals.\"}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 156, "completion_tokens": 974, "total_tokens": 1130, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 896, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 5, "sentence": "Then, the cytotoxic, apoptotic and ATR based DNA damage response (DDR) were evaluated by WST-1, Annexin V, AO/PI, cell cycle and western blot analysis.", "subject": {"text": "Annexin V", "class": "Chemical", "start": 96, "end": 104, "ids": [], "id": "Chemical:annexin_v"}, "object": {"text": "AO/PI", "class": "Chemical", "start": 107, "end": 111, "ids": [], "id": "Chemical:ao_pi"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: We aimed to assess the efficacy of ATR and [SUBJ]PARP inhibitors[/SUBJ] combination in TNBC cells and the reversal of [OBJ]PARPi[/OBJ] resistance in resistant cells.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HRTAsWPpM0MqMLp48HQ26Oy4oD", "object": "chat.completion", "created": 1763442657, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"overcomes_resistance_with\",\n  \"confidence\": 0.75,\n  \"explanation\": \"The sentence explicitly mentions the reversal of PARPi resistance in resistant cells by the ATR and PARP inhibitors combination, which aligns with a chemical combination that overcomes resistance to monotherapy (PARP inhibitors). The first clause notes efficacy but does not explicitly claim synergy.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 145, "completion_tokens": 985, "total_tokens": 1130, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 896, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 3, "sentence": "We aimed to assess the efficacy of ATR and PARP inhibitors combination in TNBC cells and the reversal of PARPi resistance in resistant cells.", "subject": {"text": "PARP inhibitors", "class": "Chemical", "start": 43, "end": 58, "ids": [], "id": "Chemical:parp_inhibitors"}, "object": {"text": "PARPi", "class": "Chemical", "start": 105, "end": 110, "ids": [], "id": "Chemical:parpi"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: HCC1937 and HCC1937-R [OBJ]Talazoparib[/OBJ] (TAL) resistant cells were treated with Elimusertib ([SUBJ]ELI[/SUBJ]) alone as ATR inhibitor (ATRi) and ELI and TAL combination.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HSKikwgCMMVEqzvgLqAXpDbXG5", "object": "chat.completion", "created": 1763442658, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"overcomes_resistance_with\",\n  \"confidence\": 0.65,\n  \"explanation\": \"The cells are TAL-resistant and are treated with Elimusertib alone and with an Elimusertib + Talazoparib combination, implying the study assesses whether the combination can overcome resistance to TAL monotherapy.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 162, "completion_tokens": 1233, "total_tokens": 1395, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1152, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 4, "sentence": "HCC1937 and HCC1937-R Talazoparib (TAL) resistant cells were treated with Elimusertib (ELI) alone as ATR inhibitor (ATRi) and ELI and TAL combination.", "subject": {"text": "ELI", "class": "Chemical", "start": 87, "end": 90, "ids": [], "id": "Chemical:eli"}, "object": {"text": "Talazoparib", "class": "Chemical", "start": 22, "end": 33, "ids": [], "id": "Chemical:talazoparib"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Then, the cytotoxic, apoptotic and [SUBJ]ATR[/SUBJ] based DNA damage response (DDR) were evaluated by WST-1, [OBJ]Annexin V[/OBJ], AO/PI, cell cycle and western blot analysis.\nAllowed predicates:\n- confers_resistance_to: Gene/protein mediates resistance to chemical/drug with specified mechanism and context (intrinsic/acquired, cancer type, fold-change).\n\n- sensitizes_to: Gene/protein or mutation increases vulnerability to chemical/drug. Include biomarker status if validated.\n\n- predicts_response_to: Gene or mutation status predicts treatment response. Specify FDA-approved/investigational biomarker status when applicable.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HTDoC8QrtYnu2phUczVGpPOGfm", "object": "chat.completion", "created": 1763442659, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.92,\n  \"explanation\": \"The sentence describes evaluating ATR-based DDR using various assays; it does not indicate conferring resistance, sensitizing, or predicting response to a treatment.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 188, "completion_tokens": 766, "total_tokens": 954, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 704, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 5, "sentence": "Then, the cytotoxic, apoptotic and ATR based DNA damage response (DDR) were evaluated by WST-1, Annexin V, AO/PI, cell cycle and western blot analysis.", "subject": {"text": "ATR", "class": "Gene", "start": 35, "end": 37, "ids": [], "id": "Gene:atr"}, "object": {"text": "Annexin V", "class": "Chemical", "start": 96, "end": 104, "ids": [], "id": "Chemical:annexin_v"}, "predicate_names": ["confers_resistance_to", "sensitizes_to", "predicts_response_to"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Then, the cytotoxic, apoptotic and ATR based DNA damage response (DDR) were evaluated by WST-1, [OBJ]Annexin V[/OBJ], [SUBJ]AO/PI[/SUBJ], cell cycle and western blot analysis.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HU0eNvyNMctghOoqfVhixuQiNJ", "object": "chat.completion", "created": 1763442660, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.8,\n  \"explanation\": \"The sentence describes evaluating cytotoxic, apoptotic, and ATR-based DDR status using assays; it does not express any interaction between chemicals, combination effects, resistance, or sequential therapy.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 156, "completion_tokens": 901, "total_tokens": 1057, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 832, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 5, "sentence": "Then, the cytotoxic, apoptotic and ATR based DNA damage response (DDR) were evaluated by WST-1, Annexin V, AO/PI, cell cycle and western blot analysis.", "subject": {"text": "AO/PI", "class": "Chemical", "start": 107, "end": 111, "ids": [], "id": "Chemical:ao_pi"}, "object": {"text": "Annexin V", "class": "Chemical", "start": 96, "end": 104, "ids": [], "id": "Chemical:annexin_v"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: HCC1937 and HCC1937-R [OBJ]Talazoparib[/OBJ] ([SUBJ]TAL[/SUBJ]) resistant cells were treated with Elimusertib (ELI) alone as ATR inhibitor (ATRi) and ELI and TAL combination.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HRUhkt82QlAoX2xbTVO5iqkwBb", "object": "chat.completion", "created": 1763442657, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"overcomes_resistance_with\",\n  \"confidence\": 0.63,\n  \"explanation\": \"The sentence describes TAL-resistant cells being treated with an ATR inhibitor alone and with the combination of ATR inhibitor and TAL, implying the combination is evaluated to overcome resistance to TAL monotherapy rather than indicating explicit synergy or sequential therapy.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 162, "completion_tokens": 977, "total_tokens": 1139, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 896, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 4, "sentence": "HCC1937 and HCC1937-R Talazoparib (TAL) resistant cells were treated with Elimusertib (ELI) alone as ATR inhibitor (ATRi) and ELI and TAL combination.", "subject": {"text": "TAL", "class": "Chemical", "start": 35, "end": 38, "ids": [], "id": "Chemical:tal"}, "object": {"text": "Talazoparib", "class": "Chemical", "start": 22, "end": 33, "ids": [], "id": "Chemical:talazoparib"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Then, the cytotoxic, apoptotic and ATR based DNA damage response (DDR) were evaluated by [SUBJ]WST-1[/SUBJ], [OBJ]Annexin V[/OBJ], AO/PI, cell cycle and western blot analysis.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HT74U01Nmvx4QreB4jNJkIjZHc", "object": "chat.completion", "created": 1763442659, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"no_predicate\",\n  \"confidence\": 0.65,\n  \"explanation\": \"The sentence describes measurement/assay methods to evaluate cytotoxicity, apoptosis, and DDR, but does not express a relationship between two Chemicals (no synergy), no resistance overcoming, and no sequential therapy context.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 156, "completion_tokens": 973, "total_tokens": 1129, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 896, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 5, "sentence": "Then, the cytotoxic, apoptotic and ATR based DNA damage response (DDR) were evaluated by WST-1, Annexin V, AO/PI, cell cycle and western blot analysis.", "subject": {"text": "WST-1", "class": "Chemical", "start": 89, "end": 93, "ids": [], "id": "Chemical:wst_1"}, "object": {"text": "Annexin V", "class": "Chemical", "start": 96, "end": 104, "ids": [], "id": "Chemical:annexin_v"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Poly(ADP-ribose) polymerase (PARP) inhibitors ([SUBJ]PARPi[/SUBJ]) have attracted significant attention in triple negative breast cancer ([OBJ]TNBC[/OBJ]) treatment.\nAllowed predicates:\n- approved_for: FDA/EMA approved for cancer subtype. Specify line of therapy and combination/monotherapy.\n\n- in_trials_for: In clinical trials. Specify phase I/II/III and NCT number if available.\n\n- resistance_emerges_in: Resistance commonly emerges in disease. Specify median time to resistance and frequency.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HQqVHb2iZyfqxZatxiNtRg1dRK", "object": "chat.completion", "created": 1763442656, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"in_trials_for\",\n  \"confidence\": 0.55,\n  \"explanation\": \"The sentence signals interest in PARP inhibitors for TNBC treatment, which aligns with being studied in clinical trials for this disease setting. It doesn't state regulatory approval or resistance.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 159, "completion_tokens": 1221, "total_tokens": 1380, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1152, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 0, "sentence": "Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) have attracted significant attention in triple negative breast cancer (TNBC) treatment.", "subject": {"text": "PARPi", "class": "Chemical", "start": 49, "end": 54, "ids": [], "id": "Chemical:parpi"}, "object": {"text": "TNBC", "class": "Disease", "start": 127, "end": 131, "ids": [], "id": "Disease:tnbc"}, "predicate_names": ["approved_for", "in_trials_for", "resistance_emerges_in"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: [SUBJ]Poly(ADP-ribose) polymerase[/SUBJ] (PARP) inhibitors (PARPi) have attracted significant attention in triple negative breast cancer ([OBJ]TNBC[/OBJ]) treatment.\nAllowed predicates:\n- prognostic_biomarker_in: Gene predicts outcome in specific cancer subtype. Specify ER+, TNBC, HER2+, and validation level.\n\n- predictive_biomarker_for: Gene predicts treatment response in cancer subtype. Distinguish from prognostic biomarkers. Specify FDA-approved/investigational status.\n\n- driver_in: Gene drives oncogenesis in specific cancer subtype. Requires evidence of causal role in tumor initiation or progression.\n\n- tumor_suppressor_in: Gene suppresses tumorigenesis in specific cancer subtype. Requires evidence of loss-of-function leading to cancer.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HQGptvIpD3wMww3Oh2wKjtdWme", "object": "chat.completion", "created": 1763442656, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.6,\n  \"explanation\": \"The sentence discusses PARP inhibitors as a treatment for TNBC and does not state that a gene predicts outcome, predicts treatment response, drives oncogenesis, or suppresses tumorigenesis. None of the four gene-centric biomarker predicates are directly supported by the sentence.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 209, "completion_tokens": 1430, "total_tokens": 1639, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1344, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 0, "sentence": "Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) have attracted significant attention in triple negative breast cancer (TNBC) treatment.", "subject": {"text": "Poly(ADP-ribose) polymerase", "class": "Gene", "start": 0, "end": 29, "ids": [], "id": "Gene:poly_adp_ribose_polymerase"}, "object": {"text": "TNBC", "class": "Disease", "start": 127, "end": 131, "ids": [], "id": "Disease:tnbc"}, "predicate_names": ["prognostic_biomarker_in", "predictive_biomarker_for", "driver_in", "tumor_suppressor_in"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Then, the cytotoxic, apoptotic and ATR based [OBJ]DNA damage response[/OBJ] (DDR) were evaluated by WST-1, [SUBJ]Annexin V[/SUBJ], AO/PI, cell cycle and western blot analysis.\nAllowed predicates:\n- inhibits: Chemical inhibits pathway. Include IC50/potency and selectivity.\n\n- targets: Chemical targets multiple nodes in pathway.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HT2qnIwC3Ztm59qCOcmUg3KIXe", "object": "chat.completion", "created": 1763442659, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.62,\n  \"explanation\": \"The sentence describes evaluating cytotoxicity, apoptosis, and ATR-based DNA damage response (DDR) using various assays. It does not state that a chemical inhibits or targets the DDR pathway; no chemical-entity relation is described.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 131, "completion_tokens": 1038, "total_tokens": 1169, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 960, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 5, "sentence": "Then, the cytotoxic, apoptotic and ATR based DNA damage response (DDR) were evaluated by WST-1, Annexin V, AO/PI, cell cycle and western blot analysis.", "subject": {"text": "Annexin V", "class": "Chemical", "start": 96, "end": 104, "ids": [], "id": "Chemical:annexin_v"}, "object": {"text": "DNA damage response", "class": "Pathway", "start": 45, "end": 63, "ids": [], "id": "Pathway:dna_damage_response"}, "predicate_names": ["inhibits", "targets"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Then, the cytotoxic, apoptotic and ATR based [OBJ]DNA damage response[/OBJ] (DDR) were evaluated by WST-1, Annexin V, [SUBJ]AO/PI[/SUBJ], cell cycle and western blot analysis.\nAllowed predicates:\n- inhibits: Chemical inhibits pathway. Include IC50/potency and selectivity.\n\n- targets: Chemical targets multiple nodes in pathway.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HU19Z8gRgn2eH161E8mZAFseHR", "object": "chat.completion", "created": 1763442660, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.85,\n  \"explanation\": \"The sentence describes evaluating cytotoxicity, apoptosis, and ATR-based DNA damage response (DDR) using various assays. It does not state that a chemical inhibits a pathway or targets multiple nodes in the pathway.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 130, "completion_tokens": 843, "total_tokens": 973, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 768, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 5, "sentence": "Then, the cytotoxic, apoptotic and ATR based DNA damage response (DDR) were evaluated by WST-1, Annexin V, AO/PI, cell cycle and western blot analysis.", "subject": {"text": "AO/PI", "class": "Chemical", "start": 107, "end": 111, "ids": [], "id": "Chemical:ao_pi"}, "object": {"text": "DNA damage response", "class": "Pathway", "start": 45, "end": 63, "ids": [], "id": "Pathway:dna_damage_response"}, "predicate_names": ["inhibits", "targets"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Then, the cytotoxic, apoptotic and ATR based DNA damage response (DDR) were evaluated by WST-1, Annexin V, [SUBJ]AO/PI[/SUBJ], [OBJ]cell cycle[/OBJ] and western blot analysis.\nAllowed predicates:\n- inhibits: Chemical inhibits pathway. Include IC50/potency and selectivity.\n\n- targets: Chemical targets multiple nodes in pathway.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HUIEOesPTNT4sDQWl6jr2W8DjZ", "object": "chat.completion", "created": 1763442660, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\"predicate\": \"none\", \"confidence\": 0.63, \"explanation\": \"The sentence describes evaluation/measurement methods (WST-1, Annexin V, AO/PI, cell cycle, western blot) for cytotoxic, apoptotic, and ATR-based DDR, not inhibition or targeting of a chemical/pathway.\"}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 130, "completion_tokens": 782, "total_tokens": 912, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 704, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 5, "sentence": "Then, the cytotoxic, apoptotic and ATR based DNA damage response (DDR) were evaluated by WST-1, Annexin V, AO/PI, cell cycle and western blot analysis.", "subject": {"text": "AO/PI", "class": "Chemical", "start": 107, "end": 111, "ids": [], "id": "Chemical:ao_pi"}, "object": {"text": "cell cycle", "class": "Pathway", "start": 114, "end": 123, "ids": [], "id": "Pathway:cell_cycle"}, "predicate_names": ["inhibits", "targets"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: We aimed to assess the efficacy of [SUBJ]ATR[/SUBJ] and [OBJ]PARP inhibitors[/OBJ] combination in TNBC cells and the reversal of PARPi resistance in resistant cells.\nAllowed predicates:\n- confers_resistance_to: Gene/protein mediates resistance to chemical/drug with specified mechanism and context (intrinsic/acquired, cancer type, fold-change).\n\n- sensitizes_to: Gene/protein or mutation increases vulnerability to chemical/drug. Include biomarker status if validated.\n\n- predicts_response_to: Gene or mutation status predicts treatment response. Specify FDA-approved/investigational biomarker status when applicable.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HR7A2rCb0ynwXbNsPpVEM1fwHS", "object": "chat.completion", "created": 1763442657, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"sensitizes_to\",\n  \"confidence\": 0.65,\n  \"explanation\": \"The sentence describes evaluating the ATR and PARP inhibitors combination and reversal of PARPi resistance in TNBC cells, which implies ATR increases vulnerability to PARP inhibitors (i.e., ATR sensitizes to PARP inhibitors), aligning with the 'sensitizes_to' predicate.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 176, "completion_tokens": 1306, "total_tokens": 1482, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1216, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 3, "sentence": "We aimed to assess the efficacy of ATR and PARP inhibitors combination in TNBC cells and the reversal of PARPi resistance in resistant cells.", "subject": {"text": "ATR", "class": "Gene", "start": 35, "end": 38, "ids": [], "id": "Gene:atr"}, "object": {"text": "PARP inhibitors", "class": "Chemical", "start": 43, "end": 58, "ids": [], "id": "Chemical:parp_inhibitors"}, "predicate_names": ["confers_resistance_to", "sensitizes_to", "predicts_response_to"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: HCC1937 and HCC1937-R Talazoparib (TAL) resistant cells were treated with [OBJ]Elimusertib[/OBJ] ([SUBJ]ELI[/SUBJ]) alone as ATR inhibitor (ATRi) and ELI and TAL combination.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HS6qgNckojEiDUD6VV5aB2kaXI", "object": "chat.completion", "created": 1763442658, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"overcomes_resistance_with\",\n  \"confidence\": 0.60,\n  \"explanation\": \"The sentence describes TAL-resistant cells being treated with Elimusertib alone and in combination with Talazoparib, implying the combination is being evaluated to overcome resistance to TAL monotherapy. No explicit synergistic effect is stated.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 162, "completion_tokens": 1235, "total_tokens": 1397, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1152, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 4, "sentence": "HCC1937 and HCC1937-R Talazoparib (TAL) resistant cells were treated with Elimusertib (ELI) alone as ATR inhibitor (ATRi) and ELI and TAL combination.", "subject": {"text": "ELI", "class": "Chemical", "start": 87, "end": 90, "ids": [], "id": "Chemical:eli"}, "object": {"text": "Elimusertib", "class": "Chemical", "start": 74, "end": 85, "ids": [], "id": "Chemical:elimusertib"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Ataxia telangiectasia and Rad3-related ([SUBJ]ATR[/SUBJ]) regulates genome integrity, and thus, the aberrant activation of ATR could play a significant role in the pathogenesis of TNBC and be associated with [OBJ]PARPi[/OBJ] resistance in especially homologous recombinant deficiency tumors.\nAllowed predicates:\n- confers_resistance_to: Gene/protein mediates resistance to chemical/drug with specified mechanism and context (intrinsic/acquired, cancer type, fold-change).\n\n- sensitizes_to: Gene/protein or mutation increases vulnerability to chemical/drug. Include biomarker status if validated.\n\n- predicts_response_to: Gene or mutation status predicts treatment response. Specify FDA-approved/investigational biomarker status when applicable.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HQAXF9kjV8RSttQIgue7XjWDDD", "object": "chat.completion", "created": 1763442656, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"confers_resistance_to\",\n  \"confidence\": 0.55,\n  \"explanation\": \"The sentence links ATR activation to PARP inhibitor (PARPi) resistance in HRD tumors, implying ATR could mediate or contribute to resistance to PARPi, which aligns with the 'confers_resistance_to' predicate in the given context.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 200, "completion_tokens": 1494, "total_tokens": 1694, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1408, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 2, "sentence": "Ataxia telangiectasia and Rad3-related (ATR) regulates genome integrity, and thus, the aberrant activation of ATR could play a significant role in the pathogenesis of TNBC and be associated with PARPi resistance in especially homologous recombinant deficiency tumors.", "subject": {"text": "ATR", "class": "Gene", "start": 111, "end": 113, "ids": [], "id": "Gene:atr"}, "object": {"text": "PARPi", "class": "Chemical", "start": 195, "end": 199, "ids": [], "id": "Chemical:parpi"}, "predicate_names": ["confers_resistance_to", "sensitizes_to", "predicts_response_to"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Then, the cytotoxic, apoptotic and ATR based DNA damage response (DDR) were evaluated by [OBJ]WST-1[/OBJ], [SUBJ]Annexin V[/SUBJ], AO/PI, cell cycle and western blot analysis.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HTV8fcSuA1Pq3zvPXlR2HDWgZ3", "object": "chat.completion", "created": 1763442659, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.72,\n  \"explanation\": \"The sentence describes evaluating cellular responses (cytotoxicity, apoptosis, DDR) using assays; it does not mention a chemical combination, synergy, overcoming resistance, or sequential therapy.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 156, "completion_tokens": 773, "total_tokens": 929, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 704, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 5, "sentence": "Then, the cytotoxic, apoptotic and ATR based DNA damage response (DDR) were evaluated by WST-1, Annexin V, AO/PI, cell cycle and western blot analysis.", "subject": {"text": "Annexin V", "class": "Chemical", "start": 96, "end": 104, "ids": [], "id": "Chemical:annexin_v"}, "object": {"text": "WST-1", "class": "Chemical", "start": 89, "end": 93, "ids": [], "id": "Chemical:wst_1"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of PARPi agents available (olaparib, [OBJ]niraparib[/OBJ], rucaparib, and talazoparib) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying [SUBJ]BRCA1/2 mutations[/SUBJ].\nAllowed predicates:\n- sensitizes_to: Gene/protein or mutation increases vulnerability to chemical/drug. Include biomarker status if validated.\n\n- predicts_response_to: Gene or mutation status predicts treatment response. Specify FDA-approved/investigational biomarker status when applicable.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJAX6Gyh6pLLSPenLjdIWHGiu1", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"predicts_response_to\",\n  \"confidence\": 0.85,\n  \"explanation\": \"The sentence indicates that patients with BRCA1/2 mutations experience prolonged OS with PARP inhibitors in metastatic CRPC, meaning BRCA1/2 mutation status predicts response to these drugs. BRCA1/2 mutation status is a biomarker used to guide PARP inhibitor therapy (FDA-approved/investigational biomarker status applicable%).\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 178, "completion_tokens": 2026, "total_tokens": 2204, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1920, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41219112", "sentence_id": 4, "sentence": "KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of PARPi agents available (olaparib, niraparib, rucaparib, and talazoparib) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations.", "subject": {"text": "BRCA1/2 mutations", "class": "Mutation", "start": 259, "end": 276, "ids": [], "id": "Mutation:brca1_2_mutations"}, "object": {"text": "niraparib", "class": "Chemical", "start": 107, "end": 116, "ids": [], "id": "Chemical:niraparib"}, "predicate_names": ["sensitizes_to", "predicts_response_to"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: HCC1937 and HCC1937-R Talazoparib (TAL) resistant cells were treated with [SUBJ]Elimusertib[/SUBJ] ([OBJ]ELI[/OBJ]) alone as ATR inhibitor (ATRi) and ELI and TAL combination.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HStQ0FDfxzYgeqm440mXkotW2v", "object": "chat.completion", "created": 1763442658, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"overcomes_resistance_with\",\n  \"confidence\": 0.60,\n  \"explanation\": \"The cells are TAL-resistant and were treated with the ATR inhibitor ELI alone and in combination with TAL; this setup suggests evaluating whether the ELI+TAL combination can overcome resistance to TAL monotherapy.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 162, "completion_tokens": 1230, "total_tokens": 1392, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1152, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 4, "sentence": "HCC1937 and HCC1937-R Talazoparib (TAL) resistant cells were treated with Elimusertib (ELI) alone as ATR inhibitor (ATRi) and ELI and TAL combination.", "subject": {"text": "Elimusertib", "class": "Chemical", "start": 74, "end": 85, "ids": [], "id": "Chemical:elimusertib"}, "object": {"text": "ELI", "class": "Chemical", "start": 87, "end": 90, "ids": [], "id": "Chemical:eli"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: In conclusion, we suggest Talazoparib treatment of [OBJ]UC[/OBJ] to be highly efficacious on all models examined when combined with [SUBJ]PLX51107[/SUBJ].\nAllowed predicates:\n- approved_for: FDA/EMA approved for cancer subtype. Specify line of therapy and combination/monotherapy.\n\n- in_trials_for: In clinical trials. Specify phase I/II/III and NCT number if available.\n\n- resistance_emerges_in: Resistance commonly emerges in disease. Specify median time to resistance and frequency.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HPmRle3VikUT8jGlDZhcXsq26G", "object": "chat.completion", "created": 1763442655, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.60,\n  \"explanation\": \"The sentence describes preclinical efficacy of talazoparib (UC) in models when combined with PLX51107. It does not state regulatory approval (approved_for), does not report clinical trial status (in_trials_for), and does not discuss resistance timing/frequency (resistance_emerges_in). Therefore, none of the allowed predicates directly apply.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 158, "completion_tokens": 1256, "total_tokens": 1414, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1152, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41216708", "sentence_id": 9, "sentence": "In conclusion, we suggest Talazoparib treatment of UC to be highly efficacious on all models examined when combined with PLX51107.", "subject": {"text": "PLX51107", "class": "Chemical", "start": 121, "end": 129, "ids": [], "id": "Chemical:plx51107"}, "object": {"text": "UC", "class": "Disease", "start": 51, "end": 53, "ids": [], "id": "Disease:uc"}, "predicate_names": ["approved_for", "in_trials_for", "resistance_emerges_in"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: HCC1937 and HCC1937-R [SUBJ]Talazoparib[/SUBJ] ([OBJ]TAL[/OBJ]) resistant cells were treated with Elimusertib (ELI) alone as ATR inhibitor (ATRi) and ELI and TAL combination.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HRe6aWTR4BUmE6AVREJilwdhfT", "object": "chat.completion", "created": 1763442657, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"overcomes_resistance_with\",\n  \"confidence\": 0.42,\n  \"explanation\": \"The sentence notes Talazoparib-resistant cells being treated with a combination including Elimusertib and Talazoparib, which implies testing whether the chemical combination overcomes resistance to TAL monotherapy. There is no explicit outcome reported, but the setup aligns with the 'overcomes_resistance_with' predicate.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 162, "completion_tokens": 1381, "total_tokens": 1543, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1280, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 4, "sentence": "HCC1937 and HCC1937-R Talazoparib (TAL) resistant cells were treated with Elimusertib (ELI) alone as ATR inhibitor (ATRi) and ELI and TAL combination.", "subject": {"text": "Talazoparib", "class": "Chemical", "start": 22, "end": 33, "ids": [], "id": "Chemical:talazoparib"}, "object": {"text": "TAL", "class": "Chemical", "start": 35, "end": 38, "ids": [], "id": "Chemical:tal"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: HCC1937 and HCC1937-R Talazoparib ([SUBJ]TAL[/SUBJ]) resistant cells were treated with [OBJ]Elimusertib[/OBJ] (ELI) alone as ATR inhibitor (ATRi) and ELI and TAL combination.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HRGYoFRKbCniIj4HI5sx9ZLyaw", "object": "chat.completion", "created": 1763442657, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"overcomes_resistance_with\",\n  \"confidence\": 0.62,\n  \"explanation\": \"The sentence mentions TAL-resistant cells being treated with an ATR inhibitor alone and in combination with TAL, suggesting the combination is studied to overcome resistance to TAL monotherapy.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 162, "completion_tokens": 1477, "total_tokens": 1639, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1408, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 4, "sentence": "HCC1937 and HCC1937-R Talazoparib (TAL) resistant cells were treated with Elimusertib (ELI) alone as ATR inhibitor (ATRi) and ELI and TAL combination.", "subject": {"text": "TAL", "class": "Chemical", "start": 35, "end": 38, "ids": [], "id": "Chemical:tal"}, "object": {"text": "Elimusertib", "class": "Chemical", "start": 74, "end": 85, "ids": [], "id": "Chemical:elimusertib"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: HCC1937 and HCC1937-R Talazoparib ([OBJ]TAL[/OBJ]) resistant cells were treated with [SUBJ]Elimusertib[/SUBJ] (ELI) alone as ATR inhibitor (ATRi) and ELI and TAL combination.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HRjq31M1uihIiGwIFRrMfeNCGp", "object": "chat.completion", "created": 1763442657, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\"predicate\": \"overcomes_resistance_with\", \"confidence\": 0.65, \"explanation\": \"The sentence describes TAL-resistant cells being treated with the ATR inhibitor Elimusertib alone and in combination with Talazoparib, implying assessment of whether the chemical combination overcomes resistance to TAL monotherapy.\"}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 162, "completion_tokens": 1099, "total_tokens": 1261, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1024, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 4, "sentence": "HCC1937 and HCC1937-R Talazoparib (TAL) resistant cells were treated with Elimusertib (ELI) alone as ATR inhibitor (ATRi) and ELI and TAL combination.", "subject": {"text": "Elimusertib", "class": "Chemical", "start": 74, "end": 85, "ids": [], "id": "Chemical:elimusertib"}, "object": {"text": "TAL", "class": "Chemical", "start": 35, "end": 38, "ids": [], "id": "Chemical:tal"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Then, the cytotoxic, apoptotic and [SUBJ]ATR[/SUBJ] based [OBJ]DNA damage response[/OBJ] (DDR) were evaluated by WST-1, Annexin V, AO/PI, cell cycle and western blot analysis.\nAllowed predicates:\n- activates: Gene activates pathway. Specify direct/indirect and cancer type where observed.\n\n- is_essential_for: Gene required for pathway function in specific context.\n\n- bypasses: Gene activation bypasses inhibition of another pathway (resistance mechanism).\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HSQ7V153OqrXlVEcvQe3xXse3z", "object": "chat.completion", "created": 1763442658, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.45,\n  \"explanation\": \"The sentence mentions ATR-based DDR and that it was evaluated using various assays, but it does not express a relationship such as ATR activating DDR, ATR being essential for DDR in a specific context, or ATR bypassing another pathway. Therefore, none of the allowed predicates neatly apply.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 154, "completion_tokens": 1112, "total_tokens": 1266, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1024, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 5, "sentence": "Then, the cytotoxic, apoptotic and ATR based DNA damage response (DDR) were evaluated by WST-1, Annexin V, AO/PI, cell cycle and western blot analysis.", "subject": {"text": "ATR", "class": "Gene", "start": 35, "end": 37, "ids": [], "id": "Gene:atr"}, "object": {"text": "DNA damage response", "class": "Pathway", "start": 45, "end": 63, "ids": [], "id": "Pathway:dna_damage_response"}, "predicate_names": ["activates", "is_essential_for", "bypasses"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: However, further preclinical and clinical investigations should be required to elucidate the underlying molecular mechanisms behind [SUBJ]ATRi[/SUBJ] and PARPi interactions in [OBJ]TNBC[/OBJ] cells.\nAllowed predicates:\n- approved_for: FDA/EMA approved for cancer subtype. Specify line of therapy and combination/monotherapy.\n\n- in_trials_for: In clinical trials. Specify phase I/II/III and NCT number if available.\n\n- resistance_emerges_in: Resistance commonly emerges in disease. Specify median time to resistance and frequency.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HYJF0dDb7d18TWGHwRBkuqvDQ6", "object": "chat.completion", "created": 1763442664, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.72,\n  \"explanation\": \"The sentence discusses needing further investigations to elucidate molecular mechanisms behind ATRi and PARPi interactions in TNBC cells; it does not claim FDA/EMA approval, that it is in clinical trials, or that resistance emerges.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 159, "completion_tokens": 717, "total_tokens": 876, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 640, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 10, "sentence": "However, further preclinical and clinical investigations should be required to elucidate the underlying molecular mechanisms behind ATRi and PARPi interactions in TNBC cells.", "subject": {"text": "ATRi", "class": "Chemical", "start": 132, "end": 136, "ids": [], "id": "Chemical:atri"}, "object": {"text": "TNBC", "class": "Disease", "start": 163, "end": 167, "ids": [], "id": "Disease:tnbc"}, "predicate_names": ["approved_for", "in_trials_for", "resistance_emerges_in"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Then, the cytotoxic, apoptotic and ATR based [OBJ]DNA damage response[/OBJ] (DDR) were evaluated by [SUBJ]WST-1[/SUBJ], Annexin V, AO/PI, cell cycle and western blot analysis.\nAllowed predicates:\n- inhibits: Chemical inhibits pathway. Include IC50/potency and selectivity.\n\n- targets: Chemical targets multiple nodes in pathway.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HT2YSUgGow8K68XK3SwtmSkQNk", "object": "chat.completion", "created": 1763442659, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.58,\n  \"explanation\": \"The sentence describes evaluating cytotoxicity, apoptosis, and DDR using various assays. It does not state that a chemical inhibits or targets the DDR; no explicit drug-target or inhibition relationship is presented.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 130, "completion_tokens": 1096, "total_tokens": 1226, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1024, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 5, "sentence": "Then, the cytotoxic, apoptotic and ATR based DNA damage response (DDR) were evaluated by WST-1, Annexin V, AO/PI, cell cycle and western blot analysis.", "subject": {"text": "WST-1", "class": "Chemical", "start": 89, "end": 93, "ids": [], "id": "Chemical:wst_1"}, "object": {"text": "DNA damage response", "class": "Pathway", "start": 45, "end": 63, "ids": [], "id": "Pathway:dna_damage_response"}, "predicate_names": ["inhibits", "targets"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: This new combination treatment allows efficient application of [SUBJ]PARPi[/SUBJ] [OBJ]Talazoparib[/OBJ] to all UC patients, independent of Cisplatin pretreatment and genetic BRCAness.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HPWONteJYvMg9BUN9vithAAA5G", "object": "chat.completion", "created": 1763442655, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"overcomes_resistance_with\",\n  \"confidence\": 0.72,\n  \"explanation\": \"The sentence describes a new combination that enables PARP inhibitor Talazoparib to be effective across all UC patients, independent of Cisplatin pretreatment and BRCA-like status, implying the combination overcomes resistance barriers to PARPi monotherapy.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 151, "completion_tokens": 1815, "total_tokens": 1966, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1728, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41216708", "sentence_id": 10, "sentence": "This new combination treatment allows efficient application of PARPi Talazoparib to all UC patients, independent of Cisplatin pretreatment and genetic BRCAness.", "subject": {"text": "PARPi", "class": "Chemical", "start": 63, "end": 68, "ids": [], "id": "Chemical:parpi"}, "object": {"text": "Talazoparib", "class": "Chemical", "start": 69, "end": 80, "ids": [], "id": "Chemical:talazoparib"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: HCC1937 and HCC1937-R Talazoparib (TAL) resistant cells were treated with [OBJ]Elimusertib[/OBJ] (ELI) alone as [SUBJ]ATR[/SUBJ] inhibitor (ATRi) and ELI and TAL combination.\nAllowed predicates:\n- confers_resistance_to: Gene/protein mediates resistance to chemical/drug with specified mechanism and context (intrinsic/acquired, cancer type, fold-change).\n\n- sensitizes_to: Gene/protein or mutation increases vulnerability to chemical/drug. Include biomarker status if validated.\n\n- predicts_response_to: Gene or mutation status predicts treatment response. Specify FDA-approved/investigational biomarker status when applicable.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HSCUtWY607vpz5v01KeuZsSnlz", "object": "chat.completion", "created": 1763442658, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"sensitizes_to\",\n  \"confidence\": 0.75,\n  \"explanation\": \"The experiment uses an ATR inhibitor (ELI) in TAL-resistant cells and tests ELI alone and in combination with TAL, implying ATR inhibition increases vulnerability/sensitivity to Talazoparib (or enhances response when combined).\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 195, "completion_tokens": 1362, "total_tokens": 1557, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1280, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 4, "sentence": "HCC1937 and HCC1937-R Talazoparib (TAL) resistant cells were treated with Elimusertib (ELI) alone as ATR inhibitor (ATRi) and ELI and TAL combination.", "subject": {"text": "ATR", "class": "Gene", "start": 101, "end": 104, "ids": [], "id": "Gene:atr"}, "object": {"text": "Elimusertib", "class": "Chemical", "start": 74, "end": 85, "ids": [], "id": "Chemical:elimusertib"}, "predicate_names": ["confers_resistance_to", "sensitizes_to", "predicts_response_to"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: The overexpression of [SUBJ]ATR[/SUBJ] and associated cell cycle proteins could play a role in [OBJ]PARPi resistance[/OBJ].\nAllowed predicates:\n- upregulated_in_resistance: Gene upregulated in resistance to specific drug. Specify fold-change, p-value, cell lines tested, acquired vs intrinsic resistance.\n\n- downregulated_in_resistance: Gene downregulated in resistance to specific drug. Include fold-change, p-value, and cell lines tested.\n\n- correlates_with_survival: Gene expression correlates with overall or progression-free survival. Include hazard ratio and p-value.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HWAXardI5Ga8SLp4M869Nxi9O5", "object": "chat.completion", "created": 1763442662, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"upregulated_in_resistance\",\n  \"confidence\": 0.85,\n  \"explanation\": \"The sentence states overexpression of ATR (and associated cell cycle proteins) could play a role in PARPi resistance, which aligns with a gene upregulated in resistance to a specific drug. No quantitative details (fold-change, p-value), cell lines, or whether resistance is acquired vs intrinsic are provided.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 167, "completion_tokens": 993, "total_tokens": 1160, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 896, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 7, "sentence": "The overexpression of ATR and associated cell cycle proteins could play a role in PARPi resistance.", "subject": {"text": "ATR", "class": "Gene", "start": 22, "end": 25, "ids": [], "id": "Gene:atr"}, "object": {"text": "PARPi resistance", "class": "Phenotype", "start": 82, "end": 98, "ids": [], "id": "Phenotype:parpi_resistance"}, "predicate_names": ["upregulated_in_resistance", "downregulated_in_resistance", "correlates_with_survival"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Ataxia telangiectasia and Rad3-related ([SUBJ]ATR[/SUBJ]) regulates genome integrity, and thus, the aberrant activation of ATR could play a significant role in the pathogenesis of [OBJ]TNBC[/OBJ] and be associated with PARPi resistance in especially homologous recombinant deficiency tumors.\nAllowed predicates:\n- prognostic_biomarker_in: Gene predicts outcome in specific cancer subtype. Specify ER+, TNBC, HER2+, and validation level.\n\n- predictive_biomarker_for: Gene predicts treatment response in cancer subtype. Distinguish from prognostic biomarkers. Specify FDA-approved/investigational status.\n\n- driver_in: Gene drives oncogenesis in specific cancer subtype. Requires evidence of causal role in tumor initiation or progression.\n\n- tumor_suppressor_in: Gene suppresses tumorigenesis in specific cancer subtype. Requires evidence of loss-of-function leading to cancer.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HQL0H3ByYclg0A8obvr9zK35M1", "object": "chat.completion", "created": 1763442656, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"predictive_biomarker_for\",\n  \"confidence\": 0.78,\n  \"explanation\": \"The sentence links ATR activation with TNBC pathogenesis and PARP inhibitor resistance in homologous recombination-deficient tumors, indicating ATR could predict treatment response (resistance) to PARP inhibitors in TNBC/HRD. This is a predictive biomarker, not a driver or tumor suppressor. Its status is investigational (not FDA-approved).\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 229, "completion_tokens": 1645, "total_tokens": 1874, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1536, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 2, "sentence": "Ataxia telangiectasia and Rad3-related (ATR) regulates genome integrity, and thus, the aberrant activation of ATR could play a significant role in the pathogenesis of TNBC and be associated with PARPi resistance in especially homologous recombinant deficiency tumors.", "subject": {"text": "ATR", "class": "Gene", "start": 111, "end": 113, "ids": [], "id": "Gene:atr"}, "object": {"text": "TNBC", "class": "Disease", "start": 167, "end": 170, "ids": [], "id": "Disease:tnbc"}, "predicate_names": ["prognostic_biomarker_in", "predictive_biomarker_for", "driver_in", "tumor_suppressor_in"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Our results showed that the ELI and [SUBJ]TAL[/SUBJ] combination could overcome TAL resistance by downregulating cell cycle checkpoint proteins and ATR-based [OBJ]DDR[/OBJ] pathways through synergistic effects (ZIP score\u2009>\u200910).\nAllowed predicates:\n- activates: Gene activates pathway. Specify direct/indirect and cancer type where observed.\n\n- is_essential_for: Gene required for pathway function in specific context.\n\n- bypasses: Gene activation bypasses inhibition of another pathway (resistance mechanism).\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HWigtXNeRR8aEaWSr30mOyt1NW", "object": "chat.completion", "created": 1763442662, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"bypasses\",\n  \"confidence\": 0.72,\n  \"explanation\": \"The sentence states that the ELI and TAL combination could overcome TAL resistance by downregulating DDR pathways, i.e., bypassing the resistance mechanism. This matches the concept of bypassing inhibition/resistance rather than activation or essentiality.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 154, "completion_tokens": 1107, "total_tokens": 1261, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1024, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 6, "sentence": "Our results showed that the ELI and TAL combination could overcome TAL resistance by downregulating cell cycle checkpoint proteins and ATR-based DDR pathways through synergistic effects (ZIP score\u2009>\u200910).", "subject": {"text": "TAL", "class": "Gene", "start": 67, "end": 70, "ids": [], "id": "Gene:tal"}, "object": {"text": "DDR", "class": "Pathway", "start": 145, "end": 148, "ids": [], "id": "Pathway:ddr"}, "predicate_names": ["activates", "is_essential_for", "bypasses"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: By analysis of experimental and public clinical data, we identified new UC-specific PARPi response predictors SLFN5, [OBJ]SLFN11[/OBJ], and [SUBJ]OAS1[/SUBJ].\nAllowed predicates:\n- physically_interacts_with: Protein-protein interaction. Specify method of detection and binding affinity if known.\n\n- co_expressed_with: Genes show correlated expression across samples. Include correlation coefficient and context.\n\n- synthetic_lethal_with: Combined inhibition is lethal in specific cancer context. Requires functional validation.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJZkMi4UvOAd5Pz2NXyyxwbjfR", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"co_expressed_with\",\n  \"confidence\": 0.58,\n  \"explanation\": \"The sentence identifies SLFN5, SLFN11, and OAS1 as predictors of PARPi response, which aligns with using gene expression data to find predictive biomarkers. 'Co_expressed_with' captures correlated expression patterns across samples. The text does not state a physical interaction or synthetic lethality, and no correlation coefficient is provided.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 152, "completion_tokens": 2599, "total_tokens": 2751, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 2496, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41216708", "sentence_id": 5, "sentence": "By analysis of experimental and public clinical data, we identified new UC-specific PARPi response predictors SLFN5, SLFN11, and OAS1.", "subject": {"text": "OAS1", "class": "Gene", "start": 120, "end": 123, "ids": [], "id": "Gene:oas1"}, "object": {"text": "SLFN11", "class": "Gene", "start": 108, "end": 113, "ids": [], "id": "Gene:slfn11"}, "predicate_names": ["physically_interacts_with", "co_expressed_with", "synthetic_lethal_with"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Our results showed that the ELI and [OBJ]TAL[/OBJ] combination could overcome TAL resistance by downregulating cell cycle checkpoint proteins and [SUBJ]ATR[/SUBJ]-based DDR pathways through synergistic effects (ZIP score\u2009>\u200910).\nAllowed predicates:\n- physically_interacts_with: Protein-protein interaction. Specify method of detection and binding affinity if known.\n\n- co_expressed_with: Genes show correlated expression across samples. Include correlation coefficient and context.\n\n- synthetic_lethal_with: Combined inhibition is lethal in specific cancer context. Requires functional validation.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HWb2PSowRFWpbnhmDtj5w13hP7", "object": "chat.completion", "created": 1763442662, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.65,\n  \"explanation\": \"The statement reports that the ELI and TAL combination overcomes TAL resistance via synergistic effects affecting cell cycle checkpoint proteins and ATR-based DDR pathways. It does not claim a direct protein-protein interaction, gene co-expression, or a synthetic-lethal relationship between the entities, so none of the three predicates applies.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 163, "completion_tokens": 1119, "total_tokens": 1282, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1024, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 6, "sentence": "Our results showed that the ELI and TAL combination could overcome TAL resistance by downregulating cell cycle checkpoint proteins and ATR-based DDR pathways through synergistic effects (ZIP score\u2009>\u200910).", "subject": {"text": "ATR", "class": "Gene", "start": 135, "end": 138, "ids": [], "id": "Gene:atr"}, "object": {"text": "TAL", "class": "Gene", "start": 36, "end": 39, "ids": [], "id": "Gene:tal"}, "predicate_names": ["physically_interacts_with", "co_expressed_with", "synthetic_lethal_with"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Then, the cytotoxic, apoptotic and [SUBJ]ATR[/SUBJ] based DNA damage response ([OBJ]DDR[/OBJ]) were evaluated by WST-1, Annexin V, AO/PI, cell cycle and western blot analysis.\nAllowed predicates:\n- activates: Gene activates pathway. Specify direct/indirect and cancer type where observed.\n\n- is_essential_for: Gene required for pathway function in specific context.\n\n- bypasses: Gene activation bypasses inhibition of another pathway (resistance mechanism).\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HSngHFjyyLIQt5mCs61K7Jw4zD", "object": "chat.completion", "created": 1763442658, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"activates\",\n  \"confidence\": 0.65,\n  \"explanation\": \"The sentence refers to an 'ATR-based DNA damage response', which implies ATR is involved in activating the DDR pathway. The data mention ATR-based DDR without specifying cancer type, so the activation is not cancer-type specific.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 152, "completion_tokens": 1293, "total_tokens": 1445, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1216, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 5, "sentence": "Then, the cytotoxic, apoptotic and ATR based DNA damage response (DDR) were evaluated by WST-1, Annexin V, AO/PI, cell cycle and western blot analysis.", "subject": {"text": "ATR", "class": "Gene", "start": 35, "end": 37, "ids": [], "id": "Gene:atr"}, "object": {"text": "DDR", "class": "Pathway", "start": 66, "end": 68, "ids": [], "id": "Pathway:ddr"}, "predicate_names": ["activates", "is_essential_for", "bypasses"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Our results showed that the ELI and [SUBJ]TAL[/SUBJ] combination could overcome TAL resistance by downregulating cell cycle checkpoint proteins and [OBJ]ATR[/OBJ]-based DDR pathways through synergistic effects (ZIP score\u2009>\u200910).\nAllowed predicates:\n- physically_interacts_with: Protein-protein interaction. Specify method of detection and binding affinity if known.\n\n- co_expressed_with: Genes show correlated expression across samples. Include correlation coefficient and context.\n\n- synthetic_lethal_with: Combined inhibition is lethal in specific cancer context. Requires functional validation.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HV560cMzuIiCRfDS5BPflV43JD", "object": "chat.completion", "created": 1763442661, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\"predicate\":\"none\",\"confidence\":0.58,\"explanation\":\"The sentence describes a synergistic combination effect between ELI and TAL that overcomes TAL resistance by downregulating cell cycle checkpoint proteins and ATR-based DDR pathways. None of the allowed predicates (physically_interacts_with, co_expressed_with, synthetic_lethal_with) directly capture a general synergistic functional relationship or mechanism; it does not specify a physical interaction, correlated expression, or lethality from combined inhibition.\"}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 163, "completion_tokens": 1323, "total_tokens": 1486, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1216, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 6, "sentence": "Our results showed that the ELI and TAL combination could overcome TAL resistance by downregulating cell cycle checkpoint proteins and ATR-based DDR pathways through synergistic effects (ZIP score\u2009>\u200910).", "subject": {"text": "TAL", "class": "Gene", "start": 36, "end": 39, "ids": [], "id": "Gene:tal"}, "object": {"text": "ATR", "class": "Gene", "start": 135, "end": 138, "ids": [], "id": "Gene:atr"}, "predicate_names": ["physically_interacts_with", "co_expressed_with", "synthetic_lethal_with"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: By analysis of experimental and public clinical data, we identified new UC-specific PARPi response predictors SLFN5, [SUBJ]SLFN11[/SUBJ], and [OBJ]OAS1[/OBJ].\nAllowed predicates:\n- physically_interacts_with: Protein-protein interaction. Specify method of detection and binding affinity if known.\n\n- co_expressed_with: Genes show correlated expression across samples. Include correlation coefficient and context.\n\n- synthetic_lethal_with: Combined inhibition is lethal in specific cancer context. Requires functional validation.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HJsy1Xs9LS2NbfUraWC7rR8Dr8", "object": "chat.completion", "created": 1763442649, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"co_expressed_with\",\n  \"confidence\": 0.62,\n  \"explanation\": \"The sentence identifies SLFN5, SLFN11, and OAS1 as predictors of UC-specific PARPi response, which aligns with gene-expression\u2013based biomarker concepts. There is no explicit mention of physical interaction or synthetic lethality in the sentence. Therefore, co_expressed_with is the most plausible given predicate among those provided. Note: a specific correlation coefficient and the context would be needed to fully specify this relationship.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 152, "completion_tokens": 2618, "total_tokens": 2770, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 2496, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41216708", "sentence_id": 5, "sentence": "By analysis of experimental and public clinical data, we identified new UC-specific PARPi response predictors SLFN5, SLFN11, and OAS1.", "subject": {"text": "SLFN11", "class": "Gene", "start": 108, "end": 113, "ids": [], "id": "Gene:slfn11"}, "object": {"text": "OAS1", "class": "Gene", "start": 120, "end": 123, "ids": [], "id": "Gene:oas1"}, "predicate_names": ["physically_interacts_with", "co_expressed_with", "synthetic_lethal_with"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Therefore, the dual targeting of [SUBJ]ATR[/SUBJ] and PARP is a promising modality to reverse [OBJ]PARPi[/OBJ] resistance with the downregulation of ATR-Chk1 based DNA damage response.\nAllowed predicates:\n- confers_resistance_to: Gene/protein mediates resistance to chemical/drug with specified mechanism and context (intrinsic/acquired, cancer type, fold-change).\n\n- sensitizes_to: Gene/protein or mutation increases vulnerability to chemical/drug. Include biomarker status if validated.\n\n- predicts_response_to: Gene or mutation status predicts treatment response. Specify FDA-approved/investigational biomarker status when applicable.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HWSP4RwkpeKKKx8pbxSJFY24Uy", "object": "chat.completion", "created": 1763442662, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"sensitizes_to\",\n  \"confidence\": 0.78,\n  \"explanation\": \"The sentence describes dual targeting of ATR and PARP to reverse PARPi resistance via downregulation of the ATR-Chk1 DDR pathway, implying ATR/PARP targeting increases sensitivity to PARP inhibitors.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 182, "completion_tokens": 1100, "total_tokens": 1282, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1024, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 9, "sentence": "Therefore, the dual targeting of ATR and PARP is a promising modality to reverse PARPi resistance with the downregulation of ATR-Chk1 based DNA damage response.", "subject": {"text": "ATR", "class": "Gene", "start": 33, "end": 36, "ids": [], "id": "Gene:atr"}, "object": {"text": "PARPi", "class": "Chemical", "start": 81, "end": 86, "ids": [], "id": "Chemical:parpi"}, "predicate_names": ["confers_resistance_to", "sensitizes_to", "predicts_response_to"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Our results showed that the ELI and [SUBJ]TAL[/SUBJ] combination could overcome TAL resistance by downregulating cell cycle checkpoint proteins and ATR-based [OBJ]DDR[/OBJ] pathways through synergistic effects (ZIP score\u2009>\u200910).\nAllowed predicates:\n- activates: Gene activates pathway. Specify direct/indirect and cancer type where observed.\n\n- is_essential_for: Gene required for pathway function in specific context.\n\n- bypasses: Gene activation bypasses inhibition of another pathway (resistance mechanism).\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HVhL6uLZp98g9ZUtTgd5nOTMYN", "object": "chat.completion", "created": 1763442661, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\"predicate\":\"bypasses\",\"confidence\":0.72,\"explanation\":\"The sentence states that the ELI and TAL combination could overcome TAL resistance by downregulating DDR pathways, which indicates bypassing the TAL resistance mechanism.\"}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 154, "completion_tokens": 1017, "total_tokens": 1171, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 960, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 6, "sentence": "Our results showed that the ELI and TAL combination could overcome TAL resistance by downregulating cell cycle checkpoint proteins and ATR-based DDR pathways through synergistic effects (ZIP score\u2009>\u200910).", "subject": {"text": "TAL", "class": "Gene", "start": 36, "end": 39, "ids": [], "id": "Gene:tal"}, "object": {"text": "DDR", "class": "Pathway", "start": 145, "end": 148, "ids": [], "id": "Pathway:ddr"}, "predicate_names": ["activates", "is_essential_for", "bypasses"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Our results showed that the ELI and [SUBJ][OBJ]TAL[/OBJ][/SUBJ] combination could overcome TAL resistance by downregulating cell cycle checkpoint proteins and ATR-based DDR pathways through synergistic effects (ZIP score\u2009>\u200910).\nAllowed predicates:\n- physically_interacts_with: Protein-protein interaction. Specify method of detection and binding affinity if known.\n\n- co_expressed_with: Genes show correlated expression across samples. Include correlation coefficient and context.\n\n- synthetic_lethal_with: Combined inhibition is lethal in specific cancer context. Requires functional validation.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HV7k83WA9TtdsUukk42iVLoG8c", "object": "chat.completion", "created": 1763442661, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.35,\n  \"explanation\": \"The sentence describes a combination (ELI and TAL) producing synergistic effects and downregulating specific pathways, but it does not provide evidence of a direct protein-protein interaction, co-expression relationship, or synthetic lethal interaction. None of the allowed predicates clearly fit the described context.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 161, "completion_tokens": 1241, "total_tokens": 1402, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1152, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 6, "sentence": "Our results showed that the ELI and TAL combination could overcome TAL resistance by downregulating cell cycle checkpoint proteins and ATR-based DDR pathways through synergistic effects (ZIP score\u2009>\u200910).", "subject": {"text": "TAL", "class": "Gene", "start": 67, "end": 70, "ids": [], "id": "Gene:tal"}, "object": {"text": "TAL", "class": "Gene", "start": 36, "end": 39, "ids": [], "id": "Gene:tal"}, "predicate_names": ["physically_interacts_with", "co_expressed_with", "synthetic_lethal_with"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Our results showed that the [SUBJ]ELI[/SUBJ] and TAL combination could overcome TAL resistance by downregulating cell cycle checkpoint proteins and ATR-based [OBJ]DDR[/OBJ] pathways through synergistic effects (ZIP score\u2009>\u200910).\nAllowed predicates:\n- activates: Gene activates pathway. Specify direct/indirect and cancer type where observed.\n\n- is_essential_for: Gene required for pathway function in specific context.\n\n- bypasses: Gene activation bypasses inhibition of another pathway (resistance mechanism).\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HUXXp5Q9iJmDFIV5Llh7jjz6PD", "object": "chat.completion", "created": 1763442660, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"bypasses\",\n  \"confidence\": 0.78,\n  \"explanation\": \"The sentence states that the ELI and TAL combination could overcome TAL resistance by downregulating DDR pathways, which describes bypassing the TAL resistance mechanism.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 153, "completion_tokens": 1282, "total_tokens": 1435, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1216, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 6, "sentence": "Our results showed that the ELI and TAL combination could overcome TAL resistance by downregulating cell cycle checkpoint proteins and ATR-based DDR pathways through synergistic effects (ZIP score\u2009>\u200910).", "subject": {"text": "ELI", "class": "Gene", "start": 28, "end": 31, "ids": [], "id": "Gene:eli"}, "object": {"text": "DDR", "class": "Pathway", "start": 145, "end": 148, "ids": [], "id": "Pathway:ddr"}, "predicate_names": ["activates", "is_essential_for", "bypasses"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: However, further preclinical and clinical investigations should be required to elucidate the underlying molecular mechanisms behind [OBJ]ATRi[/OBJ] and [SUBJ]PARPi[/SUBJ] interactions in TNBC cells.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HYDhltLWvlcoLA7zsvNa6xVPC8", "object": "chat.completion", "created": 1763442664, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.65,\n  \"explanation\": \"The sentence mentions investigating the molecular mechanisms behind ATRi and PARPi interactions in TNBC cells but does not state a specific interaction type (synergy, resistance overcoming, or sequential therapy). Therefore, none of the provided predicates is explicitly supported.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 147, "completion_tokens": 977, "total_tokens": 1124, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 896, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 10, "sentence": "However, further preclinical and clinical investigations should be required to elucidate the underlying molecular mechanisms behind ATRi and PARPi interactions in TNBC cells.", "subject": {"text": "PARPi", "class": "Chemical", "start": 141, "end": 146, "ids": [], "id": "Chemical:parpi"}, "object": {"text": "ATRi", "class": "Chemical", "start": 132, "end": 136, "ids": [], "id": "Chemical:atri"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: The overexpression of [SUBJ]ATR[/SUBJ] and associated cell cycle proteins could play a role in [OBJ]PARPi[/OBJ] resistance.\nAllowed predicates:\n- confers_resistance_to: Gene/protein mediates resistance to chemical/drug with specified mechanism and context (intrinsic/acquired, cancer type, fold-change).\n\n- sensitizes_to: Gene/protein or mutation increases vulnerability to chemical/drug. Include biomarker status if validated.\n\n- predicts_response_to: Gene or mutation status predicts treatment response. Specify FDA-approved/investigational biomarker status when applicable.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HWsMBa7ugfSenby1B8ghZvaCdB", "object": "chat.completion", "created": 1763442662, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"confers_resistance_to\",\n  \"confidence\": 0.62,\n  \"explanation\": \"The sentence suggests that ATR overexpression (and related cell cycle proteins) could contribute to resistance to PARP inhibitors, which aligns with the idea that the gene/protein mediates resistance to the drug. The statement is tentative ('could play a role') and lacks explicit context (cancer type, mechanism), so this is a provisional mapping.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 167, "completion_tokens": 1193, "total_tokens": 1360, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1088, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 7, "sentence": "The overexpression of ATR and associated cell cycle proteins could play a role in PARPi resistance.", "subject": {"text": "ATR", "class": "Gene", "start": 22, "end": 25, "ids": [], "id": "Gene:atr"}, "object": {"text": "PARPi", "class": "Chemical", "start": 82, "end": 87, "ids": [], "id": "Chemical:parpi"}, "predicate_names": ["confers_resistance_to", "sensitizes_to", "predicts_response_to"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Then, the cytotoxic, apoptotic and [SUBJ]ATR[/SUBJ] based DNA damage response (DDR) were evaluated by WST-1, Annexin V, AO/PI, [OBJ]cell cycle[/OBJ] and western blot analysis.\nAllowed predicates:\n- activates: Gene activates pathway. Specify direct/indirect and cancer type where observed.\n\n- is_essential_for: Gene required for pathway function in specific context.\n\n- bypasses: Gene activation bypasses inhibition of another pathway (resistance mechanism).\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HT1Gg0FaTw3i2Lg8P3mRpyelSe", "object": "chat.completion", "created": 1763442659, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"is_essential_for\",\n  \"confidence\": 0.65,\n  \"explanation\": \"The DDR is described as 'ATR-based,' which implies ATR is a core, essential component of that DDR pathway in the studied context. The sentence does not explicitly state activation or bypass.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 154, "completion_tokens": 1417, "total_tokens": 1571, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1344, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 5, "sentence": "Then, the cytotoxic, apoptotic and ATR based DNA damage response (DDR) were evaluated by WST-1, Annexin V, AO/PI, cell cycle and western blot analysis.", "subject": {"text": "ATR", "class": "Gene", "start": 35, "end": 37, "ids": [], "id": "Gene:atr"}, "object": {"text": "cell cycle", "class": "Pathway", "start": 114, "end": 123, "ids": [], "id": "Pathway:cell_cycle"}, "predicate_names": ["activates", "is_essential_for", "bypasses"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Our results showed that the [OBJ]ELI[/OBJ] and [SUBJ]TAL[/SUBJ] combination could overcome TAL resistance by downregulating cell cycle checkpoint proteins and ATR-based DDR pathways through synergistic effects (ZIP score\u2009>\u200910).\nAllowed predicates:\n- physically_interacts_with: Protein-protein interaction. Specify method of detection and binding affinity if known.\n\n- co_expressed_with: Genes show correlated expression across samples. Include correlation coefficient and context.\n\n- synthetic_lethal_with: Combined inhibition is lethal in specific cancer context. Requires functional validation.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HV3v446aExUOQt8htB4R1cA1qu", "object": "chat.completion", "created": 1763442661, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none_of_the_above\",\n  \"confidence\": 0.65,\n  \"explanation\": \"The sentence describes a synergistic effect in overcoming TAL resistance by downregulating cell cycle checkpoint proteins and ATR-based DNA damage response pathways, but it does not report a direct protein-protein interaction, gene co-expression, or synthetic lethality between ELI and TAL.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 163, "completion_tokens": 1242, "total_tokens": 1405, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1152, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 6, "sentence": "Our results showed that the ELI and TAL combination could overcome TAL resistance by downregulating cell cycle checkpoint proteins and ATR-based DDR pathways through synergistic effects (ZIP score\u2009>\u200910).", "subject": {"text": "TAL", "class": "Gene", "start": 67, "end": 70, "ids": [], "id": "Gene:tal"}, "object": {"text": "ELI", "class": "Gene", "start": 28, "end": 31, "ids": [], "id": "Gene:eli"}, "predicate_names": ["physically_interacts_with", "co_expressed_with", "synthetic_lethal_with"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Therefore, the dual targeting of [OBJ]ATR[/OBJ] and [SUBJ]PARP[/SUBJ] is a promising modality to reverse PARPi resistance with the downregulation of ATR-Chk1 based DNA damage response.\nAllowed predicates:\n- physically_interacts_with: Protein-protein interaction. Specify method of detection and binding affinity if known.\n\n- co_expressed_with: Genes show correlated expression across samples. Include correlation coefficient and context.\n\n- synthetic_lethal_with: Combined inhibition is lethal in specific cancer context. Requires functional validation.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HW89Zcz4gXHlbpHwZ0iMp8dsAk", "object": "chat.completion", "created": 1763442662, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"synthetic_lethal_with\",\n  \"confidence\": 0.75,\n  \"explanation\": \"The sentence discusses dual targeting of PARP and ATR to reverse PARPi resistance by downregulating ATR-Chk1 DDR, which aligns with a synthetic-lethal interaction in cancer (combined PARP and ATR inhibition). There is no explicit claim of direct physical interaction or co-expression; such a claim would require functional validation for synthetic lethality.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 157, "completion_tokens": 1321, "total_tokens": 1478, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1216, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 9, "sentence": "Therefore, the dual targeting of ATR and PARP is a promising modality to reverse PARPi resistance with the downregulation of ATR-Chk1 based DNA damage response.", "subject": {"text": "PARP", "class": "Gene", "start": 41, "end": 45, "ids": [], "id": "Gene:parp"}, "object": {"text": "ATR", "class": "Gene", "start": 33, "end": 36, "ids": [], "id": "Gene:atr"}, "predicate_names": ["physically_interacts_with", "co_expressed_with", "synthetic_lethal_with"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: HCC1937 and HCC1937-R [OBJ]Talazoparib[/OBJ] (TAL) resistant cells were treated with Elimusertib (ELI) alone as [SUBJ]ATR[/SUBJ] inhibitor (ATRi) and ELI and TAL combination.\nAllowed predicates:\n- confers_resistance_to: Gene/protein mediates resistance to chemical/drug with specified mechanism and context (intrinsic/acquired, cancer type, fold-change).\n\n- sensitizes_to: Gene/protein or mutation increases vulnerability to chemical/drug. Include biomarker status if validated.\n\n- predicts_response_to: Gene or mutation status predicts treatment response. Specify FDA-approved/investigational biomarker status when applicable.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HSMFW3w34R83ZToYodFDdTicYT", "object": "chat.completion", "created": 1763442658, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"sensitizes_to\",\n  \"confidence\": 0.72,\n  \"explanation\": \"The sentence describes TAL-resistant cells being treated with an ATR inhibitor (Elimusertib) alone and in combination with Talazoparib, implying ATR inhibition may increase vulnerability to TAL and help overcome TAL resistance (i.e., sensitization).\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 195, "completion_tokens": 1687, "total_tokens": 1882, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1600, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 4, "sentence": "HCC1937 and HCC1937-R Talazoparib (TAL) resistant cells were treated with Elimusertib (ELI) alone as ATR inhibitor (ATRi) and ELI and TAL combination.", "subject": {"text": "ATR", "class": "Gene", "start": 101, "end": 104, "ids": [], "id": "Gene:atr"}, "object": {"text": "Talazoparib", "class": "Chemical", "start": 22, "end": 33, "ids": [], "id": "Chemical:talazoparib"}, "predicate_names": ["confers_resistance_to", "sensitizes_to", "predicts_response_to"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: However, further preclinical and clinical investigations should be required to elucidate the underlying molecular mechanisms behind ATRi and [SUBJ]PARPi[/SUBJ] interactions in [OBJ]TNBC[/OBJ] cells.\nAllowed predicates:\n- approved_for: FDA/EMA approved for cancer subtype. Specify line of therapy and combination/monotherapy.\n\n- in_trials_for: In clinical trials. Specify phase I/II/III and NCT number if available.\n\n- resistance_emerges_in: Resistance commonly emerges in disease. Specify median time to resistance and frequency.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HYhVe0ZrBlt5rtSvWc9QHsCr6i", "object": "chat.completion", "created": 1763442664, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none_applicable\",\n  \"confidence\": 0.85,\n  \"explanation\": \"The sentence discusses the need for further investigations to elucidate molecular mechanisms behind ATRi and PARPi interactions in TNBC cells. It does not mention FDA/EMA approval, clinical trials, or resistance emergence, so none of the provided predicates apply.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 159, "completion_tokens": 724, "total_tokens": 883, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 640, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 10, "sentence": "However, further preclinical and clinical investigations should be required to elucidate the underlying molecular mechanisms behind ATRi and PARPi interactions in TNBC cells.", "subject": {"text": "PARPi", "class": "Chemical", "start": 141, "end": 146, "ids": [], "id": "Chemical:parpi"}, "object": {"text": "TNBC", "class": "Disease", "start": 163, "end": 167, "ids": [], "id": "Disease:tnbc"}, "predicate_names": ["approved_for", "in_trials_for", "resistance_emerges_in"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: However, further preclinical and clinical investigations should be required to elucidate the underlying molecular mechanisms behind [SUBJ]ATRi[/SUBJ] and [OBJ]PARPi[/OBJ] interactions in TNBC cells.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HX8DzfRojIIKOYlQ0RUk41sxa1", "object": "chat.completion", "created": 1763442663, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.38,\n  \"explanation\": \"The sentence discusses interactions between ATR inhibitors (ATRi) and PARP inhibitors (PARPi) in TNBC cells but does not claim synergy, resistance overcoming, or sequential therapy.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 147, "completion_tokens": 901, "total_tokens": 1048, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 832, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 10, "sentence": "However, further preclinical and clinical investigations should be required to elucidate the underlying molecular mechanisms behind ATRi and PARPi interactions in TNBC cells.", "subject": {"text": "ATRi", "class": "Chemical", "start": 132, "end": 136, "ids": [], "id": "Chemical:atri"}, "object": {"text": "PARPi", "class": "Chemical", "start": 141, "end": 146, "ids": [], "id": "Chemical:parpi"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: This new combination treatment allows efficient application of PARPi Talazoparib to all [OBJ]UC[/OBJ] patients, independent of [SUBJ]Cisplatin[/SUBJ] pretreatment and genetic BRCAness.\nAllowed predicates:\n- approved_for: FDA/EMA approved for cancer subtype. Specify line of therapy and combination/monotherapy.\n\n- in_trials_for: In clinical trials. Specify phase I/II/III and NCT number if available.\n\n- resistance_emerges_in: Resistance commonly emerges in disease. Specify median time to resistance and frequency.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HP4v5fzrBtY2iUADjdhwiIDSPR", "object": "chat.completion", "created": 1763442655, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none_of_the_above\",\n  \"confidence\": 0.65,\n  \"explanation\": \"The sentence does not state regulatory approval, trial status, or resistance dynamics; it only notes that the combination treatment enables use of Talazoparib in all UC patients irrespective of pretreatment/BRCAness. Thus none of the allowed predicates directly apply.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 164, "completion_tokens": 2331, "total_tokens": 2495, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 2240, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41216708", "sentence_id": 10, "sentence": "This new combination treatment allows efficient application of PARPi Talazoparib to all UC patients, independent of Cisplatin pretreatment and genetic BRCAness.", "subject": {"text": "Cisplatin", "class": "Chemical", "start": 116, "end": 125, "ids": [], "id": "Chemical:cisplatin"}, "object": {"text": "UC", "class": "Disease", "start": 88, "end": 90, "ids": [], "id": "Disease:uc"}, "predicate_names": ["approved_for", "in_trials_for", "resistance_emerges_in"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: HCC1937 and HCC1937-R Talazoparib ([OBJ]TAL[/OBJ]) resistant cells were treated with Elimusertib ([SUBJ]ELI[/SUBJ]) alone as ATR inhibitor (ATRi) and ELI and TAL combination.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HSr4L9wRSgmEjFpzRa6yVOjwc9", "object": "chat.completion", "created": 1763442658, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"no_predicate_applicable\",\n  \"confidence\": 0.42,\n  \"explanation\": \"The sentence describes that TAL-resistant cells were treated with ELI alone and with a combination of ELI and TAL, but does not state any outcome (synergy, resistance overcoming, or sequential therapy). Therefore, none of the provided predicates is clearly supported.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 160, "completion_tokens": 1560, "total_tokens": 1720, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1472, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 4, "sentence": "HCC1937 and HCC1937-R Talazoparib (TAL) resistant cells were treated with Elimusertib (ELI) alone as ATR inhibitor (ATRi) and ELI and TAL combination.", "subject": {"text": "ELI", "class": "Chemical", "start": 87, "end": 90, "ids": [], "id": "Chemical:eli"}, "object": {"text": "TAL", "class": "Chemical", "start": 35, "end": 38, "ids": [], "id": "Chemical:tal"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Our results showed that the [OBJ]ELI[/OBJ] and TAL combination could overcome TAL resistance by downregulating cell cycle checkpoint proteins and [SUBJ]ATR[/SUBJ]-based DDR pathways through synergistic effects (ZIP score\u2009>\u200910).\nAllowed predicates:\n- physically_interacts_with: Protein-protein interaction. Specify method of detection and binding affinity if known.\n\n- co_expressed_with: Genes show correlated expression across samples. Include correlation coefficient and context.\n\n- synthetic_lethal_with: Combined inhibition is lethal in specific cancer context. Requires functional validation.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HW7YIB0L3UJaVX3KBFjM9hRbc3", "object": "chat.completion", "created": 1763442662, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\"predicate\":\"none\",\"confidence\":0.55,\"explanation\":\"The sentence describes synergistic effects between ELI and TAL leading to downregulation of ATR-based DDR pathways and overcoming TAL resistance. It does not state a direct protein-protein interaction (physically_interacts_with), a correlated expression (co_expressed_with), or a synthetic lethal interaction (synthetic_lethal_with) as defined by the given predicates.\"}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 162, "completion_tokens": 1504, "total_tokens": 1666, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1408, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 6, "sentence": "Our results showed that the ELI and TAL combination could overcome TAL resistance by downregulating cell cycle checkpoint proteins and ATR-based DDR pathways through synergistic effects (ZIP score\u2009>\u200910).", "subject": {"text": "ATR", "class": "Gene", "start": 135, "end": 138, "ids": [], "id": "Gene:atr"}, "object": {"text": "ELI", "class": "Gene", "start": 28, "end": 31, "ids": [], "id": "Gene:eli"}, "predicate_names": ["physically_interacts_with", "co_expressed_with", "synthetic_lethal_with"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Our results showed that the ELI and TAL combination could overcome TAL resistance by downregulating cell cycle checkpoint proteins and [SUBJ]ATR[/SUBJ]-based [OBJ]DDR[/OBJ] pathways through synergistic effects (ZIP score\u2009>\u200910).\nAllowed predicates:\n- activates: Gene activates pathway. Specify direct/indirect and cancer type where observed.\n\n- is_essential_for: Gene required for pathway function in specific context.\n\n- bypasses: Gene activation bypasses inhibition of another pathway (resistance mechanism).\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HWCyeR6zTcmfeSEEZIyfuhmQrz", "object": "chat.completion", "created": 1763442662, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"bypasses\",\n  \"confidence\": 0.86,\n  \"explanation\": \"The sentence describes overcoming TAL resistance by downregulating ATR-based DDR pathways, indicating that the resistance mechanism is bypassed by the ELI and TAL combination rather than activating a pathway or showing essentiality.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 153, "completion_tokens": 1547, "total_tokens": 1700, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1472, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 6, "sentence": "Our results showed that the ELI and TAL combination could overcome TAL resistance by downregulating cell cycle checkpoint proteins and ATR-based DDR pathways through synergistic effects (ZIP score\u2009>\u200910).", "subject": {"text": "ATR", "class": "Gene", "start": 135, "end": 138, "ids": [], "id": "Gene:atr"}, "object": {"text": "DDR", "class": "Pathway", "start": 145, "end": 148, "ids": [], "id": "Pathway:ddr"}, "predicate_names": ["activates", "is_essential_for", "bypasses"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Therefore, the dual targeting of ATR and [SUBJ]PARP[/SUBJ] is a promising modality to reverse [OBJ]PARPi[/OBJ] resistance with the downregulation of ATR-Chk1 based DNA damage response.\nAllowed predicates:\n- confers_resistance_to: Gene/protein mediates resistance to chemical/drug with specified mechanism and context (intrinsic/acquired, cancer type, fold-change).\n\n- sensitizes_to: Gene/protein or mutation increases vulnerability to chemical/drug. Include biomarker status if validated.\n\n- predicts_response_to: Gene or mutation status predicts treatment response. Specify FDA-approved/investigational biomarker status when applicable.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HXmJ4aDAKHzhL7QbwrZD47bhtu", "object": "chat.completion", "created": 1763442663, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"sensitizes_to\",\n  \"confidence\": 0.68,\n  \"explanation\": \"The sentence describes dual targeting of ATR and PARP as a strategy to reverse PARP inhibitor resistance, implying increased sensitivity to PARP inhibitors via downregulation of ATR-Chk1 DNA damage response.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 182, "completion_tokens": 1420, "total_tokens": 1602, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1344, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 9, "sentence": "Therefore, the dual targeting of ATR and PARP is a promising modality to reverse PARPi resistance with the downregulation of ATR-Chk1 based DNA damage response.", "subject": {"text": "PARP", "class": "Gene", "start": 41, "end": 45, "ids": [], "id": "Gene:parp"}, "object": {"text": "PARPi", "class": "Chemical", "start": 81, "end": 86, "ids": [], "id": "Chemical:parpi"}, "predicate_names": ["confers_resistance_to", "sensitizes_to", "predicts_response_to"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Our results showed that the [SUBJ]ELI[/SUBJ] and [OBJ]TAL[/OBJ] combination could overcome TAL resistance by downregulating cell cycle checkpoint proteins and ATR-based DDR pathways through synergistic effects (ZIP score\u2009>\u200910).\nAllowed predicates:\n- physically_interacts_with: Protein-protein interaction. Specify method of detection and binding affinity if known.\n\n- co_expressed_with: Genes show correlated expression across samples. Include correlation coefficient and context.\n\n- synthetic_lethal_with: Combined inhibition is lethal in specific cancer context. Requires functional validation.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HU5cX4iDGbjMxUqRBBG2Ib5o54", "object": "chat.completion", "created": 1763442660, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none_of_the_above\",\n  \"confidence\": 0.62,\n  \"explanation\": \"The sentence describes a synergistic combination between ELI and TAL that overcomes TAL resistance by downregulating other proteins/pathways, but it does not specify a direct physical interaction, correlated expression, or a lethal interaction (synthetic lethality) as defined by the provided predicates.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 163, "completion_tokens": 1757, "total_tokens": 1920, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1664, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 6, "sentence": "Our results showed that the ELI and TAL combination could overcome TAL resistance by downregulating cell cycle checkpoint proteins and ATR-based DDR pathways through synergistic effects (ZIP score\u2009>\u200910).", "subject": {"text": "ELI", "class": "Gene", "start": 28, "end": 31, "ids": [], "id": "Gene:eli"}, "object": {"text": "TAL", "class": "Gene", "start": 36, "end": 39, "ids": [], "id": "Gene:tal"}, "predicate_names": ["physically_interacts_with", "co_expressed_with", "synthetic_lethal_with"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: HCC1937 and HCC1937-R [OBJ]Talazoparib[/OBJ] (TAL) resistant cells were treated with [SUBJ]Elimusertib[/SUBJ] (ELI) alone as ATR inhibitor (ATRi) and ELI and TAL combination.\nAllowed predicates:\n- synergizes_with: Chemicals show synergistic effect (combination index <1, specific cancer type/model).\n\n- overcomes_resistance_with: Chemical combination overcomes resistance to monotherapy.\n\n- sequential_therapy_after: Chemical B effective after progression on Chemical A.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HRGaZejRiVgIdQHyR4nB54AIpl", "object": "chat.completion", "created": 1763442657, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"overcomes_resistance_with\",\n  \"confidence\": 0.58,\n  \"explanation\": \"The sentence describes TAL-resistant cells being treated with an ATR inhibitor (ELI) alone and in combination with TAL. This implies the combination is being evaluated to overcome resistance to TAL monotherapy.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 164, "completion_tokens": 2123, "total_tokens": 2287, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 2048, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 4, "sentence": "HCC1937 and HCC1937-R Talazoparib (TAL) resistant cells were treated with Elimusertib (ELI) alone as ATR inhibitor (ATRi) and ELI and TAL combination.", "subject": {"text": "Elimusertib", "class": "Chemical", "start": 74, "end": 85, "ids": [], "id": "Chemical:elimusertib"}, "object": {"text": "Talazoparib", "class": "Chemical", "start": 22, "end": 33, "ids": [], "id": "Chemical:talazoparib"}, "predicate_names": ["synergizes_with", "overcomes_resistance_with", "sequential_therapy_after"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Therefore, the dual targeting of [SUBJ]ATR[/SUBJ] and PARP is a promising modality to reverse PARPi resistance with the downregulation of [OBJ]ATR-Chk1[/OBJ] based DNA damage response.\nAllowed predicates:\n- activates: Gene activates pathway. Specify direct/indirect and cancer type where observed.\n\n- is_essential_for: Gene required for pathway function in specific context.\n\n- bypasses: Gene activation bypasses inhibition of another pathway (resistance mechanism).\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HWA49H74ZrPTcZ6QNBUzFhzdeM", "object": "chat.completion", "created": 1763442662, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"bypasses\",\n  \"confidence\": 0.66,\n  \"explanation\": \"The sentence describes dual targeting of ATR and PARP to reverse PARPi resistance via downregulation of the ATR-Chk1\u2013based DNA damage response, i.e., the combination bypasses the resistance mechanism.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 148, "completion_tokens": 1357, "total_tokens": 1505, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1280, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 9, "sentence": "Therefore, the dual targeting of ATR and PARP is a promising modality to reverse PARPi resistance with the downregulation of ATR-Chk1 based DNA damage response.", "subject": {"text": "ATR", "class": "Gene", "start": 33, "end": 36, "ids": [], "id": "Gene:atr"}, "object": {"text": "ATR-Chk1", "class": "Pathway", "start": 125, "end": 133, "ids": [], "id": "Pathway:atr_chk1"}, "predicate_names": ["activates", "is_essential_for", "bypasses"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: HCC1937 and HCC1937-R Talazoparib ([OBJ]TAL[/OBJ]) resistant cells were treated with Elimusertib (ELI) alone as [SUBJ]ATR[/SUBJ] inhibitor (ATRi) and ELI and TAL combination.\nAllowed predicates:\n- confers_resistance_to: Gene/protein mediates resistance to chemical/drug with specified mechanism and context (intrinsic/acquired, cancer type, fold-change).\n\n- sensitizes_to: Gene/protein or mutation increases vulnerability to chemical/drug. Include biomarker status if validated.\n\n- predicts_response_to: Gene or mutation status predicts treatment response. Specify FDA-approved/investigational biomarker status when applicable.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HSQP9VN8zo5isdKOkgF6sP6QkA", "object": "chat.completion", "created": 1763442658, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"sensitizes_to\",\n  \"confidence\": 0.65,\n  \"explanation\": \"The sentence describes testing ATR inhibition (Elimusertib) alone and in combination with Talazoparib in TAL-resistant cells, implying ATR activity/modulation may alter (sensitize to) sensitivity to Talazoparib.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 193, "completion_tokens": 2068, "total_tokens": 2261, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1984, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 4, "sentence": "HCC1937 and HCC1937-R Talazoparib (TAL) resistant cells were treated with Elimusertib (ELI) alone as ATR inhibitor (ATRi) and ELI and TAL combination.", "subject": {"text": "ATR", "class": "Gene", "start": 101, "end": 104, "ids": [], "id": "Gene:atr"}, "object": {"text": "TAL", "class": "Chemical", "start": 35, "end": 38, "ids": [], "id": "Chemical:tal"}, "predicate_names": ["confers_resistance_to", "sensitizes_to", "predicts_response_to"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Our results showed that the ELI and [OBJ]TAL[/OBJ] combination could overcome TAL resistance by downregulating cell cycle checkpoint proteins and [SUBJ]ATR[/SUBJ]-based DDR pathways through synergistic effects (ZIP score\u2009>\u200910).\nAllowed predicates:\n- physically_interacts_with: Protein-protein interaction. Specify method of detection and binding affinity if known.\n\n- co_expressed_with: Genes show correlated expression across samples. Include correlation coefficient and context.\n\n- synthetic_lethal_with: Combined inhibition is lethal in specific cancer context. Requires functional validation.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HWVkmRIS5KDtDx5An82m3kOTZt", "object": "chat.completion", "created": 1763442662, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none\",\n  \"confidence\": 0.8,\n  \"explanation\": \"The sentence describes a synergistic effect of the ELI and TAL combination on overcoming resistance and downregulating DDR pathways, but it does not state a direct protein\u2013protein interaction, gene co-expression, or a synthetic-lethal interaction.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 163, "completion_tokens": 1744, "total_tokens": 1907, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1664, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 6, "sentence": "Our results showed that the ELI and TAL combination could overcome TAL resistance by downregulating cell cycle checkpoint proteins and ATR-based DDR pathways through synergistic effects (ZIP score\u2009>\u200910).", "subject": {"text": "ATR", "class": "Gene", "start": 135, "end": 138, "ids": [], "id": "Gene:atr"}, "object": {"text": "TAL", "class": "Gene", "start": 67, "end": 70, "ids": [], "id": "Gene:tal"}, "predicate_names": ["physically_interacts_with", "co_expressed_with", "synthetic_lethal_with"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Therefore, the dual targeting of ATR and [SUBJ]PARP[/SUBJ] is a promising modality to reverse PARPi resistance with the downregulation of [OBJ]ATR-Chk1[/OBJ] based DNA damage response.\nAllowed predicates:\n- activates: Gene activates pathway. Specify direct/indirect and cancer type where observed.\n\n- is_essential_for: Gene required for pathway function in specific context.\n\n- bypasses: Gene activation bypasses inhibition of another pathway (resistance mechanism).\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HXUPiOLMQVZCKVZMSHKggJsP1U", "object": "chat.completion", "created": 1763442663, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"bypasses\",\n  \"confidence\": 0.63,\n  \"explanation\": \"The sentence states that dual targeting of ATR and PARP reverses PARPi resistance via downregulation of the ATR-Chk1 DDR, which can be interpreted as bypassing the resistance mechanism.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 148, "completion_tokens": 1546, "total_tokens": 1694, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1472, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 9, "sentence": "Therefore, the dual targeting of ATR and PARP is a promising modality to reverse PARPi resistance with the downregulation of ATR-Chk1 based DNA damage response.", "subject": {"text": "PARP", "class": "Gene", "start": 41, "end": 45, "ids": [], "id": "Gene:parp"}, "object": {"text": "ATR-Chk1", "class": "Pathway", "start": 125, "end": 133, "ids": [], "id": "Pathway:atr_chk1"}, "predicate_names": ["activates", "is_essential_for", "bypasses"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Our results showed that the [SUBJ]ELI[/SUBJ] and TAL combination could overcome TAL resistance by downregulating cell cycle checkpoint proteins and [OBJ]ATR[/OBJ]-based DDR pathways through synergistic effects (ZIP score\u2009>\u200910).\nAllowed predicates:\n- physically_interacts_with: Protein-protein interaction. Specify method of detection and binding affinity if known.\n\n- co_expressed_with: Genes show correlated expression across samples. Include correlation coefficient and context.\n\n- synthetic_lethal_with: Combined inhibition is lethal in specific cancer context. Requires functional validation.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HUGfXm9CQ89qtCeX651X6fk7zQ", "object": "chat.completion", "created": 1763442660, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"synthetic_lethal_with\",\n  \"confidence\": 0.62,\n  \"explanation\": \"The sentence describes a combination of two perturbations (ELI and TAL) producing synergistic effects that overcome resistance by downregulating DDR pathways in a cancer context. This aligns with the concept of a synthetic-lethal interaction between two perturbagens, where dual perturbation yields a stronger effect than either alone; however, the sentence does not explicitly state lethality and could reflect general synergy.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 162, "completion_tokens": 2098, "total_tokens": 2260, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1984, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 6, "sentence": "Our results showed that the ELI and TAL combination could overcome TAL resistance by downregulating cell cycle checkpoint proteins and ATR-based DDR pathways through synergistic effects (ZIP score\u2009>\u200910).", "subject": {"text": "ELI", "class": "Gene", "start": 28, "end": 31, "ids": [], "id": "Gene:eli"}, "object": {"text": "ATR", "class": "Gene", "start": 135, "end": 138, "ids": [], "id": "Gene:atr"}, "predicate_names": ["physically_interacts_with", "co_expressed_with", "synthetic_lethal_with"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Our results showed that the [SUBJ]ELI[/SUBJ] and [OBJ]TAL[/OBJ] combination could overcome TAL resistance by downregulating cell cycle checkpoint proteins and ATR-based DDR pathways through synergistic effects (ZIP score\u2009>\u200910).\nAllowed predicates:\n- physically_interacts_with: Protein-protein interaction. Specify method of detection and binding affinity if known.\n\n- co_expressed_with: Genes show correlated expression across samples. Include correlation coefficient and context.\n\n- synthetic_lethal_with: Combined inhibition is lethal in specific cancer context. Requires functional validation.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HUVSU8TAyu80JtF08WGVrkrDiW", "object": "chat.completion", "created": 1763442660, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"synthetic_lethal_with\",\n  \"confidence\": 0.55,\n  \"explanation\": \"The sentence describes a two-factor (ELI and TAL) combination that produces synergy and overcomes resistance in a TAL-targeting context, implying that simultaneous perturbation of both components can be particularly effective in cancer. This aligns with the concept of a synthetic lethal interaction, though explicit lethality or functional validation is not stated.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 163, "completion_tokens": 2021, "total_tokens": 2184, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1920, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 6, "sentence": "Our results showed that the ELI and TAL combination could overcome TAL resistance by downregulating cell cycle checkpoint proteins and ATR-based DDR pathways through synergistic effects (ZIP score\u2009>\u200910).", "subject": {"text": "ELI", "class": "Gene", "start": 28, "end": 31, "ids": [], "id": "Gene:eli"}, "object": {"text": "TAL", "class": "Gene", "start": 67, "end": 70, "ids": [], "id": "Gene:tal"}, "predicate_names": ["physically_interacts_with", "co_expressed_with", "synthetic_lethal_with"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Our results showed that the [OBJ]ELI[/OBJ] and [SUBJ]TAL[/SUBJ] combination could overcome TAL resistance by downregulating cell cycle checkpoint proteins and ATR-based DDR pathways through synergistic effects (ZIP score\u2009>\u200910).\nAllowed predicates:\n- physically_interacts_with: Protein-protein interaction. Specify method of detection and binding affinity if known.\n\n- co_expressed_with: Genes show correlated expression across samples. Include correlation coefficient and context.\n\n- synthetic_lethal_with: Combined inhibition is lethal in specific cancer context. Requires functional validation.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HVAksmiuI5eAKEgtNtNBvQPn3J", "object": "chat.completion", "created": 1763442661, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"synthetic_lethal_with\",\n  \"confidence\": 0.6,\n  \"explanation\": \"The sentence describes a synergistic interaction between ELI and TAL that overcomes TAL resistance, implying a joint effect greater than either agent alone. This aligns with a synthetic lethal-type interaction in cancer contexts, though explicit lethality is not stated and functional validation is needed.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 163, "completion_tokens": 1755, "total_tokens": 1918, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1664, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 6, "sentence": "Our results showed that the ELI and TAL combination could overcome TAL resistance by downregulating cell cycle checkpoint proteins and ATR-based DDR pathways through synergistic effects (ZIP score\u2009>\u200910).", "subject": {"text": "TAL", "class": "Gene", "start": 36, "end": 39, "ids": [], "id": "Gene:tal"}, "object": {"text": "ELI", "class": "Gene", "start": 28, "end": 31, "ids": [], "id": "Gene:eli"}, "predicate_names": ["physically_interacts_with", "co_expressed_with", "synthetic_lethal_with"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Therefore, the dual targeting of ATR and PARP is a promising modality to reverse [SUBJ]PARPi[/SUBJ] resistance with the downregulation of [OBJ]ATR-Chk1[/OBJ] based DNA damage response.\nAllowed predicates:\n- inhibits: Chemical inhibits pathway. Include IC50/potency and selectivity.\n\n- targets: Chemical targets multiple nodes in pathway.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HXaKPXnUZlL6WAvPxpcM94DG4S", "object": "chat.completion", "created": 1763442663, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"targets\",\n  \"confidence\": 0.75,\n  \"explanation\": \"The sentence explicitly mentions 'dual targeting of ATR and PARP', indicating a strategy that targets multiple pathway nodes (ATR and PARP). This aligns with the 'targets' predicate (chemical targets multiple nodes in pathway).\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 125, "completion_tokens": 1422, "total_tokens": 1547, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1344, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 9, "sentence": "Therefore, the dual targeting of ATR and PARP is a promising modality to reverse PARPi resistance with the downregulation of ATR-Chk1 based DNA damage response.", "subject": {"text": "PARPi", "class": "Chemical", "start": 81, "end": 86, "ids": [], "id": "Chemical:parpi"}, "object": {"text": "ATR-Chk1", "class": "Pathway", "start": 125, "end": 133, "ids": [], "id": "Pathway:atr_chk1"}, "predicate_names": ["inhibits", "targets"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: HCC1937 and HCC1937-R Talazoparib (TAL) resistant cells were treated with Elimusertib ([OBJ]ELI[/OBJ]) alone as [SUBJ]ATR[/SUBJ] inhibitor (ATRi) and ELI and TAL combination.\nAllowed predicates:\n- confers_resistance_to: Gene/protein mediates resistance to chemical/drug with specified mechanism and context (intrinsic/acquired, cancer type, fold-change).\n\n- sensitizes_to: Gene/protein or mutation increases vulnerability to chemical/drug. Include biomarker status if validated.\n\n- predicts_response_to: Gene or mutation status predicts treatment response. Specify FDA-approved/investigational biomarker status when applicable.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HSXzMNft3DFF2ItlGJeVac56i5", "object": "chat.completion", "created": 1763442658, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"sensitizes_to\",\n  \"confidence\": 0.58,\n  \"explanation\": \"The sentence describes using an ATR inhibitor to treat TAL-resistant cells and testing an ATRi+Talazoparib combination, implying ATR pathway inhibition affects TAL sensitivity. This aligns with ATR status (gene/protein) modulating response to Talazoparib, i.e., ATR inhibition sensitizes to TAL.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 193, "completion_tokens": 2595, "total_tokens": 2788, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 2496, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 4, "sentence": "HCC1937 and HCC1937-R Talazoparib (TAL) resistant cells were treated with Elimusertib (ELI) alone as ATR inhibitor (ATRi) and ELI and TAL combination.", "subject": {"text": "ATR", "class": "Gene", "start": 101, "end": 104, "ids": [], "id": "Gene:atr"}, "object": {"text": "ELI", "class": "Chemical", "start": 87, "end": 90, "ids": [], "id": "Chemical:eli"}, "predicate_names": ["confers_resistance_to", "sensitizes_to", "predicts_response_to"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Our results showed that the ELI and [SUBJ][OBJ]TAL[/OBJ][/SUBJ] combination could overcome TAL resistance by downregulating cell cycle checkpoint proteins and ATR-based DDR pathways through synergistic effects (ZIP score\u2009>\u200910).\nAllowed predicates:\n- physically_interacts_with: Protein-protein interaction. Specify method of detection and binding affinity if known.\n\n- co_expressed_with: Genes show correlated expression across samples. Include correlation coefficient and context.\n\n- synthetic_lethal_with: Combined inhibition is lethal in specific cancer context. Requires functional validation.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HVeky9s1tryRMuyOcCT2IO621y", "object": "chat.completion", "created": 1763442661, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"physically_interacts_with\",\n  \"confidence\": 0.40,\n  \"explanation\": \"The sentence describes a combination of two entities (ELI and TAL) generating synergistic effects that downregulate specific pathways, which suggests a potential interaction between the two components underlying the observed synergy. However, no explicit physical interaction data or binding measurements are provided, so the inference is speculative and not definitive.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 161, "completion_tokens": 1890, "total_tokens": 2051, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1792, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 6, "sentence": "Our results showed that the ELI and TAL combination could overcome TAL resistance by downregulating cell cycle checkpoint proteins and ATR-based DDR pathways through synergistic effects (ZIP score\u2009>\u200910).", "subject": {"text": "TAL", "class": "Gene", "start": 36, "end": 39, "ids": [], "id": "Gene:tal"}, "object": {"text": "TAL", "class": "Gene", "start": 67, "end": 70, "ids": [], "id": "Gene:tal"}, "predicate_names": ["physically_interacts_with", "co_expressed_with", "synthetic_lethal_with"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Our results showed that the ELI and [SUBJ]TAL[/SUBJ] combination could overcome TAL resistance by downregulating cell cycle checkpoint proteins and [OBJ]ATR[/OBJ]-based DDR pathways through synergistic effects (ZIP score\u2009>\u200910).\nAllowed predicates:\n- physically_interacts_with: Protein-protein interaction. Specify method of detection and binding affinity if known.\n\n- co_expressed_with: Genes show correlated expression across samples. Include correlation coefficient and context.\n\n- synthetic_lethal_with: Combined inhibition is lethal in specific cancer context. Requires functional validation.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HVx75wMH2qega3d7jnLwEOsrWO", "object": "chat.completion", "created": 1763442661, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\n  \"predicate\": \"none_of_the_above\",\n  \"confidence\": 0.55,\n  \"explanation\": \"The sentence describes a synergistic effect of a combination (ELI and TAL) that overcomes resistance by downregulating checkpoint proteins and ATR-based DDR pathways. It does not state a direct protein-protein interaction, a co-expression relationship between genes, or a synthetic-lethal interaction. Therefore none of the provided predicates precisely fit.\"\n}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 163, "completion_tokens": 2151, "total_tokens": 2314, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 2048, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 6, "sentence": "Our results showed that the ELI and TAL combination could overcome TAL resistance by downregulating cell cycle checkpoint proteins and ATR-based DDR pathways through synergistic effects (ZIP score\u2009>\u200910).", "subject": {"text": "TAL", "class": "Gene", "start": 67, "end": 70, "ids": [], "id": "Gene:tal"}, "object": {"text": "ATR", "class": "Gene", "start": 135, "end": 138, "ids": [], "id": "Gene:atr"}, "predicate_names": ["physically_interacts_with", "co_expressed_with", "synthetic_lethal_with"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
[{"model": "gpt-5-nano-2025-08-07", "messages": [{"role": "system", "content": "You are a biomedical relation extraction assistant."}, {"role": "user", "content": "Determine which predicate (if any) fits the sentence.\nSentence: Therefore, the dual targeting of [SUBJ]ATR[/SUBJ] and [OBJ]PARP[/OBJ] is a promising modality to reverse PARPi resistance with the downregulation of ATR-Chk1 based DNA damage response.\nAllowed predicates:\n- physically_interacts_with: Protein-protein interaction. Specify method of detection and binding affinity if known.\n\n- co_expressed_with: Genes show correlated expression across samples. Include correlation coefficient and context.\n\n- synthetic_lethal_with: Combined inhibition is lethal in specific cancer context. Requires functional validation.\n\nRespond as JSON {predicate: str, confidence: float, explanation: str}."}], "response_format": {"type": "json_object"}}, {"id": "chatcmpl-Cd8HXTEelVbywrID1mW0m6SXZAV1X", "object": "chat.completion", "created": 1763442663, "model": "gpt-5-nano-2025-08-07", "choices": [{"index": 0, "message": {"role": "assistant", "content": "{\"predicate\":\"synthetic_lethal_with\",\"confidence\":0.58,\"explanation\":\"Dual targeting of ATR and PARP to overcome PARPi resistance suggests a functional interaction where simultaneous inhibition could be lethal to cancer cells in certain contexts, aligning with the concept of synthetic lethality between PARP and ATR-Chk1\u2013mediated DDR. The sentence does not explicitly claim lethality or provide validation, so this is a best-fit with caveats.\"}", "refusal": null, "annotations": []}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 157, "completion_tokens": 1892, "total_tokens": 2049, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 1792, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": null}, {"pmid": "41186828", "sentence_id": 9, "sentence": "Therefore, the dual targeting of ATR and PARP is a promising modality to reverse PARPi resistance with the downregulation of ATR-Chk1 based DNA damage response.", "subject": {"text": "ATR", "class": "Gene", "start": 33, "end": 36, "ids": [], "id": "Gene:atr"}, "object": {"text": "PARP", "class": "Gene", "start": 41, "end": 45, "ids": [], "id": "Gene:parp"}, "predicate_names": ["physically_interacts_with", "co_expressed_with", "synthetic_lethal_with"], "model_name": "gpt-5-nano-2025-08-07", "model_version": "v1", "prompt_version": "v1"}]
